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1 Introduction and theoretical background 
Computation chemistry and high throughput screening are two procedures which ena-
ble the identification of new chemical entities (NCEs) with an improved receptor inter-
action. In most cases, the increase in specificity to the target receptor, are often con-
nected with a higher lipophilicity and a respective poor water solubility of the NCE. In 
dependence of the desired doses of the active pharmaceutical ingredient (API), the 
poor water solubility causes a low oral bioavailability of the new drug. To overcome 
this solubility-dependent low bioavailability, the use of so-called “enabling technolo-
gies” is gaining more and more attention over the recent years. One of these new 
techniques is the molecular dispersive embedment of poorly water-soluble APIs in pol-
ymeric matrices to form an amorphous solid dispersion (ASD) by means of hot-melt 
extrusion (HME). Especially the formation of intermolecular interactions between API 
and polymer are important for producing a stable ASD over the shelf life. For forming 
ASD, a soluble API/polymer combination lead to a thermodynamically stable system, 
which would be superior in durability. Otherwise, an only kinetically stabilized ASD with 
a respective insoluble API/polymer combination would be prone to recrystallization dur-
ing shelf life. Furthermore, the strength of this API-polymer interactions and HME pro-
cess conditions dictates the API weight fraction which can be embedded amorphously 
in the polymeric matrix [1–11]. A better understanding of the specific interactions be-
tween API and polymer, which enable a “molecular dispersive” solubilization, is vital to 
evaluate whether a solubility prediction of APIs in polymer melts is feasible. In the early 
stage of HME formulation development, the available API amount is very limited or 
expensive. Therefore, a theoretical consideration or preselection of excipients for HME 
is beneficial. Especially HME, with its high throughput of material even at small-scale, 
a reduction of trials due to process simulation and prediction of solubility within the 
polymer matrix is desirable. The use of HME numerical simulation depends on the 
available physicochemical data of the ASD under consideration. An easy approach to 
short cut this long-lasting characterization of ASD would simplify the use of such sim-
ulation software and it reduces the effort in early HME formulation and process devel-
opment. It would encourage researchers to consider hot-melt extrusion as a formula-
tion technology in early drug product development [8–11]. 
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1.1 Solubility prediction of APIs in polymeric matrices 
In literature most publications are using the Hansen solubility theory, partially in com-
bination with the Flory-Huggins lattice theory or molecular dynamics simulations [12–
15]. 
1.1.1 Hansen solubility parameter, group contribution method 
The Hansen solubility parameters (or cohesive energy parameters) are dividing the 
cohesive forces between two molecules into three different forces, namely: hydrogen 
bonding, dipole forces and dispersive forces. If the solubility parameters of two sub-
stances are similar, miscibility is likely. In most cases, the cohesive forces are de-
scribed by means of a mathematical model in which a numerical value is given to every 
molecular group in the respective substance (group contribution method, GCM) 
[12,14,16–26]. The application of the Hansen solubility parameters for the solubility 
prediction of APIs in polymer melts has been validated several times, in some cases 
with adjustment of the original Hansen parameter calculation [16–18,27,28]. The ad-
justments comprises inter alia the splitting of hydrogen bonding into proton-donators 
and proton-acceptors [28] or changes / alternatives in the common GCM data set 
[15,16,21,29]. 
1.1.2 Flory-Huggins lattice theory 
Another assumption to estimate the solubility of APIs in polymeric matrices is based 
on the Flory-Huggins lattice theory for polymer solution with its interaction parameter 
χ. By using a mathematical term for the mixing entropy, the difference in molecular size 
between polymer and solvent can be considered [13,14]. If the free energy of mixing 
between two substances is negative, the miscibility of both components is likely. To 
adapt the original Flory-Huggins lattice theory for ASDs, several procedures has been 
published. The adaptions comprises the inclusion of the activation coefficient for the 
evaluation of the free mixing energy [22,25,26], molecular dynamic simulations 
[15,27,30–32], identification of changes in Gibbs energy by using heat capacity [33], 
evaluation of the temperature dependency [20,24,34,35] and the adoption to hot-melt 
extruded materials [19]. In the case of molecular dynamic simulations, the software 
PC-SAFT from Sadowski and co-workers is one of the promising newly developed 
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methods [27,36–38]. Using PC-SAFT, not only binary mixtures of different API/polymer 
combinations were investigated [27,36], but also the influence of humidity on the long-
term physical stability of ASD [37] or amorphous-amorphous phase separations [38] 
were evaluated. 
1.1.3 Limitations of the common solubility predictions 
The general assumption of the two named solubility prediction theories is based on 
liquid, highly diluted organic systems [12,13]. Regarding polymer melts, the solute 
(API) is substantially smaller than the “solvent” (polymer) and it is not diluted infinitively. 
Thus, an adaption of the original solubility theories to an amorphous API-polymer melt 
is questionable. Another disadvantage is the low consideration of specific API-polymer 
interactions and a missing energy term for breaking crystal lattices. Therefore, both 
solubility theories are only dealing with a possible exchange of energy due to devia-
tions in the intermolecular cohesive forces of already amorphous systems, but they do 
not handle the solubility of a crystalline API in a polymer melt [24]. Especially the Han-
sen solubility parameters have its limitation concerning the prediction of the general 
polarity from a chemical structure and the formation of hydrogen bonding. Thus only 
qualitative statements can be made without quantitative considerations [16]. The Han-
sen solubility parameters are only depict the enthalpy of such system which limits the 
application per se, since a term for entropy is missing [27]. A further disadvantage of 
both assumptions is that the melt viscosity of the polymeric matrix, which is limiting 
miscibility during the HME process, remains unconsidered [17]. In the case of the Flory-
Huggins lattice theory, the minor influence of variations in molecular chain length of 
the polymer on the interaction parameter χ might be an indication of an insufficient 
consideration of molecular chain length effects (e.g. hydrogen bonding) on the interac-
tions and miscibility of a system [39,40]. 
1.1.4 Limitations in selection of substances in literature 
A common procedure in the published literature, where Hansen solubility parameters 
or Flory-Huggins lattice theory has been investigated, is the evaluation of only one 
“model substance” [19–21,24,34,35,39–41]. In rare cases the amount of employed 
substances exceeded ten [16,23,42]. Furthermore, a systemic selection of molecules 
to establish a general valid prediction model has been rarely investigated [16,18,23], 
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whereby Just et al. had conducted a selection of similar structures and considered less 
a high variance in molecular structures. Another limitation in literature is the use of 
identical model substances to validate the prediction model (e.g. Indomethacin 
[17,21,24,25,33,40,43–46], Ibuprofen [15,18,25,41,45–47], Naproxen 
[16,18,23,39,45,46], Nifedipine [25,26,43,44,46]). To validate a general solubility pre-
diction model, covering most parts of the molecular space of APIs is mandatory but 
rarely used. 
1.1.5 Limitations in conclusive experimental data in literature 
A very common measuring technique to examine the solubility of API in polymeric ma-
trices is the differential scanning calorimetry (DSC). Especially the melting point de-
pression method by evaluating the endset of the API melting peak needs an adequate 
low heating rate and API particle size [44,48], which has not been considered in some 
publications [18,27]. Furthermore, the evaluation of the API melting/dissolution peak 
onset is questionable, since this indicates only the temperature where the API starts 
to dissolve. At this temperature point it is unknown, if the entire API weight fraction 
would dissolve or if it is just partially stable. Furthermore at low crystalline API weight 
fractions, the onset becomes broader and lower, which decreases the accuracy of on-
set determination [19,21,23]. Thus, a robust and fast measuring technique to deter-
mine the solubility of API in polymeric matrices is needed. Especially, a method which 
enables a fast equilibration of an API/polymer mixture at a certain measuring temper-
ature, thus the method would be less sensitive to the applied DSC heating rate or to 
the obtained particle size during sample preparation, is beneficial. Rational formulation 
development of hot-melt extrusion would be helpful. 
In formulation development of amorphous solid dispersions (ASDs) by means of hot-
melt extrusion (HME), the process is generally API-consuming and expensive in terms 
of time and personal [11,49–51]. Especially when the API availability is limited, one of 
the major drawbacks of HME is the high material throughput. Furthermore, the various 
process parameters (screw speed, screw configuration, throughput, temperature pro-
file, etc.) lead to a complex multivariable process, which is challenging to optimize or 
scale-up [52,53]. Therefore, several solutions to simplify the use of HME in early for-
mulation development had already been investigated to enable a rational process and 
formulation development of ASD by means of HME. 
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1.1.6 Mini- and micro-scale testing methods and procedures for HME 
A very common example to reduce the batch size for first HME trials to as little as 5 g 
is the use of small-scale co-rotating twin-screw extruders (e.g. 9 mm screw diameter) 
prior to the production scale [52,54–56]. It enables a solid dispersion formulation 
screening but due to the fundamental differences to larger scale extruders, a rational 
process development or scale-up is not feasible [57]. For process development and 
scale-up, crucial process characteristics (e.g. residence time distribution (RTD) and 
specific mechanical energy (SME)) have to be measured accurately [53,57–59]. There-
fore, extruders of 10-12 mm or larger screw diameters are needed but this will require 
throughputs of 50 g/h up to 20 kg/h. Since the extruder needs equilibration time for the 
set process conditions (approx. 15-30 min), the required material quantity to conduct 
extrusion experiments and to gain HME process information would increase drastically. 
In terms of rational solid dispersion formulation screening with a very low required 
batch-size, thermoanalytical techniques, such as differential scanning calorimetry 
(DSC) [21,24,39,43,44,46,60], hot-stage microscopy [52,57] or melt rheology (please 
see section 1.2.2) are often investigated. DSC can either be used for the glass transi-
tion temperature (Tg) determination for process development [57,61] or for the charac-
terization of the API-solubility within the polymeric matrix (please see section 1.1). Fur-
thermore, the miscibility of compounds can be determined by hot-stage microscopy, 
which additionally enables the assessment of the potential temperature range for pro-
cessing in HME [52,57].  
In general, thermoanalytical techniques are only providing hints for a subsequent pro-
duction of ASD by means of hot-melt extrusion. Especially, the determination of pro-
cess conditions is limited, and subsequent HME process results may differ from previ-
ous thermoanalytical findings. Therefore, mini-scale twin-screw extruders are needed 
to obtain better process information, however the cost of an increased batch size might 
be limiting in early formulation development. 
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1.1.7 Melt viscosity as a material characteristic 
In HME, melt rheology is one of the crucial material characteristics which defines the 
applicable process conditions for a required formulation, such as screw speed, pres-
sure and temperature profile [52,58,62–65]. It influences the addition of plasticizer, en-
ergy input or viscous heat dissipation, torque (motor load) and hence the entire extru-
sion performance [4,53,58]. Even more, melt rheology can be used for the definition of 
the applicable and optimal process window for HME [64,66–69] or as a formulation 
screening tool [70].  
In addition, melt viscosity is also one of the crucial input parameters for HME process 
simulation. By using melt viscosity in combination with HME simulation, the experi-
mental effort for defining the optimal HME process conditions can be minimized. Fur-
thermore, especially for thermo-sensitive APIs, the required long-lasting rheological 
measurement for HME simulation might be not feasible. Hence, a simple way to gain 
the rheological behavior as a function of shear and temperature for a required formu-
lation is needed. 
1.1.8 Numerical computation of hot-melt extrusion process 
To get a better insight and understanding of the extrusion process, numerical HME 
simulation is a valid and often used tool [52,63,71,72]. It identifies temperature, pres-
sure and shear profiles along the screws which is helpful to determine the process 
window of HME to manufacture ASD [73]. The two major applications of HME numer-
ical simulation are the optimization of screw configuration and the scale-up from small-
scale to production-scale extruders. 
Several research works have already been conducted with HME simulation for a better 
process understanding. For example, the quantification of the mixing capability of mix-
ing elements and kneading blocks as a function of staggering angle has been investi-
gated [74]. It was found that the quality of mixing is not significantly higher of a mixing 
element than of a normal conveying element. Regarding suspensions, the erosion and 
break-up of fillers in the HME process has also been investigated [75]. It was shown, 
that this filler behavior can accurately predicted by HME simulation software and it can 
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be used to design the optimal mixing equipment. For suspensions, the pressure-de-
pendent wall slippage at barrel and screw surfaces could be characterized [76]. Fur-
thermore, the optimization of the screw configuration was performed with the help of 
multi-objective evolutionary algorithms or genetic algorithms which were able to deal 
with this multi-objective and multimodal issue [72,77]. Another important process pa-
rameter of HME, which was investigated several times, is the residence time distribu-
tion (RTD). Several influencing factors, such as throughput and screw speed, have 
been identified and simulation models for RTD profiles were established [78–81]. In 
the case of pharmaceutical development, HME simulation has already been investi-
gated to perform a rational development, process up-scaling and formulation screening 
to form ASDs [52,59]. Especially for up-scaling, adiabatic process conditions are fa-
vorable. If non-adiabatic conditions at large-scale extruders occur, viscous dissipation 
will lead to a process which goes off the course [82]. Due to the high influence of barrel 
heating and cooling at small-scale extruders, non-adiabatic conditions can be compen-
sated and thus they are difficult to detect. HME numerical simulation is one solution to 
address this scale issue between small- and large-scale extruders. In general, there 
are two different types of computation: (i) one dimensional and (ii) three dimensional 
simulation [71,73]. A 3D model for HME simulation is more accurate, especially in 
terms of detecting hot-spots and quality of mixing. However, the computation is numer-
ically too expensive and long-lasting for simulating an entire twin-screw extruder. Thus, 
a more practical but still sufficient approach in HME formulation development is a 1D 
model which is faster and does not need any specific computerization. However, the 
3D model can be used additionally to compute a specific part of the twin-screw extruder 
or for particle tracking to calculate the mixing capability. For both simulation types, the 
main drawback is the need of experimental input variables, especially melt viscosity 
which might not be easy to access. Furthermore, the use of HME simulation in early 
formulation screening is limited, since the physicochemical characteristics has to be 
measured for every physical mixture under consideration prior to any simulation work. 
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2 Aims and scope  
Regarding hot-melt extrusion in early formulation and process development, tech-
niques and procedures are needed to simplify the application which decrease the re-
quired time and material (please see section 1). This would encourage researchers to 
validate, whether HME might be the right processing option for their final formulation 
without the drawback of an expensive and long-lasting process and formulation evalu-
ation in early stage development. As a first step to identify the optimal and stable for-
mulation for forming amorphous solid dispersions, a reliable theoretical polymer 
screening is needed. It would reduce the experimental effort prior conducting any hot-
melt extrusion trials. Furthermore, the identification of a soluble API/polymer system 
would lead to an ASD which is thermodynamically stable enabling a prolonged shelf 
life. Secondly, a theoretical consideration of process conditions would further reduce 
the number of trials needed to optimize and scale-up the HME process to achieve the 
required amorphous solid dispersion. 
Concerning the two major challenges in early formulation development of amorphous 
solid dispersions by means of hot-melt extrusion, e.g. polymer selection and process 
optimization, following aims in this thesis have been investigated: 
• Defining a robust and fast API solubility determination in polymeric matrices to 
create a wide API solubility data set for further investigations by means of dif-
ferential scanning calorimetry (see chapter 3) 
• A general overview of published measuring techniques for the solubility of APIs 
in the polymeric matrix at room temperature and the comparison to our own 
solubility prediction assumption (see chapter 4).  
• Evaluation and validation of a possible connection of glass transition tempera-
ture (Tg) and melt viscosity of an amorphous solid dispersion (see chapter 5) 
• Investigating the Tg-viscosity correlation for HME numerical simulation pur-
poses, in which model-based viscosity can be used instead of the actual melt 
viscosity (see chapter 6).  
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• Validation of the Tg-viscosity correlation and its general applicability in numerical 
simulation of hot-melt extrusion processes. It would short-cut rheological meas-
urements and simplify the application of HME numerical simulation in early 
stage process and formulation development for amorphous solid dispersions 
(see chapter 7). 
3. Micro-scale prediction method for API-solubility in polymeric matrices and process model for 
forming amorphous solid dispersions by hot-melt extrusion 
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3.1 Graphical abstract 
 
3.2 Abstract 
A new predictive micro-scale solubility and process model for amorphous solid disper-
sions (ASDs) by hot-melt extrusion (HME) is presented. It is based on DSC measure-
ments consisting of an annealing step and a subsequent analysis of the glass transition 
temperature (Tg). The application of a complex mathematical model (BCKV-equation) 
to describe the dependency of Tg on the active pharmaceutical ingredient (API)/poly-
mer ratio, enables the prediction of API solubility at ambient conditions (25 °C). Fur-
thermore, estimation of the minimal processing temperature for forming ASDs during 
HME trials could be defined and was additionally confirmed by X-ray powder diffraction 
data. The suitability of the DSC method was confirmed with melt rheological trials 
(small amplitude oscillatory system). As an example, ball milled physical mixtures of 
dipyridamole, indomethacin, itraconazole and nifedipine in poly(vinylpyrrolidone-co-
vinylacetate) (copovidone) and polyvinyl caprolactam-polyvinyl acetate-polyethylene 
glycol graft copolymer (Soluplus®) were used. 
3.3 Keywords 
amorphous solid dispersion, DSC, hot-melt extrusion, melt rheology, solubility 
3. Micro-scale prediction method for API-solubility in polymeric matrices and process model for 
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3.4 Chemical compounds studied in this article 
Dipyridamole (PubChem CID: 3108); Indomethacin (PubChem CID: 3715); 
Itraconazole (PubChem CID: 55283); Nifedipine (PubChem CID: 4485) 
3.5 Introduction 
Today, one of the major challenges in pharmaceutical research is the increasing num-
ber of active pharmaceutical ingredients (APIs) which belong to class II or IV of the 
Biopharmaceutical Classification System (BCS) and exhibit low solubility [1,2]. To 
overcome poor solubility hot-melt extrusion (HME), spray drying and cyclodextrin-com-
plexation are commonly used [3,4]. HME is a solvent-free, fast and continuous manu-
facturing process. The solubility enhancement by HME is based on forming an amor-
phous solid dispersion (ASD) [5–9], where the API is molecularly dispersed in a poly-
meric matrix. As no energy is needed to overcome the crystal lattice energy of the API, 
solubility is improved. Some of the disadvantages especially for HME, are the time- 
and material-consuming trials that have to be conducted to set the manufacturing pro-
cess variables [10]. Furthermore, predictive micro-scale assays are needed to deter-
mine if an ASD is mandatory to overcome solubility issues [11,12]. For this purpose, 
differential scanning calorimetry (DSC) is often used to evaluate the API solubility in 
polymers and their respective physical stability [13]. The physical stability of an ASD is 
not only promoted by a polymer of high glass transition temperature (Tg), but also by 
the solubility of the API in the polymer matrix [10,11,13,14]. 
Various approaches to predict the solubility of APIs in polymer melts can be found in 
the literature. They are based on either DSC trials or measurements in low molecular 
weight analogues of the polymer by neglecting the influence of molecular weight and 
steric hindrance [15,16]. DSC involves the melting or softening of the materials and 
thus is related to the HME process. Typical DSC methods are the melting point de-
pression method [17–19] and the dissolution end point method [20–22]. Both DSC 
methods are based on the API melting point determination with low heating rates using 
either the onset or the endset of the dissolution endotherm or rather melting tempera-
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ture (Tm) peak signal. By using the onset of Tm, influences of particle size and produc-
tion of the physical mixtures can be neglected. However, the onset only indicates the 
starting point of API-dissolution in the polymer without knowing whether the entire frac-
tion of API present in the mixture can be dissolved at that respective temperature [23–
25]. In contrast, the dissolution endpoint method enables the measurement of the end-
point of the dissolution step and thus might be more accurate. The disadvantage of 
this method is its strong dependence on the particle size. If the particle size is not 
sufficiently small, the melt is not able to reach its equilibrium state during heating and 
the Tm,Endset for the dissolution is shifted to higher temperatures [22]. In addition, an 
evaporation-based DSC technique was reported [26], in which samples were prepared 
by evaporating the organic solvent and further analyzing the recrystallization at ele-
vated temperatures. Due to the use of the evaporation technique, results might not be 
similar to the melting methods or representative of HME processes [27]. 
Furthermore, most techniques identify the equilibrium state of the physical mixture dur-
ing DSC method by prolonging the annealing time or decreasing the heating rate. If a 
melt is not close to equilibrated conditions after such a procedure, the blend will not 
reach its equilibrium in an investigable period of time. Consequently, proof of suitable 
conditions for DSC trials is needed.  
In order to evaluate a micro-scale solubility and process model for ASDs by hot-melt 
extrusion, a new DSC approach for the API solubility estimation in a polymer matrix 
was investigated. It consists of an annealing step and a subsequent analysis of the 
glass transition temperature. The application of a complex mathematical model 
(BCKV-equation [28]) to describe the course of Tg dependency on the API:polymer 
ratio enables the prediction of API solubility at ambient conditions (25 °C). Suitable 
annealing in time and temperature were analyzed by melt rheology with small ampli-
tude oscillatory system (SAOS) measurements. Furthermore, an estimate of the mini-
mal processing temperature (Tmin) for forming ASDs during HME trials could be defined 
and was additionally confirmed by x-ray powder diffraction (XRPD) data. 
3. Micro-scale prediction method for API-solubility in polymeric matrices and process model for 
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3.6 Material and methods 
3.6.1 Material 
Dipyridamole (DPD) was obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA). Indomethacin (IMC) and itraconazole (ITZ) were purchased from Alfa Aesar 
(Karlsruhe, Germany) and nifedipine (NIF) was obtained from Cayman Chemical (Ann 
Arbor, MI, USA). Poly(vinylpyrrolidone-co-vinylacetate) (copovidone, KVA64) and pol-
yvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®, 
SOL) were kindly donated by BASF SE (Ludwigshafen, Germany) (Fig. 3.1). 
 
Figure 3.1 Chemical structures of the substances investigated. 
3.6.2 Methods 
3.6.2.1 Preparation of physical mixtures 
For DSC and XRPD measurements, 400 mg of physical mixture, consisting of one pol-
ymer and API in various weight fractions (10 – 90 % w/w), was ball milled with a 
MM400 from Retsch GmbH (Haan, Germany) with up to 30 Hz for 6 times 5 min. In 
between the milling cycles a pause of 5 min was kept for minimization of thermal en-
ergy intake. Due to a smaller sample size for DSC, the reduction of the particles size 
by ball milling was needed however, DSC measurements with the unmilled pure sub-
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stances showed no change in solid state. For rheological measurements, physical mix-
tures of 20 % API in copovidone were prepared by mortar and pestle which were sub-
sequently homogenized using a Turbula mixer (Willy A. Bachofen AG – 
Maschinenfabrik, Muttenz, Swiss) for 10 min at 22 rpm. 
3.6.2.2 X-ray powder diffraction (XRPD) 
XRPD measurements were performed in reflection mode (X’Pert MRD Pro, 
PANalytical, Almelo, Netherlands) with an X’Celerator detector and nickel filtered 
CuKα1 radiation (λ=1.5406 Å) at 45 kV and 40 mA. Physical mixtures were analyzed 
at a scanning rate of 1.41 2Θ/min before and after annealing in a drying oven under 
the same conditions as the DSC method dictated. 
3.6.2.3 Differential Scanning Calorimetry (DSC) 
A DSC 2 from Mettler Toledo (Gießen, Germany) with nitrogen cooling, nitrogen as 
purge gas (30 ml/min) and an auto sampler was used. The system was calibrated with 
indium and zinc standards. At least three samples of approximately 10 mg from each 
mixture were analyzed using 40 μl aluminum pans with a pierced lid. Glass transition 
temperatures (Tg) and melting temperatures (Tm) of the pure polymers and APIs were 
analyzed via heating-cooling-heating cycles at 10 K/min (Table 3.1). In addition, heat 
capacities were determined by using TOPEM® (modulated DSC) with 1 K pulse height, 
15–30 second pulse width and an underlying heating and cooling rate of 2 K/min. 
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Table 3.1 Properties of the APIs and polymers investigated, in which Tm, Tg and ΔCp 
were determined via DSC. Mean values ± standard deviation. 
Substance Mw [g/mol] Tm [°C] (± S.D.) Tg [°C] (± S.D.) ΔCp [J/(g*K)] (± S.D.) 
Copovidone 45,000-70,000 - 107.1 (± 0.02) 0.40 (± 0.042) 
Soluplus® 90,000-140,000 - 71.1 (± 0.63) 0.30 (± 0.038) 
Dipyridamole 504.626 167.1 (± 0.11) 38.2 (± 1.36) 0.68 (± 0.045) 
Indomethacin 357.79 160.1 (± 0.24) 44.4 (± 0.20) 0.33 (± 0.054) 
Itraconazole 705.63 165.8 (± 0.01) 57.7 (± 0.61) 0.44 (± 0.015) 
Nifedipine 346.33 172.2 (± 0.11) 44.3 (± 0.88) 0.34 (± 0.039) 
 
3.6.2.4 Rheometer (SAOS) 
An oscillatory rheometer (Haake® MARS® III, Thermo Scientific, Karlsruhe, Germany) 
with a plate-plate geometry (d = 20 mm) and a gap height of 0.75 mm was used. All 
experiments were conducted at least in triplicate and in the controlled deformation 
AutoStrain mode (CD AutoStrain mode). An amplitude of 5.5 % was applied and was 
verified by an amplitude sweep. Frequency sweeps were conducted in 10 K steps in 
the suitable temperature range from at least 10 Hz to 0.1 Hz. Subsequently the fre-
quency sweeps in which the specimen was thermorheologically simple, were horizon-
tally shifted into one master curve at a previously defined reference temperature by 
means of Time Temperature Superposition (TTS). The resulting viscosity profile from 
the master curves were fit to the Carreau-Yasuda equation (CY-equation, Eq. (3.1)) 
[29–32], 
𝜂 =  𝜂∞ +  (𝜂0 − 𝜂∞) ∙ [1 + (𝜆?̇?)
𝑎](𝑛−1)/𝑎     (3.1) 
where η0 and η∞ are the zero shear and infinite shear viscosity, λ is the characteristic 
time, n is the Power law index and a is the Yasuda constant. To obtain a more accurate 
curve fitting, η∞ was set to zero (Eq. (3.2)). 
𝜂 =  𝜂0 ∙ [1 + (𝜆?̇?)
𝑎](𝑛−1)/𝑎      (3.2) 
During TTS, shift factor aT for each frequency sweep under investigation were obtained 
and were adjusted to a Williams-Landel-Ferry fit (WLF-fit, Eq. (3.3)) [29–32], 
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log(𝑎𝑇) =
−𝐶1 (𝑇−𝑇0)
𝐶2+(𝑇−𝑇0)
       (3.3) 
where C1 and C2 are constants, T is the intended temperature and T0 is the reference 
temperature. This WLF-fit was needed to describe the temperature dependency of λ 
(Eq. (3.4)) and η0 (Eq. (3.5)) of the CY-equation (Eq. (3.1)), 
𝑎𝑇 =
𝜂𝑇
𝜂0
       (3.4) 
𝑎𝑇 =
𝜆𝑇
𝜆0
       (3.5) 
where index T denotes the intended temperature and index 0 the reference tempera-
ture of the master curve. In summary, the CY-equation and WLF-fit enable the extrap-
olation of data by means of angular frequency and temperature within a limited range 
[33]. As an example, the results from fitting these parameters for KLVA64-blends with 
20 % API at 150 °C are shown in Table 3.2.  
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Table 3.2 Extrapolated Carreau-Yasuda and WLF fits at 150 °C for different blends 
resulting from oscillatory measurements. Mean values ± standard error*. 
Substance Carreau-Yasuda fit WLF fit 
η0 [Pa·s] 
(± S.E.) 
λ [s] 
(± S.E.) 
n  
(± S.E.) 
a 
(± S.E.) 
C1 
(± S.E.) 
C2 
(± S.E.) 
Copovidone 61,005.8  
(± 1,472.2) 
1.356  
(± 0.445) 
0.577  
(± 0.042) 
0.756  
(± 0.103) 
10.04  
(± 2.73) 
147.40  
(± 37.92) 
Soluplus® 17,156.37  
(± 58.82) 
0.757  
(± 0.027) 
0.567  
(±0.005) 
0.782  
(±0.013) 
4.75  
(± 0) 
104.67  
(± 0) 
KVA64 + 20% DPD 11,360.7  
(± 367.4) 
0.393  
(± 0.226) 
0.598  
(± 0.076) 
0.767  
(± 0.162) 
8.78  
(± 0.50) 
135.98  
(± 7.31) 
KVA64 + 20% IMC 6,555.5  
(± 142.0) 
0.288  
(± 0.075) 
0.620  
(± 0.031) 
0.807  
(± 0.106) 
8.87  
(± 2.20) 
142.36  
(± 31.15) 
KVA64 + 20% ITZ 25,630.6  
(± 683.3) 
0.850  
(± 0.534) 
0.645  
(± 0.067) 
0.741  
(± 0.159) 
4.74  
(± 0.25) 
46.99  
(± 3.05) 
KVA64 + 20% NIF 12,357.9  
(± 227.7) 
0.542  
(± 0.110) 
0.612  
(± 0.025) 
0.806  
(± 0.085) 
9.01  
(± 3.51) 
127.26  
(± 53.96) 
* Please see the supplementary data for other temperatures (Table 3.A.2) 
 
3.6.2.5 Solubility determination via DSC 
The DSC method consists of an annealing step and a subsequent analysis of the Tg 
and determination of the ratio of the solubilized API to polymer using a calibration curve 
for Tg. As a first step, Couchman-Karasz equation (CK-equation, Eqs. (3.6) & (3.7)) 
[34] was employed to predict the Tg of API:polymer physical mixtures by using the 
properties of pure materials only, 
𝑇𝑔 =
𝑤1𝑇𝑔,1+𝑘𝐶𝐾(1−𝑤1)𝑇𝑔,2
𝑤1+𝑘𝐶𝐾(1−𝑤1)
        with ∆𝑇𝑔 = 𝑇𝑔,2 − 𝑇𝑔,1  (3.6) 
𝑘𝐶𝐾 =
𝛥𝐶𝑝,2
𝛥𝐶𝑝,1
       (3.7) 
where w is the weight fraction, kCK is the Couchman-Karasz constant, Cp the heat ca-
pacity step at glass transition and the indices 1 and 2 refer to API and polymer, respec-
tively. The calculated glass transition temperature of the physical mixtures was then 
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taken into account in order to set the right annealing temperature, ensuring a sufficient 
dissolution of the API into the polymeric matrix by a low viscous melt. To confirm a 
suitable annealing in time and temperature, rheological trials were conducted with 
samples of 20 % API in KVA64 as well as the pure polymers. Furthermore, this should 
allow to estimate the minimal processing temperature for hot-melt extrusion. Finally, 
XRPD measurements were performed to check complete dissolution of the API as re-
ported by DSC. 
After annealing, the physical mixtures were analyzed in terms of glass transition tem-
perature (Tg,1), resulting from the annealing step (Fig. 3.2). Subsequently, the samples 
were reheated to temperatures above their melting points and the glass transitions 
(Tg,2) of these completely amorphous systems were determined (Fig. 3.2). This glass 
transition temperature (Tg,2) obtained from the second heating step was used to deter-
mine the solubilized API fraction at the respective annealing temperature (TAnnealing) by 
employing the Brostow Chiu Kalogeras Vassilikou-Dova equation [28] (BCKV-equa-
tion, Eq. (3.8)). The BCKV-equation was used to fit the dependence of Tg,2 on the frac-
tion of API in the system, 
𝑇𝑔 = 𝑤1𝑇𝑔,1 + (1 − 𝑤1)𝑇𝑔,2 + 𝑤1(1 − 𝑤1)[𝑎0 + 𝑎1(2𝑤1 − 1) + 𝑎2(2𝑤1 − 1)
2] (3.8) 
with a0, a1 and a2 as fitting constants. Due to its polynomial form, it enables the con-
sideration of positive and negative deviations from the CK-equation (Eq. (3.6)). To pre-
dict a phase diagram and to characterize the solubility at ambient conditions (25 °C), 
the soluble API fractions and the respective temperatures TAnnealing were used. An ex-
ponential fit of the free parameters was performed using Eq. (3.9). 
𝑇𝐴𝑛𝑛𝑒𝑎𝑙𝑖𝑛𝑔 = 𝑦0 + 𝐴 ∗ 𝑒
𝑅0∗𝑥     (3.9) 
Here, x is the soluble API fraction at TAnnealing, A and R0 are fit parameters and y0 cor-
responds to Tm of the API, but was set as a variable parameter. The result from the fit 
was employed to extrapolate x to 25 °C. 
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Figure 3.2 Example for the DSC temperature program (40% NIF-copovidone blend). 
3.6.2.6 Data processing 
All mathematical operations and curve fittings were conducted via Origin® Pro 8G of 
OriginLab (Northampton, MA, USA). The adjusted correlation coefficient (r2) of the 
equations describes the goodness of the performed fits by including the degree of free-
dom (or number of variables) of the equation used. 
3.7 Results & Discussion 
3.7.1 Couchman-Karasz equation versus BCKV-equation 
Properties of the pure substances for employing the Couchman-Karasz equation 
(Eq. (3.6), (3.7)) for physical mixtures are listed in Table 3.1. In most cases, the exper-
imental Tg differed from the CK-equation, indicating specific interactions between the 
API and the polymer which cannot be explained by simple combinatorial mixing 
(Fig. 3.3a-d, Table 3.3). 
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Figure 3.3a-d Glass transition temperatures and resulting CK- and BCKV-fits of (a) 
NIF, (b) DPD), (c) IMC and (d) ITZ) in SOL and KVA64. Mean values ± standard devi-
ation. 
Table 3.3 Deviation and shape discrepancies between CK- and BCKV-fit of the mix-
tures. 
API Polymer Max. absolute deviation of BCKV-fit 
from CK-model [±K] 
Oscillating curve shape 
NIF KVA64 
SOL 
2 
3 
Yes 
Yes 
DPD KVA64 
SOL 
9 
6 
No 
Yes 
IMC  KVA64 
SOL 
4 
6 
Yes 
Yes 
ITZ KVA64 
SOL 
1 
6 
No 
No 
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For the nifedipine physical mixtures, the experimental Tg of SOL and KVA64 systems 
oscillated around the CK-equation to a different extent (Fig. 3.3a, Table 3.3). Due to 
the higher oscillation of NIF-SOL around the CK-fit, specific interactions between NIF 
and SOL might be stronger than between NIF and KVA64. The interaction of NIF and 
SOL might be related to hydrogen bonding between the nitrogen group of NIF and 
hydroxyl groups of SOL [35]. In NIF-KVA64 blends, interactions were suggested be-
tween carbonyl groups of copovidone and the secondary amine group of NIF [36]. 
In the case of dipyridamole, the Tg-values calculated with the CK-equation exhibited 
equally strong deviations (± 6-9 K) from the experimental values for both physical mix-
tures with KVA64 and SOL, although, interestingly, with a different curve shape 
(Fig. 3.3b, Table 3.3). In the case of DPD-KVA64, the deviation suggested hydrogen 
bonding between carbonyl groups of the KVA64 and the hydroxyl group of DPD as 
suggested by Chem. et. al. [37]. Concerning DPD-SOL, hydrogen bonding between 
the hydroxyl group of DPD and the vinyl acetate groups of SOL are likely.  
Regarding physical mixtures of indomethacin, glass transitions calculated with the CK-
equation were continuously shifted towards higher temperature values compared to 
the measured Tgs (±6 K) (Fig. 3.3c, Table 3.3). This resulted in a poor fit of the CK-
model for IMC-SOL blends; however, the BCKV-model fitted the experimental data 
almost perfectly. The discrepancy between measured Tg and CK-equation can be ex-
plained by the inhibition of the dimerization of IMC and specific interaction between 
IMC acting as a proton donor and SOL acting as a proton acceptor via the amide car-
bonyl group [38]. In the case of IMC-KVA64, hydrogen bonding between carbonyl 
groups of copovidone and the carboxylic group of IMC, which had its maximum at 20–
30 % IMC, might cause the strong discrepancy at this concentration range (±4 K) 
[36,39]. 
In the case of ITZ comprising no proton donor groups and KVA64 with its proton ac-
ceptor property via carbonyl groups, specific interactions (hydrogen bonding), was ab-
sent (Fig. 3.3d, Table 3.3) [40]. This was indicated by no significant differences be-
tween CK-fit and measured Tg. Slightly positive Tg differences at low ITZ fractions in 
KVA64 might be a result of improved packing of the polymeric chains, which hinders 
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its movements. However, ITZ-SOL blends exhibited continuously lower Tg values than 
predicted via the CK-model (±6 K), which suggested hydrogen bonding as well as weak 
lipophilic interactions between the substances [41]. 
Regarding the ability of the two mathematical models to describe the course of the 
composition-dependent glass transition, BCKV-fit offers higher flexibility (Table 3.3). 
Due to its polynomial form, the BCKV-model was able to adjust to deviations from the 
purely mixing ratio based CK-model caused by specific interactions. All BCKV-fits ex-
hibited adjusted correlation coefficients r2 close to 1. However, BCKV-fits for KVA64-
mixtures featured a slightly higher goodness of fit (0.99 ≤ r2) than for SOL-mixtures 
(0.98 ≤ r2). On the other hand, the CK-equation is more appropriate for estimates prior 
to conducting experimental measurements because only the knowledge of the pure 
substances is needed. After the performing trials, the BCKV-model should be used 
instead. However in our proposed method, CK-equation was used to determine the 
desired TAnnealing by using the Tg of the physical mixture under investigation (Tab. 
3.A.1). This enabled a fast processing of the API:polymer solubility determination be-
cause no experimental trials with the physical mixtures were needed. The inaccuracy 
of the CK-model for predicting the Tg was already considered in setting TAnnealing. 
The chemical structures of KVA64 and SOL (Fig. 3.1) suggest that both polymers usu-
ally act as hydrogen acceptors, and therefore the miscibility with APIs via hydrogen 
bonding is favorable for those APIs featuring a hydrogen donor site. Additionally, 
Soluplus® might act as a hydrogen donor or favor lipophilic interactions, although to a 
minor extent. In addition, a higher recorded Tg than that predicted by the CK-equation 
may be explained by improved packing of the polymeric chains, which would hinder its 
movements, increasing Tg while at the same time decreasing the true density [40]. As 
seen in the ITZ-copovidone system, deviations from the CK-fit can not only be due to 
specific interactions between API and polymer, but also may be caused by changing 
mobility and flexibility of the polymeric chains in general [40]. 
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3.7.2 Validation of the solubility estimation method by Small Amplitude 
Oscillatory System (SAOS) trials 
In SAOS trials, every copovidone mixture reached its equilibrium viscosity state within 
2 h at temperatures approximately 60 °C above the Tg,Blend predicted by the CK-equa-
tion (Table 3.4). In the case of copovidone mixtures, this temperature (Tg,Blend + 60 °C) 
resulted in low zero shear viscosity values (η0 < 11,400 Pa·s, Table 3.4) facilitating the 
dissolution of the API in the polymer matrix until the solubility within the polymer is 
reached. Since the equilibration time prior to a frequency sweep in SAOS trials was 
set to 2 h, the same duration was also a starting point for setting the annealing time for 
the DSC experiment to measure the Tg. However, a comparison between 1 and 2 hours 
annealing revealed no significant differences in Tg and annealing was reduced to 
1 hour. This reduction in annealing time was enabled by smaller particle sizes obtained 
upon ball milling of the API / polymer mixtures prior to DSC measurements. Please 
see the supplementary data for specific annealing conditions of each physical mixture 
in DSC (Table 3.A.1). As a result of the KVA64 trials, a 2 h equilibrium period (melting 
of powder sample at T = Tg + 60 °C) prior to the frequency sweep measurements and 
an annealing time of 1 h for mixtures of a zero-shear viscosity below 11,500 Pa·s were 
set as parameters for solubility detection of API in polymer. Zero shear viscosities at 
Tg,Blend + 60 °C obtained by extrapolation of API-KVA64 blends data, according to 
Eqs. (3.2) and (3.3), were compared and revealed viscosities in the same viscosity 
range (11,361 – 2,481 Pa·s, Table 3.4). It should be mentioned that differences in zero 
shear viscosity between 2,461 and 6,178 Pa·s are negligible for rheological effects; 
macroscopic effects will start to be pronounced for changes of a decade or higher [42]. 
However, in the case of dipyridamole, zero shear viscosity resulted in a higher η0-value 
than the other API-KVA64 mixtures. This can be explained by the high positive dis-
crepancy between CK-equation and measured Tg at 20 % DPD. However, even the 
DPD-KVA64 blend reached its equilibrium within 2 h during SAOS trials and 1 h an-
nealing during DSC measurements. Consequently, deviations from the CK-equation 
had a negligible influence on the accuracy of the DSC trials and the DSC method eval-
uated was regarded to be generally valid for KVA64 blends. 
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Table 3.4 Glass transition temperatures and viscosities of Soluplus® copovidone, and 
20% API-copovidone blends. Mean values ± standard deviation. 
Substance Tg, CK [°C]  Tg, experimental [°C] 
(± S.D.)  
Tg,CK + 60 °C 
[°C] 
η0 [Pa*s] at Tg,CK + 60 °C 
Copovidone 107.1 107.1 (± 0.02) 167 5,573 
Soluplus® 71.1 71.1 (± 0.63) 131 194,038 
KVA64 + 20% DPD 86.8 97.9 (± 0.38) 147 11,361 
KVA64 + 20% IMC 96.6 88.02 (± 1.01) 157 2,481 
KVA64 + 20% ITZ 96.6 97.6 (± 0.89) 157 6,178 
KVA64 + 20% NIF 96.2 96.4 (± 0.35) 156 4,861 
 
In the case of Soluplus® mixtures, the verification of sufficient annealing was conducted 
similarly to KVA64. SOL exhibited a two decades higher zero shear viscosity at Tg,Blend 
+ 60 °C than KVA64 blends (Table 3.4). One reason may be the very broad glass tran-
sition range in DSC of 27.45 K (±2.57 K) for Soluplus® compared to 8.49 K (±0.30 K) 
for copovidone. Consequently, the annealing temperature had to be increased to 90-
100 °C above Tg,Blend where SOL exhibited a zero-shear viscosity of 2,731-5,994 Pa·s. 
This condition will facilitate the dissolution and diffusion of the API in the molten poly-
meric matrix. The same temperature should enable HME processes [43]. Trials with 
Soluplus® blends at Tg,Blend + 90-100 °C with elongated annealing time showed no sig-
nificant difference in glass transition and 1 h annealing was set for all SOL DSC meas-
urements. 
In summary, the annealing step in the DSC method is able to promote the dissolution 
of the API into the molten polymer matrix to its equilibrium state. One drawback is that 
the annealing depends heavily on the rheological properties of the polymer. Therefore, 
the annealing process should be performed at a temperature at which the viscosity is 
below 12,000 Pa·s. 
3.7.3 Estimation of the lowest processing temperature for ASDs in hot-melt 
extrusion 
In rheological trials at ~60 °C above Tg,Blend, the zero-shear viscosity was suggested to 
be low enough for enabling hot-melt extrusion trials to form ASD (Table 3.4) [43]. The 
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identified dissolved API concentrations in the polymer matrix at the relevant extrusion 
temperature are given in Table 3.5. This temperature is defined as where Tg,1 and Tg,2 
were identical and no melting peak occurred (Fig. 3.4). Data were confirmed with 
XRPD trials. An example is shown for NIF-KVA64 mixtures in Figure 3.5a-b. Please 
see the supplementary data for further XRPD data of the physical mixtures before and 
after annealing (Fig. 3.A.1). Differences in DSC and XRPD data are due to the different 
sensitivities of the measuring systems: because XRPD is able to detect remaining crys-
tals even at very low concentrations [44], the soluble concentrations can be up to 10 % 
lower than in DSC trials.  
 
Figure 3.4 Tg of annealed and completely molten samples at Tg+60°C of NIF-
copovidone blends. Mean values ± standard deviation. 
However, HME trials would be necessary to reach sufficient time and shear rate for 
dissolving the API in the polymer melt at this lowest processing temperature. The pres-
ence of high shear is reducing the melt viscosity [29,30], which is likely to decrease the 
dissolution rate of the API in the polymer melt. Extrusion trials for the confirmation of 
this statement are currently conducted. 
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Figure 3.5a-b XPRD data of NIF-KVA64 physical mixtures containing 30%, 35% and 
40% of API (a) prior and (b) after annealing where 30% was identified as completely 
soluble. 
3.7.4 Prediction of phase diagrams and solubilities at 25 °C 
To obtain a more accurate estimate of the solubility at 25 °C, that is for stability predic-
tions, additional solubility values were measured at temperatures up to 5–10 °C below 
the melting point of the API. If the solubility temperature (TS) was higher than the melt-
ing point of the API, solubility values were determined up to the respective highest 
temperature value. By using an exponential fit (Eq. (3.9)), the predicted solubility of the 
APIs at the various annealing temperatures was extrapolated to ambient conditions 
(25 °C) (Fig. 3.6a-b, Table 3.5). The measured Tg values were excellently fitted via the 
BCKV-model in the case of KVA64 (Fig. 3.6a). For SOL, the BCKV-fits were slightly 
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less accurate but still more than acceptable. Only NIF-SOL blends should be carefully 
regarded. Due to the relatively high zero shear viscosity of the system and the solubility 
behavior of the API in the polymer, measurement of more annealing temperatures for 
a better extrapolation were not feasible. 
Table 3.1 Solubilized weight fractions at THME determined via DSC or XRPD and pre-
dicted solubilities at ambient condition. 
Substance Weight fraction [-] 
THME / DSC 
Weight fraction [-] 
THME / XRPD 
Prediction for 25 °C [-] via 
DSC 
DPD + KVA64 0.30 (138°C) 0.20 (147°C) 0.03 
IMC + KVA64 0.55 (136°C) 0.55 (136°C) 0.36 
ITZ + KVA64 0.15 (159°C) 0.05 (165°C) 0 
NIF + KVA64 0.40 (144°C) 0.30 (150°C) 0.19 
DPD + SOL 0.40 (152°C) 0.40 (152°C) 0.18 
IMC + SOL 0.60 (145°C) 0.55 (146°C) 0.26 
ITZ + SOL 0.15 (158°C) 0.15 (158°C) 0 
NIF + SOL 0.50 (157°C) 0.40 (160°C) 0.23 
 
 
Figure 3.6a-b Solubilities of IMC, NIF, DPD and ITZ in (a) KVA64 (a) and (b) SOL in 
temperature and weight fraction dependence. 
Although less deviation from the CK-model was found for NIF (Fig. 3.3a), it was soluble 
in KVA64 and SOL by favoring hydrogen bonding. The data hint at a slightly better 
miscibility at 25 °C with SOL than with KVA64. Due to a less accurate exponential fit, 
this finding is not entirely convincing, however is likely, if the extent of deviation from 
the CK-equation is considered. In addition, the dissolution endpoint method of other 
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authors suggests similar results for KVA64 [20–22]. For DPD, mixtures with SOL 
showed increased solubility compared to mixtures with KVA64 (Fig. 3.6a-b). It in-
creased from 3 % to 18 %, indicating more specific interaction with SOL than with 
KVA64. However, Tg of KVA64 blends deviated to a higher extent from the CK-equa-
tion than SOL systems but with a different curve shape (Fig. 3.3b).  
IMC was the best miscible substance with both polymers in this investigation. In 
KVA64, IMC exhibited a solubility of 36 % and in SOL 26 % were dissolved at 25 °C 
(Fig. 3.6a-b). Hence, KVA64 seemed to be the better partner for hydrogen bonding or 
less sterically hindered. The solubility identified correlated to the deviation from the 
CK-model (Fig. 3.3c). Furthermore, results from a dissolution endpoint method 
achieved similar outcomes [20–22].  
In contrast, ITZ blends were the only immiscible systems at an extrapolation to ambient 
temperature (Fig. 3.6a-b). As it is generally discussed [13] that no deviation from the 
CK-equation is indicative for a poor solubility of the mixture components or rather the 
absence of specific interactions, this could be the reason for the observed immiscibility 
of our ITZ-KVA64 blends. However, although a great negative deviation for ITZ-SOL 
blends from the CK-equation was observed, the system was still immiscible at ambient 
conditions (Fig. 3.3d). Therefore, hydrogen bonding and lipophilic interaction were too 
weak to promote the dissolution of ITZ in Soluplus® or copovidone to a high extent. A 
comparison to the dissolution endpoint method revealed similar results [20]. 
In summary, deviations from the CK-model did not automatically lead to the conclusion 
of soluble systems or vice versa. Specific interactions between two compounds which 
favor mixing seem to be only one reason for the deviation from the CK-equation. Inter-
estingly, blends that have an oscillating course were more miscible than systems which 
exhibited only one broad maximum / minimum, such as ITZ-SOL and DPD-KVA64 
mixtures. Except for ITZ-KVA64, which did not deviate from the CK-equation, these 
were the immiscible or borderline miscible systems under investigation. Further evalu-
ated immiscible systems, like carbamazepine and griseofulvin in Soluplus® or copo-
vidone, confirm this result (data not shown). In conclusion, not only the extent of devi-
ation from the CK-equation but also the shape should be regarded. 
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To predict phase diagrams we employed the BCKV-fit of Tg,Onset, and the exponential 
fit of the temperature dependent solubility. An example of the resulting diagram for the 
NIF-KVA64 is shown in Figure 3.7. The Tg,Onset was used in this study because this is 
the point at which systems transform into a kinetically unstable state. The resulting 
phase diagram can be divided into kinetically and/or thermodynamically stable areas 
[20]. Therefore, it enables the evaluation of the formulation prior to extrusion experi-
ments in order to produce solid amorphous dispersions. In conclusion, the estimate of 
the temperature limit for the formation of an amorphous system can be applied. Fur-
thermore, the thermodynamically stable API fraction in the polymer matrix at ambient 
conditions can be predicted, but no statement for kinetically stabilized (thus thermody-
namically unstable) systems and hence the shelf life could be made. 
 
Figure 3.7 Predicted phase diagram for NIF-copovidone blends. Mean values ± 
standard deviation. 
3.8 Conclusion 
A micro-scale solubility and process model for forming ASDs by hot-melt extrusion and 
the API solubility prediction in a polymer based on DSC measurements was devel-
oped. The model includes an annealing step and the analysis of the glass transition 
temperatures (Tg). The application of a complex mathematical model (BCKV-equation) 
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enables the identification of the soluble API content within the polymer matrix by em-
ploying the API/polymer ratio dependent Tg course. Our methodology showed good 
accuracy for predicting the thermodynamically stabilized API content in the polymer at 
ambient conditions. An estimate of the minimal processing temperature to form ASDs 
during an HME trial (where the API is completely soluble within the polymeric matrix) 
could additionally be defined. Moreover, it was seen that not only the deviation from 
the Couchman-Karasz equation but also the course shape of Tg should be judged in 
order identify the presence of specific interactions and resulting solubility of two com-
pounds. The above mentioned DSC findings were confirmed by XRPD and melt rheo-
logical trials. Rheological investigations revealed that annealing steps should be 
adapted to the melt rheological properties of the polymer in order to reach its equilib-
rium state prior to analyzing the soluble API fraction during DSC measurements. In 
summary, our proposed method is able to reduce HME trials for the production of ASDs 
and thus it may lower costs and the time required to establish an HME process. To 
minimize the effort, XRPD to confirm data and SAOS for adjustment of TAnnealing might 
be neglected. In case of TAnnealing, the broadness of Tg can be used instead of rheolog-
ical trials to receive information about the viscosity of the polymer in the molten state. 
However, if the minimal processing temperature should be determined, rheological in-
formation at least for the pure polymer melt might be useful. 
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3.11 Supplementary data 
Table 3.A.1 Measured physical mixtures in DSC and the annealing temperatures, re-
spectively. The annealing temperature corresponds to Tg,CK + 60 °C for KVA64 blends 
and to Tg,CK + 90 or 100 °C for SOL blends. 
Substance TAnnealing [°C] Substance TAnnealing [°C] 
DPD + KVA64  DPD + SOL  
20% 147 20% 159 
30% 138 40% 152 
35% 134 45% 150 
40% 131 50% 148 
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60% 118 60% 146 
80% 107 80% 142 
IMC + KVA64  IMC + SOL  
20% 155 20% 166 
40% 145 40% 150 
50% 139 60% 145 
55% 136 65% 143 
60% 133 70% 142 
70% 126 80% 140 
80% 119   
ITZ + KVA64  ITZ + SOL  
10% 160 10% 159 
15% 159 15% 158 
20% 157 20% 158 
40% 146 25% 157 
50% 141 30% 156 
60% 137 40% 155 
70% 132 60% 152 
80% 127 80% 150 
NIF + KVA64  NIF + SOL  
20% 156 40% 160 
30% 150 50% 157 
35% 147 55% 156 
40% 144 60% 154 
45% 142 70% 152 
50% 138 80% 149 
60% 132   
70% 125   
80% 118   
90% 111   
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Table 3.A.2 Carreau-Yasuda and WLF-Fits for different blends resulting from oscilla-
tory measurements and employing TTS. Mean values ± standard error. 
T 
[°C] 
Carreau-Yasuda fit WLF fit 
η0 [Pa·s] 
(± S.E.) 
λ [s] 
(± S.E.) 
n  
(± S.E.) 
a 
(± S.E.) 
C1 
(± S.E.) 
C2 
(± S.E.) 
Copovidone 
140 329,203.2  
(± 9,414.6) 
7.151  
(± 2.810) 
0.574  
(± 0.050) 
0.748  
(± 0.119) 
10.77  
(± 0.58) 
137.35  
(± 7.93) 
150 61,005.8  
(± 1,472.2) 
1.356  
(± 0.445) 
0.577  
(± 0.042) 
0.756  
(± 0.103) 
10.04  
(± 2.73) 
147.40  
(± 37.92) 
160 14,038.6  
(± 319.3) 
0.316  
(± 0.097) 
0.578  
(± 0.039) 
0.758  
(± 0.097) 
9.42  
(± 2.25) 
157.60  
(± 33.64) 
170 3,842.8  
(± 78.9) 
0.085  
(± 0.024) 
0.577  
(± 0.036) 
0.757  
(± 0.088) 
8.86  
(± 1.37) 
167.63  
(± 22.03) 
180 1,228.9  
(± 23.0) 
0.027  
(± 0.007) 
0.577  
(± 0.033) 
0.757  
(± 0.080) 
8.26  
(± 1.06) 
176.25  
(± 18.22) 
190 465.2  
(± 8.2) 
0.010  
(± 0.002) 
0.579  
(± 0.031) 
0.765  
(± 0.077) 
7.44  
(± 0.82) 
180.74  
(± 15.08) 
Soluplus® 
150 17,156.37  
(± 58.82) 
0.757  
(± 0.027) 
0.567  
(±0.005) 
0.782  
(±0.013) 
4.75  
(± 0) 
104.67  
(± 0) 
160 6,707.56  
(± 23.00) 
0.292  
(± 0.011) 
0.567  
(±0.005) 
0.782  
(±0.013) 
4.34  
(± 0) 
114.77  
(± 0) 
170 2,959.77  
(± 10.15) 
0.131  
(± 0.005) 
0.567  
(±0.005) 
0.782  
(±0.013) 
3.98  
(± 0) 
124.48  
(± 0) 
Copovidone + 20% Dipyridamole 
140 56,917.0  
(± 1,362.6) 
1.942  
(± 0.836) 
0.600  
(± 0.056) 
0.771  
(± 0.122) 
9.47  
(± 0.12) 
126.01  
(± 1.71) 
150 11,360.7  
(± 367.4) 
0.393  
(± 0.226) 
0.598  
(± 0.076) 
0.767  
(± 0.162) 
8.78  
(± 0.50) 
135.98  
(± 7.31) 
160 2,841.1  
(± 88.6) 
0.096  
(± 0.054) 
0.595  
(± 0.074) 
0.765  
(± 0.156) 
8.19  
(± 0.31) 
146.15  
(± 4.84 
170 849.0  
(± 24.5) 
0.030  
(± 0.015) 
0.600  
(± 0.067) 
0.775  
(± 0.148) 
7.64  
(± 0.27) 
155.75  
(± 4.56) 
Copovidone + 20% Indomethacin 
130 185,056.5  
(± 4,782.0) 
7.981  
(± 2.513) 
0.618  
(± 0.038) 
0.798  
(± 0.123) 
10.40  
(± 0.55) 
123.32  
(± 7.05) 
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140 30,662.6  
(± 687.9) 
1.358  
(± 0.366) 
0.621  
(± 0.032) 
0.810  
(± 0.110) 
9.62  
(± 2.84) 
133.44  
(± 36.99) 
150 6,555.5  
(± 142.0) 
0.288  
(± 0.075) 
0.620  
(± 0.031) 
0.807  
(± 0.106) 
8.87  
(± 2.20) 
142.36  
(± 31.15) 
160 1,686.0  
(± 34.1) 
0.076  
(± 0.018) 
0.623  
(± 0.029) 
0.821  
(± 0.102) 
8.54  
(± 1.70) 
155.67  
(± 25.81) 
170 517.2  
(± 10.5) 
0.023  
(± 0.006) 
0.621  
(± 0.029) 
0.812  
(± 0.100) 
7.99  
(± 1.39) 
165.26  
(± 22.66) 
Copovidone + 20% Itraconazole 
150 25,630.6  
(± 683.3) 
0.850  
(± 0.534) 
0.645  
(± 0.067) 
0.741  
(± 0.159) 
4.74  
(± 0.25) 
46.99  
(± 3.05) 
160 3,746.1  
(± 67.1) 
0.131  
(± 0.054) 
0.651  
(± 0.044) 
0.763  
(± 0.114) 
3.90  
(± 1.35) 
56.85  
(± 16.46) 
170 992.9  
(± 11.3) 
0.035  
(± 0.009) 
0.652  
(± 0.028) 
0.770  
(± 0.074) 
3.18  
(± 1.20) 
65.13  
(± 17.51) 
180 340.3  
(± 3.5) 
0.012  
(± 0.003) 
0.654  
(± 0.025) 
0.773  
(± 0.066) 
3.14  
(± 0.81) 
80.27  
(± 13.44) 
Copovidone + 20% Nifedipine 
150 12,357.9  
(± 227.7) 
0.542  
(± 0.110) 
0.612  
(± 0.025) 
0.806  
(± 0.085) 
9.01  
(± 3.51) 
127.26  
(± 53.96) 
160 2,728.7  
(± 92.1) 
0.121  
(± 0.044) 
0.613  
(± 0.045) 
0.811  
(± 0.157) 
8.28  
(± 14.30) 
136.06  
(± 220.70) 
170 737.9  
(± 22.2) 
0.033  
(± 0.011) 
0.613  
(± 0.400) 
0.815  
(±0.141) 
7.72  
(± 5.92) 
146.18  
(± 98.80) 
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Figure 3.A.1 XRPD diagrams of the physical mixtures (DPD, IMC, ITZ, NIF in KVA64 
or SOL) before and after annealing which were amorphous after the annealing step. 
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4.1 Graphical Abstract 
 
4.2 Abstract 
The number of models for predicting the solubility of active pharmaceutical ingredients 
(APIs) in polymeric matrices on the one hand and the extent of available associated 
data on the other hand has been rising steadily in the past few years. However, ac-
cording to our knowledge an overview on the methods used for prediction and the 
respective experimental data is missing. Therefore, we compiled experimental data, 
the techniques used for their determination and the models used for predicting the 
solubility. Our focus was on polymers commonly used in spray drying and hot-melt 
extrusion to form amorphous solid dispersions (ASDs), namely polyvinylpyrrolidone 
grades (PVP), polyvinyl acetate (PVAc), vinylpyrrolidone-vinyl acetate copolymer (co-
povidone, COP), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
polymer (Soluplus®, SOL), different types of methacrylate copolymers (PMMA), poly-
ethylene glycol grades (PEG) and hydroxypropyl-methylcellulose grades (HPMC). The 
literature data were further supplemented by our own results. The final data set in-
cluded 37 APIs and two sugar derivatives. The majority of the prediction models was 
constituted by the melting point depression method, dissolution endpoint measure-
ments, indirect solubility determination by Tg and the use of low molecular weight ana-
logues. We observed that the API solubility depended more on the working group 
which conducted the experiments than on the measuring technique used. Furthermore, 
this compilation should assist researchers in choosing a prediction method suited for 
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their investigations. Finally, the data set should help researchers in training their own 
solubility prediction models. 
4.3 Keywords 
solubility, data review, amorphous solid dispersion, prediction model 
4.4 Chemical compounds studied in this article 
Bisacodyl (PubChem CID: 2391); Carbamazepine (PubChem CID: 2554); Celecoxib 
(PubChem CID: 2662); Cilostazol (PubChem CID: 2754); Clozapine (PubChem CID: 
2818); Dipyridamole (PubChem CID: 3108); Felodipine (PubChem CID: 3333); 
Gliclazide (PubChem CID: 3475); Griseofulvin (PubChem CID: 441140); Indomethacin 
(PubChem CID: 3715); Itraconazole (PubChem CID: 55283); Lamotrigine (PubChem 
CID: 3878); Loratadine (PubChem CID: 3957); Nifedipine (PubChem CID: 4485); 
Naproxen (PubChem CID: 156391); Posaconazole (PubChem CID: 468595); 
Praziquantel (PubChem CID: 4891); Probucol (PubChem CID: 4912); Ritonavir 
(PubChem CID: 392622); Telmisartan (PubChem CID: 65999); Verapamil-HCl 
(PubChem CID: 62969); Copovidone (PubChem CID: 25086-89-9) 
4.5 Introduction 
In recent years, the increasing number of poorly soluble active pharmaceutical ingre-
dients (APIs) led to the requirement of new and innovative strategies and dosage forms 
in drug formulation development [1]. One of the so-called enabling technologies to 
overcome poor API-solubility is the formation of amorphous solid dispersions (ASDs), 
either by solvent evaporation or by melting techniques (e.g. spray drying or hot-melt 
extrusion) [2–4]. In ASDs, the API is amorphously embedded (molecularly dispersed) 
in a polymeric matrix and often kinetically stabilized, especially if a supersaturated 
state at room temperature is achieved. Due to the absence of a crystal lattice, the API 
rate and extent of dissolution in aqueous media are increased and thus, the respective 
bioavailability is enhanced [5–8]. The drawback of a metastable amorphous API form, 
which is mainly kinetically stabilized in a polymeric matrix, is the overall reduced sta-
bility due to potential recrystallisation over the shelf life and the ensuing decrease in 
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bioavailability [5,9]. Therefore, a thermodynamically embedded amorphous API in a 
polymeric matrix, which is entirely soluble without supersaturation at room tempera-
ture, is favorable. This can be achieved if the API content in an (dissolved) ASD is 
completely soluble in the investigated polymeric matrix at ambient conditions [10,11]. 
It leads not only to a kinetically but more to a thermodynamically stabilized system 
which prevents recrystallization and thus prolongs the shelf life of the entire drug for-
mulation [3,12–14]. However, the measurement of the API solubility is challenging and 
a direct determination at room temperature is obstructed by the high viscosity of the 
overall system [12]. The slow kinetics of such systems result in unrealistically long 
periods to observe recrystallization and determine the limit of API solubility, respec-
tively. Therefore, either the use of surrogate systems with a low weight analogue to the 
respective polymer or measurements at elevated temperatures and subsequent ex-
trapolation to room temperature are used to obtain the desired information on an ex-
perimental basis [9,15–17].  
Several techniques and assumptions, with corresponding data sets, are available in 
the literature which can be used to elucidate the solubility of an API in a given polymeric 
matrix [5,10,12,15]. Commonly used techniques are based on differential scanning cal-
orimetry (DSC) methods or measurements in low molecular weight analogues. The 
most widely investigated DSC methods include DSC measurements, the melting point 
depression method [10,17,18] and the dissolution endpoint method [19–21]. During 
measurement and while applying a sufficiently low heating rate to the specimen, either 
the onset or the endset of the melting endotherm can be analyzed. Furthermore, indi-
rect measurements of the API solubility in polymeric matrices by using the glass tran-
sition temperature (Tg) of recrystallized or annealed samples have been reported 
[22,23]. Further measuring techniques, which make use of heat capacity differences 
between the solid solution and its unmixed components, solution calorimetry or high-
energy mechanical milling on processed solid dispersions have also been investigated 
[24–26]. In the case of measurements in low molecular weight analogous, the limiting 
factor of the high viscosity of an ASD at room temperature is circumvented by employ-
ing the polymer’s low molecular weight analogue and extrapolating the obtained solu-
bility to the polymer of interest [27,28]. 
However, most of the data sets used to train solubility prediction methods encompass 
only one or a limited number of APIs. Thus, the overall applicability of such prediction 
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model is questionable. The aim of our study is 1) to compare the available data sets 
and models published so far and 2) to supplement these data with our own work and 
data on predicting API solubility in polymeric matrices. This leads to a compilation of 
API-polymer solubility data, which should assist researchers in choosing an adequate 
prediction method and should provide researchers with a data set for training solubility 
prediction models. Finally, we were able to prove the validity of our own DSC method 
by comparing it to a wide data set, based on other methods presented in literature. 
4.6 Material and methods 
4.6.1 Material 
Bisacodyl, dipyridamole, gliclazide, naproxen and verapamil-HCl were received from 
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Griseofulvin, indomethacin and itra-
conazole were obtained from Alfa Aesar GmbH & Co. KG (Karlsruhe, Germany). 
Clozapine, ritonavir and posaconazole were received from Swapnroop Drug and Phar-
maceuticals (Aurangabad, India). Loratadine and telmisartan were purchased from sris 
Pharmaceuticals (Telangana, India). Nifedipine and probucol were from Cayman 
Chemical (Ann Arbor, MI, USA). Celecoxib was purchased from Cadila Pharmaceuti-
cals Ltd. (Ahmedabad, India) and cilostazol was received from Amsal Chem Pvt Ltd. 
(Mumbai, India). Felodipine was obtained from Molekula Limited (Newcastle, UK), 
lamotrigine was received from Maps Laboratories Pvt. Ltd. (Gujarat, India), 
praziquantel was received from Divis Laboratories Ltd. (Telangana India). 
Vinylpyrrolidone-vinyl acetate copolymer (copovidone, Kollidon® VA 64, COP), 
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft polymer (Soluplus®, 
SOL) and carbamazepine were kindly donated by BASF SE (Ludwigshafen, Germany) 
(Table 4.1).   
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Table 4.1 Physicochemical properties of substances under investigation. Molecular weight 
was taken from PubChem Substance and Compound databases [29], all other parameters 
were experimentally determined. 
Substance Mw  
[g/mol] 
Tm 
[°C] 
Tg  
[°C] 
Cp step at 
Tg [J/g·K] 
Soluble in 
COP at 100 °C   
Bisacodyl 361.4 133.6 16.1 0.36 Yes 
Carbamazepine 236.3 175.1 
190.2 
52.7 0.38 No 
Celecoxib 381.4 160.9 56.8 0.39 Yes 
Cilostazol 369.5 158.6 31.2 0.46 No 
Clozapine 326.8 182.1 59.7 0.35 No 
Dipyridamole 504.6 167.1 38.2 0.68 Yes 
Felodipine 384.3 144.2 45.0 0.30 Yes 
Gliclazide 323.4 170.5 39.6 0.48 No 
Griseofulvin 352.8 218.3 88.9 0.30 No 
Indomethacin 357.8 160.1 44.4 0.33 Yes 
Itraconazole 705.6 165.8 57.7 0.44 No 
Lamotrigine 256.1 215.8 93.3 0.54 No 
Loratadine 382.9 134.6 34.9 0.30 No 
Naproxen 230.3 156.1 6.7* 0.31* Yes 
Nifedipine 346.3 172.2 44.3 0.34 Yes 
Posaconazole 700.8 167.7 59.8 0.43 No 
Praziquantel 312.4 138.3 35.9 0.37 No 
Probucol 516.8 126.3 25.6 0.46 Yes 
Ritonavir 720.9 121.8 48.6 0.46 Yes 
Telmisartan 514.6 268.3 129.5 0.35 No 
Verapamil-HCl 491.1 142.3 55.2 0.51 No 
Copovidone (COP) 45,000 - 70,000 - 107 0.40 - 
Soluplus® (SOL) 90,000 – 140,000 - 71.1 0.30 - 
* measured with 10% COP weight fraction due to APIs recrystallization tendency. 
4.6.2 Methods 
4.6.2.1 Differential Scanning Calorimetry (DSC) 
A DSC 2 from Mettler Toledo (Gießen, Germany) was used to analyze glass transition 
temperatures (Tgs), heat capacity steps at Tg and the API solubility in polymer melts. 
The system was equipped with an auto sampler, nitrogen cooling and nitrogen as 
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purge gas (30 ml/min). Calibration of the DSC was performed by using n-octane, in-
dium and zinc standards. Every investigated material was analyzed in triplicate placing 
approx. 10 mg sample in a 40 μl aluminum pan with a pierced lid and using 10 K/min 
as heating and cooling rate. In the case of heat capacities, measurements were con-
ducted against a sapphire standard and in TOPEM® mode (modulated DSC) with 1 K 
pulse height, 15-30 s pulse width and an underlying heating rate of 2 K/min. For heat 
capacity measurement, the samples were annealed prior to analysis to enable homo-
geneous API-distribution in the polymeric matrix. Before conducting any DSC meas-
urement, samples were prepared by using a MM400 ball mill of Retsch GmbH (Haan, 
Germany) with 30 Hz and 3x 5 min milling cycles. 
4.6.2.2 Solubility determination via DSC 
The solubility determination of APIs in COP and SOL were conducted by using a pro-
tocol of our recent work [23]. The method was based on an indirect measurement of 
the API solubility by using the Tg. First, the sample was annealed at a certain temper-
ature, were the melt viscosity of the specimen allowed the API to dissolve. Secondly, 
the Tg of this annealed sample was determined and a further Tg analysis of the respec-
tive amorphous system with the completely dissolved API fraction was conducted. This 
procedure was repeated at different API/polymer weight fractions. Further, the second 
analyzed Tgs served for the determination of the weight fraction-dependent curve pro-
gression of Tg by employing the Brostow Chiu Kalogeras Vassilikou-Dova fit (BCKV-
fit, Eq. 4.1), 
𝑇𝑔 = 𝑤1𝑇𝑔,1 + (1 − 𝑤1)𝑇𝑔,2 + 𝑤1(1 − 𝑤1)[𝑎0 + 𝑎1(2𝑤1 − 1) + 𝑎2(2𝑤1 − 1)
2] (4.1) 
where at Tg,1 and Tg,2 are the Tgs of API and polymer, respectively, w1 is the weight 
fraction of the API and a0, a1 and a2 are variables [30]. Due to its polynomial form, the 
BCKV-fit is able to consider positive and negative deviations from the Couchman-
Karasz fit [31]. Thus, it was appropriate to identify the solubilized API fraction of the 
annealed samples by employing the API weight fraction-dependent curve progression 
of glass transition temperature. Finally, for predicting the API solubility phase diagram, 
Equation 2 was fitted to the solubility curve progression, 
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𝑇𝐴𝑛𝑛𝑒𝑎𝑙𝑖𝑛𝑔 = 𝑦0 + 𝐴 ∗ 𝑒
𝑅0∗𝑥      (4.2) 
where x is the soluble API fraction (wAPI/wpolymer) at the respective temperature, A and 
R0 are fitting constants and y0 corresponds to the API melting point but was set as a 
variable. All API solubility results were further confirmed with XRPD measurements 
(data not shown). 
4.6.2.3 Empirical model of solubility in COP 
In short, to predict if the solubility in COP at 100°C is at least 0.20 (w/w), we used R, a 
freely available language and environment for statistical computing and graphics [32]. 
Molecular descriptors of the API in COP in Table 4.1 of the manuscript were computed 
with MOE [33]. These descriptors were enriched with data obtained from experiments 
and the PubChem database [29]. Features that had no value or had the same value 
for 50% or more of the compounds were removed. Features were not standardized at 
the beginning of the computations. Instead, standardization was performed prior to any 
model training. 
An initial estimate of the necessary number of descriptors was obtained using the pack-
age glmnet [34], whereas selection of features was performed using the LiblineaR 
package [35], which provides a wrapper for the LIBLINEAR C/C++ library for machine 
learning [36]. The predictive accuracy was assessed using balanced accuracy com-
puted by the package caret [37]. 
Features were selected using recursive feature elimination [38]. The optimal value of 
the hyperparameter of each regularized logistic regression model was estimated by a 
leave-one out crossvalidation. To assess the predictive accuracy of our models for 
unseen data, we performed nested crossvalidation: in an additional outer loop we em-
ployed leave-one out crossvalidation to compute the balanced accuracy for test sam-
ples. The selection of the features for the final model was based on the full set of 
compounds. 
A more detailed description of our approach is given in the supplementary material 
(Appendix A). 
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4.7 Results & Discussion 
The data of API solubility in polymeric matrices from literature, together with our own 
results, are given in Table 4.2. In general, solubility data were given in weight fractions 
(wAPI/wpolymer). Regarding the data set, the focus was on polymers which were com-
monly known for their application in hot-melt extrusion and on solubility determinations, 
which were based on experimental results. The following polymers occurred frequently 
enough in literature to warrant inclusion in our compilation: polyvinylpyrrolidone grades 
(PVP), polyvinyl acetate (PVAc), vinylpyrrolidone-vinyl acetate copolymer (copo-
vidone, COP), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft poly-
mer (Soluplus®, SOL), different types methacrylate copolymers (PMMA), polyethylene 
glycol (PEG) and hydroxypropyl-methylcellulose grades (HPMC). To expand the data 
set, solubility data of further 20 APIs in COP and SOL of our own work were added. In 
total, the final data set was comprised of 37 APIs and 2 sugar derivatives with a varying 
extent of available polymer data and several measuring techniques to obtain the API 
solubility in polymeric matrices. A detailed compilation of the physicochemical charac-
teristics of the APIs and sugar derivatives under investigation is listed in the supple-
mentary section (Appendix B). Although different measuring techniques were used, 
the majority of techniques were based on DSC. Observed differences in the solubilities 
for the same substance likely depended on both the measuring technique, obviously, 
but also on the working group which conducted the measurements. 
4.7.1 Measuring techniques 
In the data set presented in Table 4.2, only API solubilities which were derived from 
experimental values were considered. The index next to the solubility value depicts the 
measuring technique used. They were divided into melting point depression methods 
by using the onset of the melting point (Tm) (index 1), dissolution endpoint methods 
using the endset of Tm (index 2), indirect measurements via the glass transition tem-
peratures (index 3), measurements in low molecular weight analogues (index 4) and 
further measuring techniques (index 5). The fifth category of measuring techniques 
includes for example, a technique based on a thermodynamic model to calculate the 
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Gibbs energy change while forming a drug-polymer solution [24], using solution calo-
rimetry to determine enthalpies of mixing [25] or investigating the stability of ASDs 
against high-energy mechanical milling [26]. 
Melting point depression method 
In the case of the melting point depression method, an adequately low heating rate 
(approx. 0.2-2 K/min) is applied to a physical mixture and the onset of the melting 
endotherm characterizes the temperature which enables the dissolution of the entire 
API fraction [10,17,18]. Employing the Flory-Huggins lattice theory and the proposed 
calculation of the interaction parameter χ by Marsac et al. was able to extrapolate the 
API solubility to ambient temperatures using the melting point depression of a soluble 
API/polymer system [39,40]. One of the drawbacks of this method is that at a low crys-
talline API weight fraction, the melting peak becomes more broad and flat, making it 
challenging to define the onset accurately [10,41,42]. Furthermore, the onset only char-
acterizes the starting point of the API dissolution within the polymeric matrix. It remains 
unknown whether the entire API fraction would dissolve at this temperature or probably 
at temperatures above the onset [43–45]. However, this method is more robust against 
the sample preparation method used. While for the dissolution endpoint method a cer-
tain maximal particle size of the specimen needs to be defined for an appropriate sol-
ubility determination, this drawback is less critical for the melting point depression 
method [19,22]. 
Dissolution endpoint method 
Regarding the dissolution endpoint method, a cryo-milled physical mixture and the ap-
plication of an adequately low heating rate (approx. 0.2-2 K/min) enables the accurate 
characterization of the melting endotherm endset, which serves as the temperature 
point where the API fraction is entirely soluble within the polymeric matrix [19–21]. This 
method is prone to errors due to measurements in a non-equilibrated state as a result 
of high heating rates (>2 K/min) or insufficiently large particle sizes, as cryo-milling 
seemed to be necessary for an accurate determination of the melting point endset 
[19,22]. Due to the strong dependency of the resulting solubility on the preparation 
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method, this method is prone to error. The extrapolation to ambient temperature can 
either be performed by using the Flory-Huggins lattice theory [39,40], the empirical 
assumption of Kyeremateng et.al. [21] or the relatively new PC-SAFT (perturbed-chain 
statistical associating fluid theory) software from Sadowski and co-workers, which is 
based on a perturbation theory for chain molecules [44,46–48]. In the case of PC-
SAFT, not only binary mixtures of different API/polymer combinations were investi-
gated [44,46], but also the influence of humidity on the long-term physical stability of 
ASD [47] as well as amorphous-amorphous phase separations [48] were evaluated. 
Indirect solubility determination by Tg 
Indirect measurements of the API solubility in a polymeric matrix are based on analysis 
of annealed or recrystallized samples [22,23]. We employed this approach in our own 
studies. For detailed information, the reader is kindly referred to subsection 4.6.2.2.. In 
the case of the recrystallization method, a supersaturated amorphous solid dispersion 
is prepared by solvent evaporation and annealed at different temperatures. Subse-
quently, the Tg of the annealed sample is analyzed and compared to the API weight 
fraction-dependent course of Tg by employing the Gordon-Taylor equation [49]. Ex-
trapolation to room temperature was conducted by employing the Flory-Huggins lattice 
theory [39,40]. Due to the use of the Gordon-Taylor equation to identify the soluble API 
weight fraction, the weight fraction-dependent course of Tg has to follow this equation. 
Otherwise a regression can only be performed between two measuring points which is 
statistically questionable [50]. However, the comparability of this indirect measurement 
to melting point depression techniques has already been proven [51]. 
Measurement in low molecular weight analogues 
In this method, the measurement is performed in the low molecular weight analogue 
monomer (e.g. 1-ethyl-2-pyrrolidone instead of PVP) of a desired polymer [27,39]. Re-
garding copolymers, the measurements are conducted separately in the respective 
analogous monomers and in dependence of the composition of the copolymer, the 
solubility is calculated. By using a liquid analogue, the API solubility in the low molec-
ular weight analogue can be directly determined at room temperature and it is further 
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extrapolated to the polymer of interest. Therefore, difficulties in achieving an equili-
brated state during solubility measurements of a highly viscous ASD are circumvented. 
However, whether the effect of the polymer’s molecular weight and probable steric 
hindrances are negligible at all times is questionable. Hints of an existing threshold for 
the influence of molecular mobility have already been found [50]. 
4.7.1.1 Comparison of the common measuring techniques 
Upon investigation of the deviation due to different measuring techniques used to ob-
tain API solubility data, no trend was observed to rank the measuring techniques ac-
cording to their reliability (Table 4.2). Conducting the chosen measuring technique in 
an accurate way to ensure the sample is in its equilibrated state during analysis seems 
more important than the method itself. For example, the determined solubility 
(wAPI/wpolymer) of felodipine in PVP seemed more dependent on the working group who 
conducted the experiments than on the measuring technique itself. The felodipine-PVP 
(K12-K90) solubility fraction determined by using the dissolution endpoint method 
ranged between 0.00 and 0.24 [43,52], whereas the use of low molecular weight ana-
logues resulted in a solubility from 0.05 to 0.31 [39,53], independent of the PVP grade 
used. More striking is the discrepancy in solubility data for measurements with an in-
domethacin-COP system by Kyeremateng et al. (0.32 at 25 °C) [21] and by Knopp et 
al. (0.06 at 25 °C) [53], both using the dissolution endpoint method. Although they used 
the same methodology, the obtained indomethacin solubility varied. In comparison to 
other publications, the obtained solubility by Kyeremateng et al. seemed more con-
sistent (Table 4.2) than the one of Knopp et al., leaving the accuracy in solubility de-
termination in the last case questionable. 
4.7.2 Consistency of the obtained literature data set 
To evaluate the consistency within the solubility data in Table 4.2, APIs with a wide set 
of available data were chosen, namely acetaminophen, celecoxib, felodipine, indo-
methacin, naproxen and nifedipine. In most of the cases, the largest data sets were 
obtained for PVP and COP, therefore these two polymers served as the basis to judge 
the accuracy of solubility results. 
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In the case of acetaminophen, the solubility data were mainly derived by Rades and 
co-workers [53,54] or by Sadowski and co-workers [21,47,55]. Regarding the solubility 
of acetaminophen-PVP, it varied from 0.17 to 0.32, whereas the API was insoluble in 
PVAc. Consequently, the solubility in COP (6:4) decreased slightly to 0.21-0.28, com-
pared to PVP. A further COP grade (3:7) with a lower PVP content led to a further 
reduction in solubility to 0.02-0.05. Therefore, a consistent data set in terms of aceta-
minophen could be presented, but with a slight variation in acetaminophen-PVP solu-
bility. Regarding celecoxib, the entire data set for PVP, PVAc and COP was found in 
publications from Rades and co-workers [50,51,53,54], except two data points of our 
own work in COP and SOL. Our measured COP solubility was in good agreement with 
literature. However, the solubility in SOL seemed to be underestimated by our own 
approach. In general, celecoxib was found to be soluble in most of the investigated 
polymers, but its solubility in PVAc might be very low. In the case of felodipine, a wide 
data set reported by a variety of authors was found, namely the obtained solubility in 
PVP ranged from 0.00 to 0.31. Due to the low solubility in PVAc and the average sol-
ubility of 0.21 in COP, the higher solubilities in PVP might be more consistent with the 
overall data set. Furthermore, our results for the felodipine-COP system were in good 
accordance with the overall data set. For indomethacin, a comparably large data set 
to felodipine was obtained. As mentioned above for other APIs, the solubility in PVP 
was highly variable (0.08-0.54), which makes it difficult to comment about the solubility 
of indomethacin in PVP. However, the solubility in COP (6:4, PVP:PVAc) was reported 
in a narrow range of 0.31-0.36. Due to the insoluble indomethacin-PVAc system, a 
PVP-solubility which was higher than the COP-solubility would be plausible. In the case 
of naproxen, mainly two groups of authors had worked on its solubility, Paudel et al. 
[17] and Sadowski and co-workers [21,47,55]. Paudel et al. determined a solubility in 
PVP of 0.06 for naproxen, whereas the group of Sadowski exceeded a solubility of 
0.31 to 0.36. With respect to the low solubility in PVAc and in comparison to the results 
for COP (6:4) in the range of 0.19-0.28, in which our own data point was included, the 
higher solubility of Sadowski and co-workers seemed more reliable. Regarding 
nifedipine, data from Marsac et al. (0.05-0.07 in PVP) [27,28], Kyeremateng et al. (0.21 
in PVP, 0.12 in COP) [21] and solubility of our own investigations (0.19 in COP) were 
obtained. Similar to the afore-mentioned APIs in PVP or COP, for a nifedipine-PVP 
system a solubility around 0.21 seems more plausible than a lower value. Otherwise 
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due to the insoluble nifedipine-PVAc system, the present solubility in COP would be 
unexplainably high. Furthermore, our determined solubility in COP (0.19) was in good 
accordance to literature values [21]. 
To conclude, in most of the regarded cases, a higher solubility in the respective poly-
mer seemed to be more plausible than lower findings. The underestimation of API sol-
ubility might be a reason of measurements in a non-equilibrated state of the system 
under investigation. Therefore, before conducting measurements, the kinetic factor of 
melt viscosity must be considered, and it has to be assured that this is not influencing 
the desired solubility determination. 
4.7.3 Solubility in polymer-dependency 
The focus for this data review was on polymers which can be used to form ASD, either 
by spray-drying or by HME, namely PVP, PVAc, COP, SOL, PMMA, PEG and HPMC 
(Table 4.2). The largest data set was obtained for the various PVP grades, followed by 
COP, SOL and PVAc. Only limited publications were found for PMMA, PEG and 
HPMC. 
For PVP, a variety of molecular weight grades from K12 (approx. 2,500 g/mol) to K90 
(approx. 1,250,000 g/mol) were investigated. In general, no connection or tendency 
between molecular weight and API solubility could be made, which might be also a fact 
of the high variability in API solubility found in literature. However, PVP was the poly-
mer which enabled the highest API solubility throughout the investigated polymers due 
to its high ability to form hydrogen bonds [56]. The highest solubility in PVP was found 
for celecoxib (up to 0.60), indomethacin (up to 0.54) and chloramphenicol (up to 0.52) 
[50,51,53]. In contrast, most APIs were sparely soluble in PVAc, due to the lack of 
specific interactions, especially hydrogen bonding [56]. The API solubility in PVAc did 
not exceeded 0.1 for the entire data set, except for celecoxib where a solubility of up 
to 0.16 was reported [54]. Regarding copovidone COP, consisting of PVP and PVAc 
in different weight ratios, the API solubility was slightly decreased in comparison to 
PVP. Furthermore, a decrease in PVP weight ratios always went hand in hand with a 
further reduction in the respective API solubility [46,50,57]. Therefore, regarding APIs 
in COP, the solubility of an API mainly depended on the hydrogen bonding capability 
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of PVP, whereas PVAc seemed more important for the processability of the copolymer 
than for improving the API solubility. 
In the case of SOL, similar API solubilities compared to COP were achieved. The high-
est solubilities in SOL were found for celecoxib (0.34) naproxen (0.32) and indometh-
acin (0.31) [51]. Regarding the structure of SOL, it consists inter alia of PEG and PVAc 
units. As already stated, PVAc was sparely able to form specific interactions, e.g. hy-
drogen bonding, with a desired API. Thus, instead of the PVAc part, the PEG in SOL 
might be influencing or promoting the API solubility. In the case of indomethacin, the 
API solubilities in PEG (0.22-0.25) and SOL (0.20-0.31) were comparable. Further-
more, ketoconazole was insoluble in both polymers. However, discrepancies in solu-
bility for sulfadimidine (SOL 0.00; PEG 0.12) and sulfathiazole (SOL 0.07; PEG 0.22) 
were found. Thus, due to the limits in the data set, no statement about the solubility-
dependent polymer parts in SOL could be made, except that the PVAc fraction is un-
likely to improve the API solubility. For PMMA and HPMC, again only a limited data set 
was found, which hindered any evaluation. However, the solubility in PMMA or HPMC 
was always lower or comparable to PVP. 
4.7.4 Empirical model of solubility in COP 
We performed an initial assessment of the number of features necessary to separate 
compounds exhibiting 0.2 (w/w) solubility at 100 °C in COP from those that are less 
soluble. The following 12 features were selected from the available 146 features 
(sorted by rank): PEOE_VSA_FPNEG, BCUT_SLOGP_0, std_dim2, b_rotR, a_don, 
SlogP_VSA6, E_tor, balabanJ, Tg, dens, SlogP_VSA8, E_ang. To better estimate the 
number of necessary features, we plotted the balanced accuracy of the models for 
unseen data obtained by recursive feature elimination versus the number of features 
used by the models (Figure 4.1). This plot indicates that the balanced accuracy levels 
off at 71% with 8 features. Further evaluation of the results using up to 12 features 
showed that celecoxib, dipyridamole, gliclazide, lamotrigine, loratadine and probucol 
were mispredicted in almost all cases. This hints at the existence of at least two clus-
ters of compounds, since celecoxib, dipyridamole, gliclazide and lamotrigine were the 
only APIs with a positive deviation from the Couchman-Karasz equation [31] in the 
investigated data set. However, the connection between misprediction and positive 
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deviation from Couchman-Karasz fit remained unclear and could not be ascribed to a 
solubility measuring issue. 
 
Figure 4.1 Balanced accuracy for unseen data obtained by recursive feature elimina-
tion versus the number of features used by the models. 
Performing recursive feature elimination using all compounds resulted in selecting the 
following features (sorted by rank): a_don, SlogP_VSA8, Tg, PEOE_VSA_FPNEG, 
E_oop, b_rotR, SlogP_VSA6, BCUT_SLOGP_0. 
Two different approaches were used in selecting the two sets given above, so differ-
ences between the two sets are possible. However, there is an overlap between both 
sets of selected features. Some of the computed features are of special interest. For 
example, a_don is the number of hydrogen bond donor atoms and 
PEOE_VSA_FPNEG is the fractional negative polar van der Waals surface area. Both 
these features may be important to describe the interaction between the compound 
and COP. b_rotR is the number of rotatable bonds divided by the total number of 
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bonds. Interestingly, the experimentally determined glass transition temperature is se-
lected as well. Using only these 4 features and removing the putative outliers results 
in a training error of zero. 
Further computations need to be carried out to confirm the existence of different sub-
groups of compounds and whether the set of four features may be replaced by other 
combinations with the same or even a lower cardinality.  
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Table 4.2 Solubility review in (w/w) at 25 °C (Methods: Index 1= Melting point depression method; Index 2= Dissolution endpoint 
method; Index 3= Indirect solubility determination by Tg; Index 4= Measurement in low molecular weight analogues; Index 5= others; 
Polmers: PVP (K-value); COP (PVP:PVAc ratio); PEG (mol>ecular weight); PMMA (EPO: Eudragit® E PO/ E100: Eudragit® E100/ 
L100: Eudragit® L100); HPMC (E5: Ethocel® E5/ AS: HPMC acetate succinate)). 
API Polymer       
PVP PVAc COP SOL PEG PMMA HPMC 
Aceclofenac    0.271 [58]    
Acetaminophen 0.175 (K17) [54] 
0.184 (K17) [53] 
0.195 (K17) [54] 
0.232 (K25) [21,47] 
0.291 (K17) [54] 
0.322 (K25) [47,55] 
 
0.004 [53] 
0.011 [54] 
0.015 [54] 
0.015 [54] 
0.212 (6:4) [21,47] 
0.282 (6:4) [47,55] 
 
0.022 (3:7) [53] 
0.033 (3:7) [53] 
0.051 (3:7) [53] 
0.054 (3:7) [53] 
0.041 [54] 
0.095 [54] 
0.105 [54] 
  0.022 (AS) [55] 
Albendazole   0.041 (6:4) [59] 0.061 [59]  0.021 (EPO) [59]  
Bisacodyl   0.083 (6:4) 0.223    
Carbamazepine  0.023 (K12) [51]  0.003 (6:4) 0.001 [42] 
0.003 
   
Celecoxib (1) 0.383 (K12) [51] 
0.385 (K17) [54] 
0.385 (K17) [54] 
0.403 (K12) [60] 
0.414 (K17) [53] 
0.023 [60] 
0.034 [53,60] 
0.081 [54] 
0.135 [54] 
0.165 [54] 
0.062 (6:4) [53] 
0.173 (6:4) [53] 
0.251 (6:4) [53] 
0.264 (6:4) [53] 
0.333 (6:4) 
0.093 
0.235 [54] 
0.235 [54] 
0.251 [54] 
0.291 [51] 
 0.205 (EPO) [26] 
0.411 (EPO) [26] 
0.253 [51] 
0.321 [51] 
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API Polymer       
PVP PVAc COP SOL PEG PMMA HPMC 
Celecoxib (2) 0.431 (K17) [54] 
0.441 (K12) [51] 
0.604 (K12) [60] 
 0.333 (6:4) [60] 
0.384 (6:4) [60] 
 
0.083 (3:7) [60]  
0.184 (3:7) [60] 
0.203 (5:5) [60] 
0.264 (5:5) [60] 
0.363 (7:3) [60] 
0.424 (7:3) [60] 
0.343 [51]    
Chloramphenicole 0.395 (K17) [54] 
0.405 (K17) [54] 
0.401 (K17) [54] 
0.524 (K17) [53] 
0.004 [53] 
0.041 [54] 
0.055 [54] 
0.065 [54] 
0.052 (5:5) [53] 
0.143 (5:5) [53] 
0.151 (5:5) [53] 
0.264 (5:5) [53] 
0.115 [54] 
0.141 [54] 
0.145 [54] 
 
   
Cilostazol  0.001 (K29/32) [61]  0.001 (6:4) [61] 
0.003 (6:4) 
0.003   0.001 (E5) [61] 
Cinnarizine  0.011 (K30) [62]   0.001 [16]    
Clozapine    0.003 (6:4) 0.003    
Curcumin  0.001 (K90) [63]    0.001 (8000) [63] 0.001 (EPO) [63] 0.001 (E5) [63] 
Dipyridamole 0.001 (K30) [62]  0.033 (6:4) [23] 0.183 [23]    
Felodipine (1) 0.002 (K25) [43] 
0.032 (K15) [43] 
0.054 (K17) [53] 
0.002 [65] 
0.044 [53] 
0.002 (6:4) [43] 
0.112 (6:4) [65] 
0.223 (6:4) 
0.002 [64] 
0.203 
 
 0.002 (EPO) [66] 
0.205 (EPO) [26] 
0.311 (EPO) [26] 
0.002 (AS) [64] 
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API Polymer       
PVP PVAc COP SOL PEG PMMA HPMC 
Felodipine (2) 0.061 (K17) [53] 
0.072 (K12) [43] 
0.074 (K12) [27] 
0.073 (K17) [53] 
0.074 (K29/32) [27] 
0.074 (K90) [27] 
0.082 (K17) [53] 
0.102 (K15) [64]  
0.185 (K29/32) [25] 
0.242 (K25) [65] 
0.254 (K29/32) [39] 
0.314 (K12) [39] 
 0.305 (6:4) [26] 
0.421 (6:4) [26] 
    
Gliclazide    0.003 (6:4) 0.083    
Griseofulvin 0.095 (K30) [24]  0.003 (6:4) 0.003   0.095 (E100) [24] 
0.125 (L100) [24] 
 
Ibuprofen 0.502 (K25) [65] 0.052 [65] 0.412 (6:4) [65]     
Ibuprofen sodium   0.002 (6:4) [21] 0.002 [21]    
Indomethacin (1) 0.085 (K30) [24] 
0.134 (K90) [27] 
0.134 (K29/32) [27] 
0.144 (K12) [27] 
0.201 (K30) [67] 
0.001 [67] 
0.002 [19–21] 
0.012 [39] 
0.014 [46] 
0.311 (6:4) [67] 
0.322 (6:4) [19–21] 
0.331 (6:4) [18] 
0.342 (6:4) [46] 
0.363 (6:4) [23] 
0.203 [51] 
0.263 [23] 
0.311 [51] 
0.222 (6000) [44] 
0.252 (35000) [44] 
0.095 (E100) [24] 
0.105 (L100) [24] 
0.083 [51] 
0.271 [51] 
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API Polymer       
PVP PVAc COP SOL PEG PMMA HPMC 
Indomethacin (2) 0.271 (K12) [67] 
0.303 (K12) [22] 
0.314 (K17) [53] 
0.314 (K25) [68] 
0.314 (K30) [68] 
0.314 (K90) [68] 
0.334 (K12) [68] 
0.393 (K30) [68] 
0.403 (K12) [68] 
0.403 (K90) [68] 
0.413 (K25) [68] 
0.415 (K29/32) [25] 
0.432 (K12, K15) [19–
21] 
0.432 (K25) [46] 
0.541 (K12) [51] 
0.543 (K12) [51] 
 0.062 (7:3) [53]  
0.193 (7:3) [53] 
0.224 (7:3) [53] 
0.351 (7:3) [53] 
0.212 (3:7) [46] 
    
Itraconazole  0.095 (K30) [24]  0.002 (6:4) [21] 
0.003 (6:4) [23] 
0.002 [21] 
0.003 [23] 
0.001 (6000) [62] 0.085 (E100) [24] 
0.135 (L100) [24] 
 
Ketoconazole 0.014 (K12) [27] 
0.014 (K29/32) [27] 
0.014 (K90) [27] 
     0.002 [70] 
  
 
 
69 
API Polymer       
PVP PVAc COP SOL PEG PMMA HPMC 
Lacidipine 0.001 (K12) [67] 
0.001 (K30) [67] 
0.001 [67] 0.001 (6:4) [67]  0.051 (8000) [67] 
0.221 (10000) [67] 
  
Loratadine   
 
 0.003 (6:4) 0.003     
Mannitol 0.002 (K12, K15) [19–
21] 
      
Naproxen 0.064 (K12) [17] 
0.064 (K25) [17] 
0.064 (K90) [17] 
0.312 (K25) [21,47] 
0.312 (K25) [47,55] 
0.362 (K25) [46] 
0.012 [46] 0.192 (6:4) [46] 
0.212 (6:4) [47,55] 
0.253 (6:4) 
0.282 (6:4) [21,47] 
 
0.072 (3:7) [46] 
0.323   0.032 (AS) [55] 
Nifedipine 0.054 (K12) [27] 
0.054 (K29/32) [27] 
0.054 (K90) [27] 
0.064 (K29/32) [39] 
0.074 (K12) [39] 
0.212 (K12) [19–21] 
0.002 [20,21] 0.122 (6:4) [19–21] 
0.193 (6:4) [23] 
0.051 [71] 
0.233 [23] 
 
   
Posaconazole   0.003 (6:4) 0.003    
Praziquantel   0.003 (6:4) 0.003    
Probucol   0.143 (6:4) 0.133    
Ritonavir (1) 0.261 (K12) [51]  0.033 (6:4) 0.003    
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API Polymer       
 PVP PVAc COP SOL PEG PMMA HPMC 
Ritonavir (2)    0.001 [51]    
Sucrose 0.024 (K12) [27] 
0.024 (K29/32) [27] 
0.024 (K90) [27] 
   0.001 (6000) [41]   
Sulfadiazine 0.002 (K17) [72]   0.002 [72]    
Sulfadimidine 0.182 (K17) [21,72]   0.002 
[21,72] 
0.122 (35000) [44]   
Sulfamerazine 0.112 (K17) [21,72]   0.002 [72]    
Sulfamethoxazole    0.131 [71]    
Sulfathiazole 0.272 (K17) [21,72]   0.072 
[21,72] 
0.222 (35000) [44]   
Tadalafil   0.253 (6:4) [13]     
Telmisartan 0.002 (K25) [73]  0.003 (6:4) 0.002 [73]  0.002 (E100) [73] 0.002 (E5) [73] 
Temazepam 0.001 (K30) [74]    0.031 (6000) [74]   
Verapamil-HCl   0.003 (6:4)     
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4.8 Conclusion 
We compiled data available in literature on API solubility in polymers. The final data 
set comprises seven polymers (PVP, PVAc, COP, SOL, PEG, PMMA and HPMC), 37 
APIs and two sugar derivatives in total. It also includes our own so far unpublished 
data set which was found to be consistent with previously published data. The majority 
of studies used the melting point depression method, dissolution endpoint measure-
ments, indirect solubility determination by Tg or low molecular weight analogues. It ap-
pears that the resulting API solubility depended not only on the method used, but rather 
more on the working group and authors who conducted the measurements. The API 
solubility measurement itself is prone to bias due to difficulties in reaching the equili-
brated state of a system prior any solubility determination. Hence, working group-spe-
cific analytical methods, once inadequately chosen, seemed to be maintained. Further-
more, no simple relation between API solubility and the molecular weight of PVP was 
observed. PVP always exhibited the highest API solubility, whereas APIs showed the 
poorest solubility in PVAc. This is underlined by the findings for COP, a copolymer of 
PVP and PVAc. Here, the API solubility changes as a function of the PVP/PVAc ratio. 
Only a limited number of publications were found for PEG, PMMA and HPMC and 
therefore no statement considering these polymers can be made. In conclusion, a com-
parison of the available data set and models in literature on the API solubility prediction 
in polymeric matrices has been made. Using the example of COP we have shown that 
the data now available may be utilized in developing fast computational models to pre-
dict the solubility in polymers. In summary, this data review should assist researchers 
in choosing a prediction method suited for their studies and the data set presented 
here should facilitate training newly developed solubility prediction models. 
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4.11 Appendix A: Empirical model of solubility in COP 
A.1. Data used 
To predict if the solubility at 100°C is at least 0.2 (w/w), we used R, a freely available 
language and environment for statistical computing and graphics [1]. Molecular de-
scriptors of the compounds in Table 1 were computed with MOE [2]. These data were 
imported into our program using ChemmineR [3] and enriched with data from our ex-
periments as well as those found in the PubChem database [4]. 
A.2. Initial model building using LASSO 
To obtain an initial estimate of the number of descriptors necessary to separate soluble 
and insoluble compounds, we performed regularized logistic regression using the 
package glmnet [5]. We used the LASSO regularization, which basically adds a penalty 
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term |β1| to the log likelihood function used in regular logistic regression. Simply put, 
LASSO sets the coefficients of features that contribute most to the error of the model 
to zero. Thus, LASSO regression may be used for feature selection. 
A.3. Optimal number of features 
Then, to obtain an estimate of the error for new (unseen) data as a function of the 
number of features employed we performed nested leave-one out crossvalidation 
(LOOCV). The outer loop was used to predict the binary outcome (soluble at 100 °C: 
yes/no), while the inner loop was used to train the hyperparameter of the regularized 
logistic regression model. Prior to training a model, the features were standardized 
such that the mean and standard deviation of all features in the training set were zero 
and one, respectively. The features of the left-out compound were standardized using 
the values of the training set. Regularized regression modelling was performed using 
the LiblineaR package [6]. Balanced accuracy was used for the selection of the hy-
perparameter and to assess the predictive accuracy and was computed using the 
package caret [7]. 
By leaving out one compound, a first model was trained using the 146 features for the 
remaining 20 compounds (outer loop). The optimal value for the hyperparameter of 
this model was identified by leave-one out crossvalidation and a given sequence of 
values for the hyperparameter (inner loop). The solubility of the left-out compound was 
predicted, and the result was stored for later use. The least-ranking feature was re-
moved, and the process was repeated until only a single feature remained (recursive 
feature elimination). The whole process was performed for each compound in turn. 
By plotting the predictive accuracy as a function of the number of features used we 
may estimate the optimal number of features. We restricted the plot to the number of 
features selected by the LASSO approach and observed the predictive accuracy lev-
eling off when using 8 features. 
A.4. Final feature selection 
The final set of 8 features was selected by recursive feature elimination as above. 
However, all compounds were used for building the nested models.  
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4.12 Appendix B: detailed compilation of physicochemical characteristics of 
APIs and sugar derivates under investigation 
 
 
API MW [g/mol] Tm [°C] H(fus) [J/g] Tg [°C]
ΔCp at Tg 
[J/(g*K)] Tm/Tg [-]
True density 
(g/cm^3)
Aceclofenac 354,2 149,3 144,3 15,0 - 10,0 1,5
Acetaminophen 151,2 170,5 193,5 23,3 0,6 7,3 1,2
Albendazole 265,3 197,7 145,57 61,2 0,2 3,2 1,4
Bisacodyl 361,4 133,6 101,35 16,1 0,4 8,3 1,3
Carbamazepine 236,3 175,1 43,4 52,7 0,4 3,3 1,3
190,2 92,4 3,6
Celecoxib 381,4 160,9 95,8 56,8 0,4 2,8 1,5
Chloramphenicol 323,1 150,0 92,91 29,5 0,5 5,1 1,5
Cilostazol 369,5 158,6 124,9 31,2 0,5 5,1 1,3
Cinnarizine 368,5 118,3 102,2 8,6 0,6 13,8 1,1
Clozapine 326,8 182,1 59,7 59,7 0,4 3,1 1,3
Curcumin 368,4 176,0 113,46 69,0 0,5 2,6 0,9
Dipyridamole 504,6 167,1 55,3 38,2 0,7 4,4 1,3
Felodipine 384,3 144,2 78,4 45,0 0,3 3,2 1,4
Gliclazide 323,4 170,5 124,6 39,6 0,5 4,3 1,2
Griseofulvin 352,8 218,3 113,9 88,9 0,3 2,5 1,5
Ibuprofen 206,3 75,3 105,5 -44,4 0,4 -1,7 1,1
Ibuprofen sodium 228,3 200,1 72,24 - - - 1,2
Indomethacin 357,8 160,1 87,7 44,4 0,3 3,6 1,4
Itraconazole 705,6 165,8 74,2 57,7 0,4 2,9 1,4
Ketoconazole 531,4 148,1 101,81 42,9 0,3 3,5 1,3
Lacidipine 455,6 182,1 110,3 43,7 - 4,2 -
Lamotrigine 256,1 215,8 136,15 93,3 0,5 2,3 1,6
Loratadine 382,9 134,6 72,1 34,9 0,3 3,9 1,3
Mannitol 182,2 166,1 328,7 12,6 - 13,2 1,5
Naproxen 230,3 156,1 124,4 6,7 0,3 23,3 1,3
Nifedipine 346,3 172,2 98,2 44,3 0,3 3,9 1,4
Posaconazole 700,8 167,7 63,9 59,8 0,4 2,8 1,3
Praziquantel 312,4 138,3 95,2 35,9 0,4 3,9 1,2
Probucol 516,8 126,3 64,6 25,6 0,5 4,9 1,1
Ritonavir 720,9 121,8 90,2 48,6 0,5 2,5 1,3
Sucrose 342,3 189,3 132,8 66,1 0,6 2,9 1,4
Sulfadiazine 250,3 259,9 159,41 not measurable - 1,5
Sulfadimidine 278,3 196,7 129,35 74,0 0,5 2,7 1,3
Sulfamerazine 264,3 237,1 138,86 62,0 0,8 3,8 1,4
Sulfamethoxazole 253,3 169,9 113,3 15,9 - 10,7 1,4
Sulfathiazole 255,3 201,7 112,42 58,0 0,4 3,5 1,5
Tadalafil 389,4 302,3 120,29 149,9 - 2,0 -
Telmisartan 514,6 268,3 108,7 129,5 0,4 2,1 1,3
Temazepam 300,7 159,4 90,9 66,1 0,3 2,4 -
Verapamil-HCl 491,1 142,3 112,2 55,2 0,5 2,6 1,3
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API
molar volume 
[cm^3/mol]
H-donors 
[-]
H-acceptors [-
]
Ionization 
potential [eV] logP [-] logS [-]
Aceclofenac 2 5 -5,2
Acetaminophen 187,9 2 2 9,50 1,42 -1,6
Albendazole 953,5 2 4 9,87 3,32 -4,1
Bisacodyl 244,0 0 5 10,05 1,86 -5,5
Carbamazepine 314,9 1 1 9,08 4,15 -3,2
Celecoxib 294,2 1 7 7,70 5,30 -4,9
Chloramphenicol 227,60 3 5 7,88 1,82 -2,8
Cilostazol 344,3 1 5 10,70 3,60 -4,1
Cinnarizine 749,8 0 2 8,87 4,98 -5,3
Clozapine 514,8 1 4 10,87 1,48 -3,2
Curcumin 2 6 -4,8
Dipyridamole 887,9 4 12 8,11 0,11 -2,7
Felodipine 347,4 1 5 10,82 4,29 -4,7
Gliclazide 300,0 2 4 9,18 3,43 -3,2
Griseofulvin 13,6 0 6 11,59 2,81 -3,8
Ibuprofen 222,3 1 2 8,55 3,07 -3,5
Ibuprofen sodium 0 2
Indomethacin 1008,1 1 4 8,31 3,93 -5,2
Itraconazole 697,2 0 9 10,00 5,71 -4,9
Ketoconazole 587,7 0 6 9,93 4,21 -4,8
Lacidipine 1 7 -5,3
Lamotrigine 292,6 2 5 11,14 3,17 -2,7
Loratadine 445,9 0 3 10,00 4,83 -4,5
Mannitol 218,2 6 6 10,21 999,00 0,1
Naproxen 394,1 1 3 7,71 3,04 -3,6
Nifedipine 288,9 1 7 9,06 3,03 -4,3
Posaconazole 703,1 1 11 8,15 4,70 -4,8
Praziquantel 496,6 0 2 8,06 2,41 -2,9
Probucol 477,8 2 4 9,13 9,91 -7,1
Ritonavir 2085,8 4 9 10,00 7,08 -5,8
Sucrose 238,3 8 11 7,89 1,59 0,4
Sulfadiazine 225,0 2 6 10,00 2,59 -2,6
Sulfadimidine 292,0 2 6 10,00 3,21 -3,1
Sulfamerazine 2 6 -2,9
Sulfamethoxazole 217,65 2 6 9,33 3,10 -2,7
Sulfathiazole 2 6 -2,4
Tadalafil 480,5 1 4 7,35 2,09 -3,2
Telmisartan 546,1 1 4 7,95 7,26 -5,2
Temazepam 414,9 1 3 10,50 1,97 -3,8
Verapamil-HCl 571,3 1 6 6,39 5,09 -5,1
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API
refractive 
index [-]
dipole moment 
[Debye] Specific references
Aceclofenac Tm, Tg, ρ, H(fus) [51]
Acetaminophen 1,33 2,7 Tg, ΔCp, ρ, H(fus) [46]; Tm [40]
Albendazole 1,55 9,9
Bisacodyl 1,85 3,1
Carbamazepine 1,40 2,9
Celecoxib 1,45 2,0
Chloramphenicol 1,57 2,7 Tg, ΔCp, ρ, [46]
Cilostazol 1,28 2,7
Cinnarizine 1,40 1,2
Tm, H(fus) [16]; Tg, ρ [55];  ΔCp [A. Alhalaweh, A. Alzghoul, D. 
Mahlin, C.A.S. Bergström, Physical stability of drugs after storage 
above and below the glass transition temperature: Relationship to 
glass-forming ability, International Journal of Pharmaceutics. 495 
(2015) 312–317. doi:10.1016/j.ijpharm.2015.08.101.]
Clozapine 1,17 2,0
Curcumin Tm, Tg, H(fus), ΔCp, ρ [56]
Dipyridamole 1,36 1,7
Felodipine 1,39 2,7
Gliclazide 1,41 2,7
Griseofulvin 99,00 2,7
Ibuprofen 1,56 2,4
Ibuprofen sodium
Tm, H(fus),ρ [R. Censi, V. Martena, E. Hoti, L. Malaj, P. Di Martino, 
Sodium ibuprofen dihydrate and anhydrous: Study of the 
dehydration and hydration mechanisms, Journal of Thermal 
Analysis and Calorimetry. 111 (2013) 2009–2018. 
doi:10.1007/s10973-012-2194-9.]
Indomethacin 1,53 2,7
Itraconazole 1,32 2,0
Ketoconazole 1,24 2,7 Tm, H(fus), ρ [27]
Lacidipine Tm, H(fus), Tg [60]
Lamotrigine 1,41 1,4
Loratadine 1,34 2,7
Mannitol 1,29 2,8 Tm, H(fus), Tg [60]
Naproxen 1,61 2,7
Nifedipine 1,55 2,0
Posaconazole 1,32 2,0
Praziquantel 1,27 2,3
Probucol 1,39 3,9
Ritonavir 1,48 2,7
Sucrose 1,24 3,9 Tm, H(fus) [60]; ρ [27]
Sulfadiazine 1,59 1,2 Tm, H(fus), Tg, ΔCp, ρ [65]
Sulfadimidine 1,51 1,2 Tm, H(fus), Tg, ΔCp, ρ [65]
Sulfamerazine Tm, H(fus), Tg, ΔCp, ρ [65]
Sulfamethoxazole 1,43 1,6 Tm, H(fus), Tg, ρ [64]
Sulfathiazole Tm, H(fus), Tg, ΔCp, ρ [65]
Tadalafil 1,12 2,7
Tm, Tg [13]; H(fus) [J.-S. Choi, J.-S. Park, Design of PVP/VA S-630 
based tadalafil solid dispersion to enhance the dissolution rate, 
European Journal of Pharmaceutical Sciences. 97 (2017) 269–276. 
doi:10.1016/j.ejps.2016.11.030.]
Telmisartan 1,65 2,7
Temazepam 1,28 3,0
Tm, H(fus), Tg [67];  ΔCp [G. Van den Mooter, P. Augustijns, R. 
Kinget, Stability prediction of amorphous benzodiazepines by 
calculation of the mean relaxation time constant using the 
Williams–Watts decay function, European Journal of Pharmaceutics 
and Biopharmaceutics. 48 (1999) 43–48. doi:10.1016/S0939-
6411(99)00013-2.]
Verapamil-HCl 1,22 1,2
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General references
Molecular weight
PubChem database [S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, 
G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, J. 
Wang, B. Yu, J. Zhang, S.H. Bryant, PubChem Substance and 
Compound databases, Nucleic Acids Research. 44 (2016) 
D1202–D1213. doi:10.1093/nar/gkv951.]
H-acceptors
PubChem database [S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, 
G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, J. 
Wang, B. Yu, J. Zhang, S.H. Bryant, PubChem Substance and 
Compound databases, Nucleic Acids Research. 44 (2016) 
D1202–D1213. doi:10.1093/nar/gkv951.]
H-donors
PubChem database [S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, 
G. Fu, A. Gindulyte, L. Han, J. He, S. He, B.A. Shoemaker, J. 
Wang, B. Yu, J. Zhang, S.H. Bryant, PubChem Substance and 
Compound databases, Nucleic Acids Research. 44 (2016) 
D1202–D1213. doi:10.1093/nar/gkv951.]
Ionization potential Estimated with MOPAC6
logP estimated with ObenBabel 2.4.0
logS
Drugbank.ca database, estimated with ALOGPS  [D.S. Wishart, 
Y.D. Feunang, A.C. Guo, E.J. Lo, A. Marcu, J.R. Grant, T. Sajed, 
D. Johnson, C. Li, Z. Sayeeda, N. Assempour, I. Iynkkaran, Y. 
Liu, A. Maciejewski, N. Gale, A. Wilson, L. Chin, R. Cummings, 
D. Le, A. Pon, C. Knox, M. Wilson, DrugBank 5.0: a major 
update to the DrugBank database for 2018, Nucleic Acids 
Research. 46 (2018) D1074–D1082. doi:10.1093/nar/gkx1037.]
refractive index Estimated with method adopted from van Krevelen and Vogel
dipole moment Estimated with MOPAC6
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5.1 Graphical abstract 
 
5.2 Abstract 
The feasibility of predicting melt rheology by using the glass transition temperature (Tg) 
of a desired amorphous solid dispersion (ASD) for hot-melt extrusion (HME) and other 
melt-based processes is presented. Three groups of three different active pharmaceu-
tical ingredients (APIs) or plasticizer/copovidone mixtures, with identical glass transi-
tion in rheological testing, were used. Their rheological behavior as a function of tem-
perature and frequency were analyzed by means of small amplitude oscillatory shear 
(SAOS) on an oscillatory rheometer. The zero-shear viscosity (η0) identified at 150 °C 
was compared to Tg, measured by differential scanning calorimetry (DSC) and SAOS. 
A strong correlation between η0 and Tg was identified, independent of the API or plas-
ticizer used to achieve Tg of the mixture. To evaluate and rate the discrepancy in η0 of 
the different mixtures at same Tg, hot-melt extrusion trials were conducted to measure 
torque and mean residence time. In this paper, carbamazepine, dipyridamole, indo-
methacin, ibuprofen, polyethylene glycol (PEG 1500) in vinylpyrrolidone-vinyl acetate 
copolymer (copovidone) as matrix polymer were used. 
5.3 Keywords 
Hot-melt extrusion, melt rheology, glass transition temperature, amorphous solid dis-
persion, small amplitude oscillatory shear, prediction model 
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5.4 Chemical compounds studied in this article 
Carbamazepine (PubChem CID: 2554); Dipyridamole (PubChem CID: 3108); 
Ibuprofen (PubChem CID: 3672); Indomethacin (PubChem CID: 3715); Nifedipine 
(PubChem CID: 4485); Itraconazole (PubChem CID: 55283); Furosemide (PubChem 
CID: 3440) 
5.5 Introduction 
In recent years, hot-melt extrusion (HME) as a solvent free and rational to scale pro-
cess has been gaining more and more attention, especially for the production of amor-
phous solid dispersions (ASDs) to increase bioavailability of poorly soluble active phar-
maceutical ingredients (APIs) [1]. Despite the given availability of small scale extruders 
for early formulation development, the material consumption exceeds usually 10 g per 
batch for small scale extruders comprising a modular screw design. Often the API is 
expensive and/or its availability limited. Therefore, microscale tests and simulations to 
minimize the effort for setting-up extrusion trials close to optimal conditions are re-
quired. To identify a suitable matrix polymer for forming a thermodynamically stable 
ASD with a specific API, various prediction methods to determine the solubility of an 
API in a polymeric matrix have been reported [2–8]. Concerning the extrusion process 
itself, simulation software attracts more and more attention to estimate good starting 
conditions for HME trials but, relies heavily on the availability of viscosity data for the 
formulation of interest [9–11]. 
Out of the nature of the process, melt rheology of the material to be extruded is useful 
[12,13] for process design and control and can even be performed in material sparing 
micro-scale assays. Melt rheology as an expression of applied shear and resulting vis-
cosity influences the temperature profile along screws, energy input or viscous heat 
dissipation, torque (motor load) and hence the extrusion performance [1,12,14]. The 
viscosity of obtained extrudates can be changed by screw speed during extrusion 
(shear rate variation) [15]. Furthermore, viscosity is an important factor for process 
control and for the minimization of energy input by screw design, screw speed, through-
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put or the addition of plasticizer. In general, plasticizer is not recommended as it in-
creases the drug’s mobility in the more flexible polymer matrix. Even more, viscosity is 
an essential input variable for process simulation. Therefore, rheological testing in-
forms the optimal process parameter set-up for HME [16–18]. By using melt rheology 
prior to extrusion, the effort associated with process development can be minimized 
and number of trials needed to achieve the desired condition for extrusion can be re-
duced. For instance, the easy accessible zero-shear viscosity (η0), which is indicating 
the viscosity at finite small shear rates, can be used as a polymer screening tool for 
HME [19]. However, polymer melts exhibit a shear thinning behavior, therefore the 
zero-shear viscosity does not reflect the rheological properties in HME processes at 
higher applied shear rates. 
Generally, two different types of rheometric systems are available for polymer melts, 
capillary or oscillatory rheometers [13]. Capillary rheometers have the advantage that 
they directly investigate the shear rate range close to that generated in the HME pro-
cess, but their use is limited. First, they require the use of large amounts of material, 
on the order of > 10 g per measurement, which is cost prohibitive in the early stages 
of pharmaceutical product development. In addition, due to force and as such pressure 
limitations of the capillary rheometer to push the material out of the cylinder through 
the die, lower temperatures were not feasible. The applicable temperature range of the 
capillary rheometer was hence smaller compared to small amplitude oscillatory shear 
(SAOS) measurements [20–22]. Another advantage of SAOS rheology is the far lower 
material consumption (< 1 g) compared to capillary rheology. Furthermore, SAOS en-
ables a viscoelastic characterization of materials which is important in hot-melt extru-
sion since a plastic deformation is required to obtain a homogeneous extrusion strand. 
Unfortunately, melt rheology is still a time-consuming business and trained personal is 
needed. A full characterization (e.g. in shear rate- and temperature-dependency) of 
one melt via SAOS can consume three to five working days. 
Regarding the viscosity of ASDs, the dissolved API usually acts as a solid state plasti-
cizer in the API-polymer melt if its glass transition temperature (Tg) is lower than the 
one of the polymer, decreasing the zero-shear viscosity [20,23–25]. This plasticizing 
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effect can be characterized easily by a decrease in Tg by means of differential scanning 
calorimetry (DSC). Of course, different API-polymer blends will achieve different Tg 
and will end up with different melt viscosity, even when API concentration is constant. 
The question is, whether other aspects, e.g. shear rate- or temperature-dependency 
of the polymer melt viscosity, do change if the Tg of the API-polymer blend is similar 
and only the API (i.e. chemical species) is exchanged? Our hypothesis was that a 
change in Tg would only cause a "constant" shift in shear rate and temperature de-
pendence of the rheological profile of the pure polymer, independent of the API or 
plasticizer used, due to the Tg being connected to a specific change in the melt viscos-
ity. Therefore, our hypotheses assume that only the mobility of polymeric chain is in-
fluenced by the addition of an API or plasticizer but without changing the polymeric 
chain architecture in general. If our assumption is true, a simple Tg measurement by 
DSC would provide the necessary additional information concerning the desired API-
polymer melt viscosity, given the general melt behavior of the pure polymer is already 
known. Confirmation of the validity of our hypothesis would lead to a tremendous ease 
in HME development, since the only information required for extrusion set-up will be 1) 
the rheological behavior of the pure polymer and 2) the decrease in Tg by the plasticiz-
ing effect of an API or plasticizer, independent of its nature.  
The purpose of this work was hence to characterize the influence of PEG 1500 and 
various APIs on the melt rheological behavior of copovidone and to correlate it with the 
glass transition temperature of the API-polymer blends used. The variation in viscosity 
profiles and their potential effect on the HME process is evaluated. Only APIs which 
are completely soluble in the polymer melt have been considered. 
In addition, the authors are aware of specific interactions, such as hydrogen bonding, 
which will influence the viscosity to an unknown and unpredictable extent [26,27]. How-
ever, the prediction of shear viscosity via DSC measurement might be suitable to set-
up early HME simulation and extrusion trials, saving costs and time. 
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5.6 Material and methods 
5.6.1 Material 
Dipyridamole (DPD) was obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA), Indomethacin (IMC) and PEG 1500 (PEG) were purchased from Alfa Aesar 
(Karlsruhe, Germany). Vinylpyrrolidone-vinyl acetate copolymer (copovidone, Kol-
lidon® VA64, COP), Carbamazepine (CBZ) and Ibuprofen (IBU) were provided by 
BASF SE (Ludwigshafen, Germany) (Table 5.1). The APIs were chosen due to their 
different glass transition temperatures (Table 5.1), high (DPD) or low (IBU, IMC) re-
crystallization tendencies, high (IMC) or low (CBZ) solubilities in COP, and high (PEG) 
or low (all API) molecular weights. 
Table 5.1 Physicochemical properties of substances under investigation. 
Substance Molecular weight 
[g/mol] 
Melting point 
[°C] 
Glass transition 
temperature [°C] 
Indomethacin (IMC) 358 160 44 
Carbamazepine (CBZ) 236 175 53 
Dipyridamole (DPD) 505 167 38 
Ibuprofen (IBU) 206 75 -44 
PEG 1500 (PEG) 1,500 47 -42 
Copovidone (COP) 45,000 - 70,000 - 107 
 
5.6.2 Methods 
5.6.2.1 Preparation of physical mixtures 
For DSC trials, a MM400 ball mill from Retsch GmbH (Haan, Germany) with 30 Hz and 
3x 5 min milling cycles was used. In the case of rheological trials, a batch mill (Tube 
Mill control, IKA®-Werke GmbH & Co.KG, Staufen, Germany) with 15000 rpm for 
10 sec and additional 5 sec after some minutes was employed, except mixtures con-
taining PEG 1500. Those with PEG 1500 were treated with an agate mortar and pestle 
instead to ensure homogeneous mixing. For extrusion trials, physical mixtures were 
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prepared by using a Turbula mixer (Willy A. Bachofen AG – Maschinenfabrik, Muttenz, 
Swiss) for 10 min at 22 rpm. 
5.6.2.2 Defining the API or plasticizer weight fraction by rheological trials 
The content of API or plasticizer in its copovidone blend was experimentally adjusted 
to a specific transition temperature (Tg, Rheo) by means of rheological measurements 
(temperature sweeps, see below). Due to their Tg, Rheo, three groups consisting of three 
different blends were defined based on which had similar glass transitions to compare 
their rheological behavior in further experiments (Table 5.2). In this way, defined weight 
fractions of API or plasticizer were characterized as soluble in copovidone in our pre-
vious work [4]. 
Table 5.2 Determined weight fractions of API or PEG/COP mixtures used, adjusted to 
their Tg in SAOS and corresponding Tg in DSC. 
Mixture weight fraction [-] Tg identified by 
tan(δ) [°C] 
Tg identified by 
DSC [°C] 
COP - 126 107 
Group 1 (Tg, Rheo: ~124 °C; Tg, DSC: ~102 °C) 
IMC/COP 0.050 123 102 
PEG/COP 0.014 125 102 
CBZ/COP 0.047 125 103 
Group 2 (Tg, Rheo: ~117 °C; Tg, DSC: ~91 °C) 
IMC/COP 0.200 116 91 
PEG/COP 0.040 118 92 
DPD/COP 0.325 118 91 
Group 3 (Tg, Rheo: ~104 °C; Tg, DSC: ~80 °C) 
IMC/COP 0.450 103 79 
PEG/COP 0.085 104 76 
IBU/COP 0.105 104 86 
 
5.6.2.3 Rheometry (SAOS) 
An oscillatory rheometer (Haake® MARS® III, Thermo Scientific, Karlsruhe, Germany) 
equipped with a plate-plate geometry (d = 20 mm) was used. All experiments were 
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conducted at least three times in controlled deformation AutoStrain mode with a gap 
height of 0.75 mm. Amplitude sweeps conducted at the beginning verified that an am-
plitude of 5 % was suitable for all rheological tests. 
To compare the results of SAOS with DSC experiments later, a transition temperature 
(Tg, Rheo) was identified by temperature sweeps with an angular frequency of 6.28 rad/s 
(1 Hz), where the blend was softened and subsequently cooled down (3 K/min) until 
the peak of loss factor tan(δ) (Eq. (5.1)) was exceeded. This local peak (or maximum) 
of tan(δ) determines the point where the material behaves equally elastic and plastic 
at same time. Below this point, the elastic properties dominate, whereas above this 
point the polymer melt act more viscous. The inflection point of tan(δ) was identified as 
Tg, Rheo (Fig 5.1). 
𝑡𝑎𝑛(𝛿) =
𝐺′′
𝐺′
         (5.1) 
 
Figure 5.1 Temperature sweep of copovidone with the local peak of tan(δ) deter-
mined as transition temperature as an example. 
Frequency sweeps were conducted from 62.83 rad/s (10 Hz) to 0.63 rad/s (0.1 Hz) in 
10 K steps in a suitable temperature range (Fig 5.2a). To identify the temperature 
range where the specimen was thermorheologically simple during frequency sweeps, 
the van Gurp-Palmen plot was employed (Fig 5.2b) and identified the application of 
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time temperature superposition (TTS) as suitable. In TTS, all frequency sweeps were 
horizontally shifted into one master curve (Fig 5.2c) at a prior set reference tempera-
ture.  
 
Figure 5.2a-d Frequency sweeps (a), van Gurp-Palmen plot (b) and resulting master 
curve (c) with corresponding shift factors aT (d) of copovidone at 150 °C as an example. 
The viscosity of resulting master curves was fit to the Carreau-Yasuda equation (CY-
equation, Eq. (5.2)) [28–31], 
𝜂 =  𝜂∞ +  (𝜂0 − 𝜂∞) ∙ [1 + (𝜆?̇?)
𝑎](𝑛−1)/𝑎     (5.2) 
where η0 and η∞ are the zero shear and infinite shear viscosity, λ is the characteristic 
time, n is the Power law index and a is the Yasuda constant. Due to a more accurate 
curve fitting, η∞ was set to zero (Eq. (5.3)). 
𝜂 =  𝜂0 ∙ [1 + (𝜆?̇?)
𝑎](𝑛−1)/𝑎      (5.3) 
  
 
 
95 
By applying TTS, shift factors aT for each frequency sweep in TTS were obtained 
(Fig 5.2d) and were adapted to Williams-Landel-Ferry fit (WLF-fit, Eq. (5.4)) [28–31], 
log(𝑎𝑇) =
−𝐶1 (𝑇−𝑇0)
𝐶2+(𝑇−𝑇0)
       (5.4) 
where C1 and C2 are constants, T is the intended temperature and T0 is the reference 
temperature. It describes the temperature dependence of λ (Eq. (5.5)) and η0 
(Eq. (5.6)) of the CY-equation (Eq. (5.2)), 
𝑎𝑇 =
𝜂𝑇
𝜂0
      (5.5) 
𝑎𝑇 =
𝜆𝑇
𝜆0
      (5.6) 
where subscript T denotes the intended temperature and subscript 0 the reference 
temperature of the master curve. In conclusion, CY-equation and WLF-fit enable the 
extrapolation of data by means of angular frequency and temperature within a limited 
range [32]. All mathematical operations and curve fittings were conducted by using 
Origin® Pro 8G (OriginLab, Northampton, MA, USA). 
In SAOS, unsteady shear conditions are applied, whether the results are comparable 
to steady shear conditions, e.g. flow through pipes, need be tested. It is assumed, that 
the viscosity obtained in oscillatory experiments can be converted into a shear-rate-
dependent viscosity, this is known as the empirical Cox-Merz rule [33] (general invalid 
for suspensions, gels and crosslinked materials). In the case of the pure polymer COP, 
the application of the Cox-Merz rule was tested by high pressure capillary rheometry 
which identified a similar flow profile as in SAOS (data not shown). Due to upcoming 
measuring issues (applicable temperature range, plug flow), all other COP-blends 
were tested in rotation on the rheometer at shear rates up to 10 s-1 (data not shown). 
Due to the viscoelastic properties of the investigated blends, higher shear rates were 
inapplicable at the rotational rheometer. In the case of pure COP and all COP-blends, 
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the conducted experiments showed that the Cox-Merz rule could be applied, confirm-
ing that tests under unsteady shear conditions are comparable to steady shear condi-
tions. 
5.6.2.4 Differential Scanning Calorimetry (DSC) 
A DSC 2 (Mettler Toledo, Gießen, Germany) equipped with an auto sampler, nitrogen 
cooling and nitrogen as purge gas (30 ml/min) was used. The system was calibrated 
with indium and zinc standards. At least three samples of approximately 5 – 10 mg of 
each mixture were analyzed, using 40 μl aluminum pans with a pierced lid. Glass tran-
sition temperatures (Tg, DSC) and melting temperatures (Tm) were analyzed via heating-
cooling-heating cycles of 10 K/min (Tables 5.1 and 5.2). 
5.6.2.5 Extrusion trials 
For hot-melt extrusion, a co-rotating twin-screw extruder ZE 12 from Three-Tec GmbH 
(Seon, Switzerland) with a functional length of 25:1 L/D, 12 mm screws, 2 mm die and 
a maximum torque of 15 N·m was used. The screw configuration consists of 125 mm 
conveying elements (18 mm and 12 mm pitch), 18 mm kneading element (30°), 18 mm 
kneading element (60°), 36 mm conveying element (12 mm and 9 mm pitch), 18 mm 
kneading element (60°), 18 mm kneading element (90°) and 66 mm conveying element 
(12 mm pitch). The throughput was kept constant at 2.0 g/min and the screw speed 
was set to 100 rpm to enable a high filling ratio of the extruder. Mean residence times 
(MRTs) were measured and calculated by using ExtruVis3 of ExtruVis (Riedstadt, Ger-
many). To determine the feed rate during MRT measurements more precisely, the ex-
truded material over a certain time was collected and weighed (Table 5.5). The extru-
sion temperature was chosen due to the zero-shear viscosity (10,000-1,000 Pa·s) of 
the blends investigated. This is only a rough estimation of an extrusion temperature 
set-up to enable the extrusion process by a low viscous melt. Due to the set screw 
speed and the shear thinning behavior of the blends, an even lower viscosity might be 
achieved during the extrusion process. The extrusion temperature was defined as 
160 °C for Tg-group 1, 150 °C for Tg-group 2 and 140 °C in the case of Tg-group 3 (Ta-
bles 5.3 and 5.5). 
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5.7 Results 
5.7.1 Characterization of melt rheological properties 
To compare the melt rheological behavior of the API/polymer or plasticizer/polymer 
blends investigated in this study, the zero-shear viscosity (η0) obtained by CY-equation 
at temperatures measured is listed in Table 5.3. An increase in temperature or a re-
duction in Tg, mixture resulted in the decrease of η0 values (Fig 5.3a, c and e), whereas 
aT seemed to remain constant for all Tg-groups (Fig 5.3b, d and f). In general, if the 
logarithmical dependence of viscosity is kept in mind, within a Tg-group similar results 
for η0 can be obtained. In Figure 5.3, the melt rheological behavior at 150 °C of each 
blend, including its CY-fit and WLF-fit, is shown in more detail.  
Table 5.3 Comparison of zero-shear viscosity in the measurable temperature range of 
mixtures investigated. 
Mixture Zero-shear viscosity η0 [Pa∙s]  
140 °C 150 °C 160 °C 170 °C 180 °C 
COP 329,203 61,006 14,039 3,843 1,229 
Group 1 (Tg, Rheo: ~124 °C; Tg, DSC: ~102 °C) 
IMC/COP 5 % - 32,521 7,734 2,189 729 
PEG/COP 1.38 % - 30,119 7,551 2,274 - 
CBZ/COP 4.7 % - 42,469 9,395 2,472 786 
Group 2 (Tg, Rheo: ~117 °C; Tg, DSC: ~91 °C) 
IMC/COP 20 % 30,408 7,315 2,034 653 234 
PEG/COP 4 % 46,028 11,409 3,303 1,113 - 
DPD/COP 32.5 % - 3,660 1,044 352 133 
Group 3 (Tg, Rheo: ~104 °C; Tg, DSC: ~80 °C) 
IMC/COP 45 % 2,361 597 187 71 - 
PEG/COP 8.5 % 5,711 1,796 649 275 - 
IBU/COP 10.5 % 6,947 1,977 648 - - 
 
In the case of Tg-group 1 (Tg, Rheo= ~124 °C) and in comparison to pure COP, the zero-
shear viscosity was reduced from ~60,000 Pa·s to 30,000 - 40,000 Pa·s (Fig 5.3a, b). 
Based on identical curve magnitude and curve progression of CY-fit and WLF-fit for 
IMC/COP, PEG/COP and CBZ/COP in Tg-group 1, these mixtures show identical melt 
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rheology and identical frequency- and temperature-dependent viscosity. This result is 
in accordance with almost identical Tgs of the individual mixtures. 
Regarding Tg-group 2 (Tg, Rheo = 117 °C), the viscosity was decreased to 3,000-
11,000 Pa·s (Fig 5.3c, d), due to an increase in API or plasticizer content and lower 
glass transition. Compared to Tg-group 1, the individual CY-fits of the melt viscosity 
showed higher discrepancy in curve magnitude. The higher content of API/plasticizer 
or the highly-reduced glass transition might have promoted this difference in viscosity. 
However, almost identical curve progression of the CY-fits and identical aT and WLF-
fits indicated a similar frequency and temperature dependence for IMC/COP, 
PEG/COP and DPD/COP blend of Tg-group 2. 
In Tg-group 3 (Tg, Rheo = 104 °C), a clear discrepancy in viscosity between IMC/COP 
(~600 Pa·s) and PEG/COP or IBU/COP (~2,000 Pa·s) was seen (Fig 5.3e, f). IMC low-
ered the viscosity much more than PEG or IBU and led to a larger difference in viscosity 
curve magnitude compared to Tg-group 1 and 2. It is unclear whether this was related 
to the behavior of IMC with its highly specific interactions to COP [34,35], or is generally 
valid for all APIs with similar weight fractions or plasticizing effects. Nevertheless, al-
most half by weight of the polymer was replaced by IMC but still the accuracy in tem-
perature and frequency dependence was comparable to Tg-group 1 and 2. 
Overall, the temperature dependency of the Tg-groups, described by WLF-fit and aT, 
led to similar results and to the conclusion of smaller difference among the individual 
blends when compared to each other or to pure COP (Fig 5.3 and 5.2d). Regarding 
the curve progression of CY-fits, almost similar outcomes were obtained, indicating a 
similar frequency dependence. However, the variability in curve magnitude of CY-fits 
for a given Tg-group varied as a function of the reduced COP glass transition. Hence, 
correlation between Tg and η0 decreased slightly with increasing plasticization. 
Whether this limitation in correlation influences extrusion experiments, or if it can be 
neglected, is later discussed in section 5.7.3 and compared to hot-melt extrusion trials. 
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Figure 5.3a-f Carreau-Yasuda fits and corresponding WLF fits at 150 °C for Tg-group 1 
(a, b), Tg-group 2 (c, d) and Tg-group 3 (e, f). 
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5.7.2 Comparison of zero shear viscosity and corresponding glass transition 
To evaluate the relationship between the melt viscosity and the transition temperature 
of API/ or plasticizer/COP mixtures measured by both DSC and SAOS, Tg and corre-
sponding η0 at 150 °C of various COP blends are shown in Figure 4. In addition to the 
measured Tg and η0 of blends investigated, several other additional APIs and weight 
fractions of earlier experiments were included to expand the data set and improve sub-
sequent curve fitting. The regression curve fitting was performed for the entire data set 
(21 data points), again for only IMC (6 data points) and once again for only PEG (8 
data points). 
 
Figure 5.4a-b Correlation between Tg, Rheo (a) or Tg, DSC (b) and corresponding zero-
shear viscosity at 150 °C of various API- or plasticizer/COP mixtures, regression 
curves were performed for IMC/COP, PEG/COP and the entire data set (NIF = nifedi-
pine; ITZ = itraconazole; FUR = furosemide). 
In general, since the measuring techniques by DSC and SAOS are not comparable, 
the values of Tg, DSC and Tg, Rheo differ. First, this is rooted at the different parameters 
which were used to identify the Tg hence, leading to deviating values in Tg. Secondly 
in DSC, the Tg is analyzed during a heating ramp, whereas in SAOS Tg, Rheo was de-
termined during a cooling ramp. 
In the case of η0 to Tg, Rheo, all regression curves showed an adjusted correlation coef-
ficient (r2) of more than 0.9, indicating a strong dependence of η0 to Tg and an accurate 
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mathematical description by a simple exponential fit with two variables only (Eq. (5.7), 
Table 5.4, Fig 5.4a). 
𝜂0 = 𝑎 ∙ 𝑒
(𝑏∙𝑇𝑔)     (5.7) 
Table 5.4 Regression curve parameters of zero-shear viscosity and corresponding 
glass transition for IMC/COP mixtures, PEG/COP mixtures and the whole data set. 
Data Result of fit [𝜼𝟎 = 𝒂 ∙ 𝒆
(𝒃∙𝑻𝒈)] 
a b adjusted r2 
All Tg, Rheo 3.29 E-5 0.167 0.920 
All Tg, DSC 1.11 E-3 0.170 0.963 
IMC Tg, Rheo 7.89 E-7 0.198 0.997 
IMC Tg, DSC 9.05 E-4 0.171 0.977 
PEG Tg, Rheo 2.07 E-5 0.171 0.925 
PEG Tg, DSC 1.07 E-1 0.124 0.948 
 
In all curve fittings for Tg, Rheo, the variable a tended to zero, whereas the variable b 
was between 0.17 – 0.20. In the case of IMC/COP, the highest r2 of 0.997 was 
achieved, proving the direct dependence of η0 on Tg, if only one API is regarded. Con-
cerning PEG/COP and its r2 of 0.925, the lower r2 might be an effect of the higher 
molecular weight of PEG, its higher viscosity, and thus higher contribution to the vis-
cosity of the mixture, compared to a small API molecule. Consequently, PEG itself 
might have an additional specific effect on the rheological behavior beyond plasticizing, 
causing the slight decrease in regression curve accuracy, although negligible extent. 
For the entire data set, an accuracy of r2=0.920 in curve fitting was achieved. This 
correlation confirms the original assumption that the magnitude of the viscosity is 
mainly influenced by the Tg and to a lesser extent by specific nature of the API or 
plasticizer, given a constant polymeric matrix (COP). 
Compared to Tg, Rheo, Tg, DSC versus η0 and the respective regression curves of PEG 
and IMC varied more without compromising the adjusted r2; however, a and b showed 
increasing difference (Table 5.4, Fig 5.4b). The variable a for IMC was 0.17 and for 
PEG 0.12. The variable b was increased slightly, especially for PEG, but still tended to 
zero. In particular, the PEG fit deviated with respect to Tg, Rheo curve fitting. Compared 
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to SAOS, this may be an effect of pronounced phase separation due to less intensive 
mixing, without shear stress, in DSC trials. Additional DSC measurements with 15 % 
PEG in COP already showed two glass transitions, hence a phase separation. Due to 
the detection limit of DSC, this phase separation might occur already at lower PEG 
weight fractions and may have caused the difference in regression curve progression. 
Therefore, two points (7 % and 8.5 %) of PEG data were eliminated to perform the 
regression curve fitting for the entire data set which is in good accordance with the IMC 
and Tg, Rheo results. In conclusion, as was for Tg, Rheo versus η0, the dependence of η0 
on Tg, DSC is obvious and seemed independent of the API or plasticizer used. 
5.7.3 Extrusion trials and mean residence time (MRT) measurements 
The extrusion performance of mixtures in Tg-groups 1-3 are listed in Table 5.5. During 
hot-melt extrusion, the melt temperature in the die was always 10 K higher than the set 
barrel temperature of the last barrel sections, leading to a lower viscous melt than orig-
inally intended (Tables 5.3 and 5.5).  
Table 5.5 Extrusion performance at 100 rpm and 2 g/min of blends investigated. 
Mixture TExtrusion 
[°C] 
TSensor 
[°C] 
Torque 
[N·m] 
Feed rate 
[g/min] 
MRT 
[s] 
COP 170 180.1 6.5 2.3 290 
Group 1 (Tg, Rheo: ~124 °C; Tg, DSC: ~102 °C) 
IMC/COP 5 % 160 169.8 6.7 2.1 304 
PEG/COP 1.38 % 160 169.8 7.3 1.9 305 
CBZ/COP 4.7 % 160 170.0 5.9 1.8 310 
Group 2 (Tg, Rheo: ~117 °C; Tg, DSC: ~91 °C) 
IMC/COP 20 % 150 160.3 5.9 2.0 325 
PEG/COP 4 % 150 160.2 9.5 1.9 366 
DPD/COP 32.5 % 150 159.9 5.2 2.1 323 
Group 3 (Tg, Rheo: ~104 °C; Tg, DSC: ~80 °C) 
IMC/COP 45 % 140 148.9 3.9 2.0 336 
PEG/COP 8.5 % 140 149.3 8.7 1.8 393 
IBU/COP 10.5 % 140 150.2 8.6 2.1 343 
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In the case of Tg-group 1, the torque varied only 1.4 N·m between the different COP-
based blends, indicating an identical behavior during extrusion. The similarity in pro-
cessing within the Tg-groups was confirmed by both the low difference in torque and in 
mean residence time (6 s MRT difference). Therefore, no important variation in extru-
sion was found between IMC/COP, PEG/COP and CBZ/COP of Tg-group 1, which was 
in good accordance with the melt rheological behavior (Fig 5.3a, b). 
Regarding Tg-group 2 and its torque and MRT values, IMC/COP and DPD/COP 
achieved identical behavior during extrusion. PEG/COP instead resulted in higher 
torque and higher MRT, which might be an effect of higher viscosity (Fig 5.3c, d). How-
ever, the specific behavior of PEG during extrusion seemed more reasonable. The 
material built up in the extruder and was not conveyed well which resulted in a higher 
torque and MRT. In conclusion for Tg-group 2, the behavior might be similar in extru-
sion but in the case of PEG, further investigations are needed to clarify the cause of 
higher torque and MRT. 
For Tg-group 3, the results of melt rheology were reflected in extrusion. PEG/COP and 
IBU/COP had almost identical torque, whereas IMC achieved a much lower value 
(Fig 5.3e, f). This could be easily explained by the lower viscosity of IMC/COP com-
pared to PEG/COP and IBU/COP, which might be related to specific interactions be-
tween IMC and COP [34,35]. Nevertheless, MRT was almost identical for IMC/COP 
and IBU/COP. The increase in MRT of PEG/COP might be triggered by the same rea-
son as for PEG/COP of Tg-group 2. During extrusion, the material stuck to the screws, 
causing an increase in MRT.  
In conclusion, similar behavior at extrusion is likely but in light of the specific behavior 
of PEG and IMC, further investigations with additional API or plasticizer in COP and 
identical Tg are needed. However, the authors are confident that further investigations 
will prove similar behavior in extrusion for melts containing material with the identical 
plasticizing effect. 
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5.8 Discussion 
In general, for predicting melt viscosity and dependent extrusion performance of ASDs, 
a suitable correlation between Tg, Rheo and η0 was identified, independent of API or 
plasticizer and its molecular weight, recrystallization tendency, weight fraction and 
plasticizing effect with only few exceptions (Fig 5.4).  
Regarding the physical background of the Tg – zero-shear viscosity correlation, the 
dependency becomes obvious: In general, the molecular mobility of a specimen can 
be described as a cooperative site exchange process. The extent of this site exchange 
process depends on the available free volume, known as the free volume theory [36–
38]. To enable viscous flow, a molecule must be able to change its position with an-
other, where the new position has to be unoccupied. Consequently, a certain free vol-
ume has to be present to enable this site change. If the free volume is increased, site 
exchanges increase and the irreversible resistance against viscous flow decreases. 
Hence, the viscosity of a system decreases with increasing free volume in tempera-
ture-dependency. Below the Tg, the present free volume is too small to facilitate this 
cooperative site exchange processes, the molecular mobility of molecular chain seg-
ments is decreased, leaving the system frozen in a non-equilibrated state. Conse-
quently, viscosity and glass transition depend on the free volume in the specimen, it is 
obvious that both parameters are likely to correlate. As plasticizers or API are mainly 
influencing the extent of free volume, it seems logical that they are changing the vis-
cosity and Tg to a similar extent without compromising their correlation. 
Moreover, APIs with strong specific interactions, e.g. hydrogen bonding, such as IMC 
should be regarded carefully. Specific interactions might affect the resulting melt vis-
cosity, especially at higher API weight fractions, causing a slight deviation from the 
correlation of Tg to η0 (Fig 5.3 and 5.4). However, extrusion trials only detected differ-
ences in torque, while MRT seemed unaffected. Due to the higher dependence of MRT 
on temperature independent variables n and a of CY-fit compared to temperature de-
pendent η0 and λ, similar MRT values can be explained (Fig 5.3) [39]. In conclusion, 
due to similar rheological behavior as a function of frequency and temperature of the 
investigated blends (Fig 5.3), strong specific interactions are only affecting torque at 
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unchanged MRT in HME. Furthermore, specific interactions are only decreasing torque 
and hence are not limiting the extrusion at the desired temperature. With respect to 
similar MRT, changes in thermal stress to the extruded material are unlikely. Conse-
quently, the MRT at a given screw configuration can be estimated via the Tg of a re-
quired mixture. This enables an easy optimization of MRT, which is needed for thermal 
instable APIs or for dissolving poorly soluble APIs in a polymeric matrix during HME. 
However, further investigations are needed to evaluate the impact of the temperature 
profile along the screws.  
In addition, an increase in API or plasticizer weight fraction triggered a slight decrease 
in correlation of Tg to η0. In the case of IMC/COP 20 % and DPD/COP 32.5 % and their 
discrepancy in viscosity at 150 °C (Fig 3c), extrusion trials indicated the variation in 
viscosity as negligible (Table 5.5). 
Nevertheless, material build-up during polymer extrusion due to added API or plasti-
cizer, especially employing substances of low melting point, led to an unpredictable 
increase in torque and increase in MRT (Table 5.5). This increase might be triggered 
by material which stuck to the screws, as it was observed for PEG/COP mixtures. An 
abnormal behavior in extrusion of added material was therefore limiting the prediction 
of extrusion performance by using Tg and η0. Furthermore, inhomogeneous specimens 
during DSC measurements and corresponding change in Tg, as was observed for 
PEG/COP high weight fractions, was limiting the correlation of η0 to Tg, DSC but did 
not compromise the correlation to Tg, Rheo (Fig 5.4). 
Overall, the assumption of a general connection between Tg and a corresponding 
change in melt viscosity was confirmed, independent of the added API or plasticizer to 
COP with only few exceptions. A simple Tg measurement by DSC enables an estimate 
of the melt viscosity of a material, if the general melt behavior of the pure polymer is 
known. In this way, the effort in gaining an estimate of the melt viscosity information of 
an API- or plasticizer-polymer mixture can be reduced drastically. However, the math-
ematical description of such Tg-viscosity correlation is expected to be polymer-depend-
ent and needs to be elucidated or confirmed for every polymeric matrix. 
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5.9 Conclusion 
A correlation between glass transition temperature (Tg) and melt viscosity was con-
firmed and enables the prediction of amorphous solid dispersion (ASD) extrusion per-
formance. The melt rheological behavior was largely independent of added active 
pharmaceutical ingredient (API) or plasticizer to copovidone with respect to different 
molecular weight, recrystallization tendency, weight fraction and plasticizing effect with 
only few exceptions. Regarding extrusion performance, abnormal behavior of added 
API or plasticizer and specific interactions between the materials were limiting the pre-
diction. In the case of specific interactions between API and matrix polymer, only torque 
was reduced but no effect on mean residence time (MRT) was observed. The effort in 
gaining melt viscosity information of an ASD can be reduced to Tg measurement by 
differential scanning calorimetry (DSC) and knowledge of the rheological behavior of 
the pure matrix polymer. In conclusion, material and costs to set-up extrusion trials to 
the desired conditions can be reduced. 
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6.1 Graphical abstract 
 
6.2 Abstract 
Simulation of HME processes is a valuable tool for increased process understanding 
and ease of scale-up. However, the experimental determination of all required input 
parameters is tedious, namely the melt rheology of the amorphous solid dispersion 
(ASD) in question. Hence, a procedure to simplify the application of hot-melt extrusion 
(HME) simulation for forming amorphous solid dispersions (ASD) is presented. The 
commercial 1D simulation software Ludovic® was used to conduct (i) simulations using 
a full experimental data set of all input variables including melt rheology and (ii) simu-
lations using model-based melt viscosity data based on the ASDs glass transition and 
the physical properties of polymeric matrix only. Both types of HME computation were 
further compared to experimental HME results. Variation in physical properties (e.g. 
heat capacity, density) and several process characteristics of HME (residence time 
distribution, energy consumption) among the simulations and experiments were eval-
uated. The model-based melt viscosity was calculated by using the glass transition 
temperature (Tg) of the investigated blend and the melt viscosity of the polymeric matrix 
by means of a Tg-viscosity correlation. The results of measured melt viscosity and 
model-based melt viscosity were similar with only few exceptions, leading to similar 
HME simulation outcomes. At the end, the experimental effort prior to HME simulation 
could be minimized and the procedure enables a good starting point for rational devel-
opment of ASDs by means of HME. As model excipients, vinylpyrrolidone-vinyl acetate 
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copolymer (COP) in combination with various APIs (carbamazepine, dipyridamole, in-
domethacin, and ibuprofen) or polyethylene glycol (PEG 1500) as plasticizer were 
used to form the ASDs. 
6.3 Keywords 
hot-melt extrusion, melt rheology, glass transition temperature, amorphous solid dis-
persion, simulation, prediction model 
6.4 Chemical compounds studied in this article 
Carbamazepine (PubChem CID: 2554); Dipyridamole (PubChem CID: 3108); Ibu-
profen (PubChem CID: 3672); Indomethacin (PubChem CID: 3715); Copovidone 
(PubChem CID: 25086-89-9) 
6.5 Introduction 
In formulation development, the so-called enabling technology hot-melt extrusion 
(HME) is often used to overcome the poor solubility of active pharmaceutical ingredi-
ents (APIs) by forming amorphous solid dispersions (ASDs). Unfortunately, the extru-
sion process-based formulation development is often API-consuming and expensive 
in terms of time and personal [1–4]. To reduce the effort in early development, several 
methods and techniques to facilitate a rational procedure have been previously re-
ported [5–8].  
A very common example is the use of small-scale co-rotating twin-screw extruders 
prior the production scale [5,9–11]. It reduces the batch size down to as little as 5 g 
and they are accepted as screening tools for solid dispersion formulations. Unfortu-
nately due to fundamental differences between lab-scale extruders (e.g. 9 mm screw 
diameter) and larger scale extruders, a rational scale-up is not feasible [8]. To perform 
process development and scale-up, extruders of 10-12 mm, respectively 24-27 mm 
screw diameter should be used instead but this increases the batch size to approx. 
50 g/h up to 20 kg/h. Furthermore, the scale-up to production scale can be conducted 
volumetrically or adiabatically [7,8,12,13]. The most crucial process characteristics in 
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scale-up are the residence time distribution (RTD) and the specific mechanical energy 
(SME) [12]. Both parameters should be kept constant by adjusting the various other 
extrusion parameters (e.g. temperature, screw configuration, screw speed and feed 
rate) during scale-up.  
Another way to perform a rational screening of solid dispersion formulations are micro-
scale testing methods by using thermo-analytical techniques such as differential scan-
ning calorimetry (DSC) [14–20], melt rheology [21–23], hot-stage microscopy (HSM) 
[8,9] and many more. For example, differential scanning calorimetry can be used to 
determine the glass transition temperature (Tg) for later process conditions [8,24] or for 
the API-solubility characterization within the polymeric matrix. This solubility prediction 
can be conducted by using the melting point depression method [14–16], dissolution 
endpoint method [17–19] or by using the API/polymer ratio-dependent glass transition 
temperature (Tg) [20,25]. Hot-stage microscopy is a very powerful analytical technique 
to determine the miscibility of compounds and to assess first hints for an applicable 
temperature range in extrusion [8,9]. Melt rheology is particularly useful in that it can 
be used to identify possible process conditions [23,26]. The main advantage of all 
these methods is the small amount of material required to obtain significant knowledge 
for subsequent hot-melt extrusion processing. In general, they enable the estimation 
of a feasible extrusion range and they can be very helpful to predict the shelf life of 
extruded formulations. 
An even more theoretical approach is the simulation of HME processes [27–30] and 
the use of molecular modelling [14,31,32] or solubility parameters [5,8,24] to estimate 
a good and early starting point prior any experimental consideration. Prediction of glass 
transition temperature (Tg) [31], API solubility within the polymeric matrix [5,24,33] and 
detailed computation of extrusion runs represent only a few applications in HME pro-
cess analytics. In the case of adiabatic scale-up from small-scale to production-scale 
extrusion, HME simulation can be most appropriate solution to identify adiabatic con-
ditions in small-scale extruders [13]. The high impact of barrel set temperature here is 
disguising adiabatic conditions, especially for small scale extruders (<= 12 mm) where 
heat conduction governs energy uptake rather than viscous dissipation. However, ad-
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iabatic conditions can be identified by employing HME simulation. At the end, all men-
tioned approaches and methods, such as mini-scale twin screw extruders, micro-scale 
testing methods and HME simulation, enable a rational development of ASDs to over-
come the poor solubility of modern APIs. This leads to a not only trial-and-error based 
formulation but a process development in the sense of quality by design. 
Regarding the extrusion computation, a major drawback is the need for experimental 
input data (e.g. melt viscosity) in order to run the simulation properly. In early stage 
development, several formulations for an API have to be tested, which is time-consum-
ing, especially in the case of rheological measurements. To enable certain “shortcuts” 
regarding the estimation of melt viscosity by using only the Tg of the formulation has 
already been reported in our previous work [34]. To continue this work, we applied our 
model-based estimates of Tg-viscosity correlation to simulate HME processes for form-
ing ASDs. 
The objective of our study reported here was the comparison of extrusion experiments 
with the computations of the commercial 1D simulation software Ludovic®. The soft-
ware was fed either with measured melt viscosity data of the respective ASD (including 
API) or with model-based melt viscosity data by using the Tg of the investigated blends. 
To evaluate the application of our first estimates of the melt viscosity by using only Tg, 
several process characteristics of HME (e.g. residence time distribution, energy con-
sumptions) and physical properties (e.g. heat capacity, density, melt rheology) of vari-
ous mixtures has been investigated. The goal was not to replace extrusion experiments 
but more to enable a good and early starting point for HME trials by using only the Tg 
of a desired ASD and characteristics of the polymeric matrix in HME simulation. There-
fore, a rational development is supported. This leads to a reduction of needed extrusion 
trials to define the best formulation and process conditions for forming ASDs. As model 
excipient, vinylpyrrolidone-vinyl acetate copolymer (COP) in combination with various 
API or PEG as plasticizer were used to form ASDs. 
6. Numerical simulation of hot-melt extrusion processes for amorphous solid dispersions using model-
based melt viscosity  
 
 
116 
6.6 Material and methods 
6.6.1 Material 
Dipyridamole (DPD) was obtained from Swapnroop Drugs & Pharmaceuticals (Maha-
rashtra, India) and Indomethacin (IMC) was purchased from Swati Spentose Pvt. Ltd 
(Mumbai, India). PEG 1500 (PEG) were obtained from Alfa Aesar (Karlsruhe, Ger-
many). Vinylpyrrolidone-vinyl acetate copolymer (copovidone, Kollidon® VA 64, COP), 
Carbamazepine (CBZ) and Ibuprofen (IBU) were kindly donated by BASF SE (Lud-
wigshafen, Germany) (Table 6.1). The APIs were chosen due to their various physico-
chemical characteristics. The API or plasticizer weight fraction was experimentally ad-
justed to a specific glass transition temperature (Tg) of the blend, as was already re-
ported in our previous work [34].  
Table 6.1 Physicochemical properties of substances under investigation [34]. 
Substance Molecular weight 
[g/mol] 
Melting point 
[°C] 
Glass transition 
temperature [°C] 
Indomethacin (IMC) 358 160 44 
Carbamazepine (CBZ) 236 175 53 
Dipyridamole (DPD) 505 167 38 
Ibuprofen (IBU) 206 75 -44 
PEG 1500 (PEG) 1,500 47 -42 
Copovidone (COP) 45,000 - 70,000 - 107 
 
6.6.2 Methods 
6.6.2.1 Preparation of physical mixtures 
For DSC trials, a MM400 ball mill (Retsch GmbH, Haan, Germany) with 30 Hz and 3 x 
5 min milling cycles was used. For extrusion trials, physical mixtures were prepared by 
using a Turbula mixer (Willy A. Bachofen AG – Maschinenfabrik, Muttenz, Swiss) for 
10 min at 50 rpm.  
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6.6.2.2 Helium pycnometer 
The true density of powder blends and extrudates were analyzed by using the helium 
pycnometer AccuPyc 1330 (Micromeritics GmbH, Norcross, USA). During measure-
ments, the chamber was purged with 20 purge cycles and a fill pressure of 
136.86 kPa·g. Subsequently, samples were analyzed with a fill pressure of 
136.86 kPa·g and an equilibration rate of 0.0345 kPa·g/min. The sample was analyzed 
in 25 runs or until a standard deviation of 0.01 % was reached. For every material, the 
procedure was repeated two times. 
6.6.2.3 Differential scanning calorimetry (DSC) 
A DSC 2 (Mettler Toledo, Gießen, Germany) equipped with an auto sampler, nitrogen 
cooling and nitrogen as purge gas (30 ml/min) was used. The system was calibrated 
with n-octane, indium and zinc standards. At least three samples of approximately 
10 mg of each mixture were analyzed, using 40 μl aluminum pans with a pierced lid. 
Heat capacities were measured against a sapphire standard in TOPEM® mode (mod-
ulated DSC) with 1 K pulse height, 15-30 s pulse width and an underlying heating rate 
of 2 K/min. Prior to heat capacity analysis, the samples were annealed at elevated 
temperatures to promote a homogenous distribution of the API/plasticizer in the poly-
meric matrix. 
6.6.2.4 Extrusion trials and residence time distribution (RTD) 
For hot-melt extrusion, a co-rotating twin-screw extruder ZE 12 (Three-Tec GmbH, 
Seen, Switzerland) with a functional length of 25:1 L/D, 12 mm screws, 2 mm die and 
a maximum torque of 15 N·m was used. The screw configuration is shown in Fig 6.1.  
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Figure 6.1 Extruder and screw configuration used (S = conveying element; K = knead-
ing element). 
The throughput was kept constant at 2.0 g/min and the screw speed was set to 
100 rpm to enable a high filling ratio of the extruder. Mean residence times (MRTs) 
were measured with iron oxide (Sicovit® Red 30 E 172, BASF SE, Ludwigshafen, Ger-
many) and calculated by using ExtruVis3 (ExtruVis, Riedstadt, Germany). To deter-
mine the feed rate during MRT measurements more precisely, the extruded material 
was collected and weighed over time. Afterwards, the feed rate was adjusted to a range 
of 2.0 ± 5 % g/min. The extrusion barrel temperature was set to 150 °C. Furthermore, 
extrusion data of our previous work were also considered for extrusion simulation in 
this work [34]. The specific mechanical energy (SME) of extrusion experiments was 
calculated by using following equation (Eq. (6.1)), 
𝑆𝑀𝐸 =
2𝜋∙𝑛∙𝜏
?̇?∙60
       (6.1) 
where n is the screw speed [rpm] and ṁ characterizes the feed rate [kg/h]. The variable 
τ determines the maximum torque per shaft [N·m] where the torque of idling speed 
(1.2 N·m) has been subtracted.  
6.6.2.5 Simulation software Ludovic® 
The simulation software Ludovic® V6.0.1 PharmaEdition (Sciences Computers Con-
sultants, Saint Etienne, France) was used for computing the flow conditions of hot-melt 
extrusion processes. It is a one-dimensional approach for flow modelling and allows 
the calculation of various parameters along the screw profile (e.g. temperature, pres-
sure, shear rate, residence time, global energy distributions, etc.). The model assumes 
non-isothermal flow conditions and an instantaneous melting prior to the first restrictive 
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screw element. Due to the unknown filling ratio of a starve-fed extruder, the computa-
tion starts at the die and proceeds backwards in an iterative procedure until the final 
product temperature is achieved [35]. 
6.7 Results 
6.7.1 Physical properties of investigated blends and pure COP 
To evaluate the difference in physical properties of the investigated blends, true density 
and heat capacity of physical mixtures and extrudates were analyzed and compared 
to pure COP (Table 6.2).  
Table 6.2 Glass transition temperature, true density and heat capacity of COP-blends 
investigated. 
Mixture Tg [°C] ρ [kg/m3] 
powder 
ρ [kg/m3] 
extrudate 
Cp [J/(g·K)] 
at 25 °C 
Cp [J/(g·K)] 
at 150 °C 
COP 107 1,178 1,191 1.013 1.720 
 Group 1 (Tg: ~102 °C) 
IMC 5 % 102 1,190 1,198 0.966 1.730 
PEG 1.38 % 102 1,179 1,191 1.138 1.877 
CBZ 4.7 % 103 1,197 1,197 1.020 1.782 
 Group 2 (Tg: ~91 °C) 
IMC 20 % 91 1,216 1,221 1.067 1.867 
PEG 4 % 92 1,200 1,191 0.851 1.439 
DPD 32.5 % 91 1,226 1,211 0.964 1.651 
 Group 3 (Tg: ~80 °C) 
IMC 45 % 79 1,249 1,250 0.930 1.616 
PEG 8.5 % 76 1,195 1,195 0.863 1.570 
IBU 10.5 % 86 1,173 1,178 0.840 1.400 
 
Regarding pure COP, the true density increased slightly from powder at 1,178 kg/m3 
to its extrudate with 1,191 kg/m3. In comparison, the densities of physical mixtures and 
extrudates of all COP-blends were similar to pure COP, respectively. The highest de-
viation of 6 % from pure COP was found for IMC/COP 45 %, which was likely triggered 
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by the highest API content in this investigation. In the case of the temperature-depend-
ent heat capacity, an increase for COP from 1.013 J/(g·K) at 25 °C to 1.720 J/(g·K) at 
150 °C was obtained. An increase in heat capacity as a function of temperature was 
also observed for COP blends but in most cases with an overall reduced value com-
pared to pure COP. Especially the blends of Tg-group 3, which had the lowest glass 
transitions, decreased up to approx. 20 %. 
Although density and heat capacity are required input parameters for the Ludovic® 
simulation software, extrusion simulation is mostly effected by extrusion set-up (e.g. 
throughput, screw speed and screw configuration) or melt viscosity. Small differences 
in further physical properties between the pure polymeric matrix and ASD thereof might 
be less important. Therefore, the difference in heat capacity and true density of pure 
COP to its COP-blends might be negligible for simulation. Consequently, the use of 
physical properties of pure COP instead of probably unknown data of desired COP 
blends was sufficient to simulate extrusion and to estimate a good starting point for 
later extrusion experiments. 
6.7.2 Comparison of energy consumption during extrusion and conventional 
extrusion simulation with measured melt viscosity 
To determine the variation in energy consumption, conventional simulation by the soft-
ware Ludovic® and the specific mechanical energy (SME) derived by extrusion exper-
iments were compared (Fig. 6.2).  
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Figure 6.2a-b Energy consumption of simulated and experimental extrusion runs at a 
fixed temperature (150 °C) (a) and temperature gradient (140 – 170 °C) (b). Bar charts 
represent the simulated energy consumption, whereas the stars are indicating the ex-
perimental SME. 
In the case of the conventional simulation, physical properties and melt viscosity of the 
desired blend were used. In simulation, the sum of specific energy, dissipated energy 
of screw/die and melting energy constitutes the SME. Due to the used 12 mm small-
scale extruder, obtained data for the die attributed dissipated energy were negligible 
(data not shown) and were not further employed. In the case of melting energy, the 
heat of fusion of the APIs were not considered in simulation because Ludovic® offers 
only one entry field for melting/softening temperature. In our case, the Tgs of investi-
gated blends were entered, which did not possess any heat of fusion. For simulation 
and extrusion, two temperature regimes were investigated: extrusion at 150 °C as a 
fixed temperature and a variable temperature profile (140 °C to 170 °C) where the melt 
viscosity of COP and COP-blends during extrusion were similar. 
Concerning the specific energy derived by simulation, the variation between the indi-
vidual blends of all Tg-groups (ASDs of identical Tg) were negligible. The specific en-
ergy indicated the energy dedicated to heat up the material from ambient temperature 
to its melting point or glass transition temperature. This suggested that the variation in 
physical properties of the blends (see section 6.7.1) was not influencing the simulation 
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results to a major extent (up to 8 %). Only in the case of 45 % IMC-COP blend, a 
variation of 20 % was found, which was triggered by the high API-content in combina-
tion with the respective low viscosity melt and the low viscous dissipation energy 
thereof. Thus, in the case of simulation trials, the variation in physical properties might 
be neglected. Consequently, the data of pure COP instead of the data of each individ-
ual blend for simulation purposes was feasible for further simulation trials.  
Since the screw related dissipated energy and the total conduction energy were melt 
viscosity-dependent, a deviation between the individual blends and between the two 
temperature regimes was expected. The screw related dissipated energy character-
ized the energy which is generated by screw rotation through viscous dissipation ef-
fects and the conduction energy determined the energy generated by barrel regulation-
induced heat flux. During simulation at extrusion temperature 150 °C, the dissipated 
energy and the total conduction energy were the highest for pure COP and were con-
tinuously alleviated with decreasing Tg from Tg-group 1 to Tg-group 3 (Fig 6.2a). This 
behavior can be easily explained by a decrease in melt viscosity as a function of glass 
transition temperature. Since the variation in melt viscosity was the lowest for Tg-group 
1, the variation in energy consumption between IMC 5 %, PEG 1.38 % and CBZ 4.7 % 
was as expected low, too [34]. In comparison to Tg-group 1, due to higher deviation of 
melt viscosity among Tg-group 2 (IMC 20 %, PEG 4 % and DPD 32.5 %), the deviation 
in energy consumption likewise increased. Regarding the energy consumptions of Tg-
group 3 in simulation, values for IMC 45 % were much lower than for PEG 8.5 % and 
for IBU 10.5 %, respectively. This reflected the behavior in melt viscosity perfectly. IMC 
45 % exhibited a much lower melt viscosity than PEG 8.5 % and IBU 10.5 %. In Fig 
6.3b, the extrusion temperatures enabled a similar melt viscosity of all investigated 
blends and pure COP, which led to roughly similar energy consumptions in simulation, 
compared to extrusion temperature at 150 °C [34]. 
Comparing simulation results to extrusion experiments, likely due to loss of energy 
between the gearbox of the extruder and the screws or further friction, the SME of 
extrusion experiments were always higher than calculated by Ludovic®. In the case of 
pure COP and IMC, CBZ or DPD containing blends, the experimental SME did not 
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differ more than approx. 50 kWh/t from the simulated value. However, blends contain-
ing PEG or IBU achieved a much higher SME in extrusion trials than in simulation. 
Especially the SME of PEG 4 % was more than doubled. This deviation in SME might 
be rooted in the low melting point of IBU and PEG (Table 6.1), which were even lower 
than the Tg of their COP blends (Table 6.2). Consequently, IBU and PEG would melt 
prior the softening of COP during extrusion and producing a sticky suspension in the 
first zones of the extruder. To take the effect of a low melting point into account, the 
point of melting in the simulation was shifted from zone 3 (120 °C) (initial data not 
shown) to the beginning of zone 2 (80 °C) (Fig 6.2). Furthermore, due to the early 
melting of IBU and PEG, a phase segregation in the first extruder zones was likely. 
Molten IBU and PEG may have sunken to the bottom of the extruder barrel and a 
concentration gradient was produced, which subsequently might cause a melt viscosity 
gradient during extrusion. To investigate whether phase segregation effects occurred, 
blends containing IBU and PEG were extruded twice at 150 °C to evaluate the variation 
of SME between both extrusion experiments (Fig 6.2a). In the second extrusion run, 
milled extrudates of the first run were fed into the extruder. Feeding this homogeneous 
material suppressed phase segregation effects and a lower SME was obtained. At the 
end, the SME of the second extrusion runs were more consistent to the simulated val-
ues by Ludovic® than the SMEs of the first extrusion runs and the highest variation of 
85 kWh/t was found for PEG 4 %, confirming the phase segregation hypothesis. The 
increase in SME for low melting substances (IBU, PEG) and the still existing difference 
between experimental and calculated SME can be further explained as follows: In prin-
ciple, if low melting substances are present, the material will melt prior to the softening 
of the polymer and it will produce a low viscous melt as already stated. The remaining 
polymer particles tend to “swim” in this melt, because the large difference between the 
melt viscosity of API and polymer inhibited a sufficient dispersion by the extruder. Fur-
thermore, with respect to the low viscous melt, an increase in temperature by shearing 
in the kneading blocks is prohibited and softening of the polymer particles is prolonged 
and shifted to the following conveying zone. Due to absence of high shear stress and 
resulting temperature increase in this conveying zone, the highly viscous state of the 
blend and softening of the polymer particles is further prolonged. At the end, an in-
crease in torque and SME is obtained, as it was observed for PEG and IBU containing 
COP blends [36]. 
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In summary, Ludovic® could simulate extrusion trials with exceptions. Since the soft-
ware is not able to consider any phase segregation effects and further specific behavior 
of blends with low melting point substances (IBU and PEG), the experimental SME 
might be higher than calculated by Ludovic®. However, except few limitations the soft-
ware reliably estimates extrusion trials. Thus, Ludovic® can be used to validate, 
whether the model-based melt viscosity, derived from our Tg-viscosity correlation, is 
leading to the same outcome as measured melt viscosity would do. This procedure 
would enable a computation with less effort for estimating a good starting point for 
extrusion trials in early drug development.  
6.7.3 Estimation of viscosity data and their application for extrusion simulation 
In the Ludovic® simulation software, the melt viscosity has to be defined as a function 
of shear rate and temperature. In this study, we used the Carreau-Yasuda equation for 
the shear rate-dependency and the William-Landel-Ferry fit for the temperature-de-
pendency [37–40]. To estimate the melt viscosity by using only the Tg of an ASD and 
the melt viscosity of pure COP, we applied the following procedure: 
In our recent work, we proposed a correlation between Tg and zero-shear viscosity 
which was described by (Eq. (6.2)), 
𝜂0 = 𝑎 ∙ 𝑒
𝑏∙𝑇𝑔       (6.2) 
where η0 is the zero-shear viscosity at a set reference temperature, a and b are varia-
bles [34]. The reference temperature is the temperature where the melt viscosity was 
derived from to estimate a and b (Fig 6.3).  
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Figure 6.3a-b Correlation between glass transition temperature and zero-shear vis-
cosity (a) and the temperature dependency of a (b). 
Further investigations indicated that variable b was constant as a function of tempera-
ture whereas variable a had a logarithmic temperature-dependency (Fig 6.3b). There-
fore, extrapolation was conducted by setting b as constant and only a was separately 
adjusted for each temperature (Fig 6.3). This Tg-viscosity correlation was applied to 
calculate η0 of the investigated blends to use it for the Carreau-Yasuda equation. A 
reduced version of the Carreau-Yasuda equation was employed to describe the shear 
rate-dependent flow (Eq. (6.3)), 
𝜂 =  𝜂0 ∙ [1 + (𝜆?̇?)
𝑎](𝑛−1)/𝑎        (6.3) 
where n and a are constants and λ is a temperature-dependent relaxation time [37,38]. 
For the later procedure, n and a were taken from pure COP to estimate the melt vis-
cosity of a desired blend. In the case of λ and due its temperature- and Tg-dependency, 
it was adjusted by (Eq. (6.4)), 
𝑎𝑇 =  
𝜂0,𝑏𝑙𝑒𝑛𝑑
𝜂0,𝐶𝑂𝑃
     and     𝑎𝑇 =  
𝜆𝑏𝑙𝑒𝑛𝑑
𝜆𝐶𝑂𝑃
       (6.4) 
where the index “COP” denotes the data of pure COP at a set reference temperature 
and index “blend” the desired blend with known Tg.  
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Furthermore, the William-Landel-Ferry fit (WLF-fit, Eq. (6.5)) was employed to describe 
the temperature-dependency of melt viscosity, 
log(𝑎𝑇) =
−𝐶1 (𝑇−𝑇0)
𝐶2+(𝑇−𝑇0)
       (6.5) 
where C1 and C2 are empirical constants, T0 is the reference temperature and T is the 
desired temperature [39,40]. In our further procedure, C1 and C2 were taken from pure 
COP data at a set reference temperature. In summary to estimate the melt viscosity of 
a desired blend with the help of the Carreau-Yasuda and WLF-fit, η0 and λ were ad-
justed to the desired blend by using its Tg, whereas all other parameters were taken 
from pure COP data at the same reference temperature.  
In Figure 6.4, model-based and measured melt viscosity of the investigated blends 
were shown. In the case of model-based melt viscosity, IMC 5 % and PEG 1.38 % had 
identical glass transition temperatures thus the same model-based melt viscosity curve 
was obtained, the same happened for IMC 20 % and DPD 32.5 %. In the case of Tg-
group 1, the melt viscosity data were almost identical.  
 
Figure 6.4 Comparison of Carreau-Yasuda fits from experimental (dark colour) and 
estimated viscosity (pale colour) at 150 °C, Tg-group 1 in black, Tg-group 2 in red and 
Tg-group 3 in blue. 
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With increasing API-content and decreasing Tg, the difference between the model-
based melt viscosity and measured viscosity increased from Tg-group 1 to Tg-group 3. 
The highest variation was found for PEG 8.5 % where the model-based melt viscosity 
(η0 = 415 Pa·s) was much lower than the measured melt viscosity (η0 = 1,796 Pa·s). 
This behavior might be triggered by inhomogeneities in the PEG-COP mixture during 
DSC measurements, as we already described in our recent work [34]. Therefore, this 
variation is more due to measuring issues in DSC than to a limitation in our correlation. 
Concerning the two temperature regimes, no substantial difference in data accuracy 
between them could be found. 
To investigate, whether the difference in model-based and measured melt viscosity is 
mainly influencing the simulation of extrusion trials, measured SME in extrusion trials, 
conventional simulation and simulation by using a model-based melt viscosity and 
COP physical properties, were compared (Fig 6.5).  
 
Figure 6.5a-b Comparison of specific mechanical energy (SME) evaluated by extru-
sion experiments, extrusion simulation with measured and estimated viscosity at a 
fixed temperature (150 °C) (a) and temperature gradient (140 – 170 °C) (b). 
In all cases, the model-based simulation was similar to the conventional simulation. 
Due to measuring issues during Tg determination by means of DSC, PEG 8.5 % had 
the highest deviation of 38 % between model-based and conventional simulation by 
Ludovic®. In most cases, the simulated SMEs by using model-based melt viscosity 
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deviated not more than approx. 10 % from the conventional simulation with measured 
melt viscosity of the blend. However, due to the high API content of IMC 45 % and 
DPD 32.5 %, the SME varied of approx. 25 % from the conventional simulation. At the 
end, the simulation of IMC 45 % and DPD 32.5 % with model-based viscosity super-
imposed more with the experimental SME, compared to the conventional simulation 
but this might be coincidental.  
In conclusion, an estimation of melt viscosity for amorphous solid dispersion to predict 
the energy consumption of later extrusion trials by using the simulation software Lu-
dovic® was feasible. Accordingly, our proposed procedure can be used prior any ex-
trusion run in early stage development. It reduces the effort of physicochemical char-
acterization of each formulation that should be investigated. However, as a proof of 
concept, the evaluation of APIs in COP and ASD thereof, which were not considered 
to establish the Tg-viscosity correlation in the first place, is still ongoing work.  
6.7.4 Comparison of residence time distribution 
Residence time distribution (RTD) was compared between the experimental data, con-
ventional simulation and simulation by using model-based melt viscosity. The time of 
onset (tOnset), peak (tPeak), mean (tMean) and offset (tOffset), where 95 % of the API/Tracer 
was washed out, were investigated. Both temperature regimes were evaluated but no 
variation in data could be found (data not shown). Therefore, only RTD measurements 
and computation at 150 °C are presented (Table 6.3).  
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Table 6.3 Residence time distributions at 150 °C of extrusion experiments and com-
putation by Ludovic® using either experimental characteristics of the COP-blend, or 
estimated viscosity and physical properties of pure COP. 
RTD 
parameter 
[s] 
 
Tg-group 1  
(Tg: ~102 °C) 
Tg-group 2 
(Tg: ~91 °C) 
Tg-group 3 
(Tg: ~80 °C) 
COP 
IMC 
5% 
PEG 
1.38% 
CBZ 
4.7% 
IMC 
20% 
PEG 
4% 
DPD 
32.5% 
IMC 
45% 
PEG 
8.5% 
IBU 
10.5% 
Measured residence time distribution 
tOnset 
(± SD) 
116 
(± 12) 
110 
(± 5) 
129 
(± 9) 
114 
(± 13) 
147 
(± 20) 
137 
(± 17) 
139 
(± 22) 
136 
(± 5) 
162 
(± 19) 
159 
(± 36) 
tPeak 
(± SD) 
246 
(± 28) 
260 
(± 18) 
289 
(± 25) 
258 
(± 17) 
280 
(± 8) 
301 
(± 3) 
299 
(± 11) 
293 
(± 22) 
328 
(± 7) 
319 
(± 21) 
tMean 
(± SD) 
297 
(± 31) 
315 
(± 7) 
339 
(± 21) 
310 
(± 8) 
327 
(± 2) 
354 
(± 4) 
331 
(± 26) 
361 
(± 6) 
376 
(± 5) 
383 
(± 4) 
tOffest (95%) 
(± SD) 
472 
(± 50) 
497 
(± 1) 
529 
(± 69) 
477 
(± 23) 
488 
(± 5) 
522 
(± 2) 
501 
(± 58) 
557 
(± 11) 
578 
(± 9) 
578 
(± 31) 
Simulated residence time distribution with measured viscosity  
tOnset 
(± SD) 
153 
(± 23) 
154 
(± 13) 
157 
(± 17) 
154 
(± 6) 
164 
(± 7) 
157 
(± 7) 
152 
(± 6) 
172 
(± 8) 
165 
(± 7) 
159 
(± 12) 
tPeak 
(± SD) 
262 
(± 40) 
264 
(± 23) 
267 
(± 33) 
263 
(± 10) 
282 
(± 13) 
268 
(± 10) 
260 
(± 11) 
296 
(± 13) 
282 
(± 14) 
269 
(± 24) 
tMean 
(± SD) 
350 
(± 54) 
354 
(± 32) 
356 
(± 44) 
352 
(± 15) 
377 
(± 18) 
358 
(± 15) 
347 
(± 15) 
397 
(± 18) 
376 
(± 18) 
360 
(± 32) 
tOffest (95%) 
(± SD) 
606 
(± 96) 
613 
(± 57) 
614 
(± 78) 
610 
(± 26) 
655 
(± 32) 
617 
(± 26) 
602 
(± 27) 
690 
(± 32) 
651 
(± 31) 
622 
(± 57) 
Simulated residence time distribution with estimated viscosity, physical properties of pure 
COP 
tOnset 
(± SD) 
- 
154 
(± 13) 
161 
(± 11) 
153 
(± 6) 
161 
(± 7) 
157 
(± 6) 
149 
(± 6) 
172 
(± 8) 
165 
(± 7) 
159 
(± 12) 
tPeak 
(± SD) 
- 
263 
(± 24) 
275 
(± 22) 
261 
(± 10) 
276 
(± 13) 
257 
(± 11) 
256 
(± 11) 
269 
(±13) 
282 
(± 14) 
269 
(± 24) 
tMean 
(± SD) 
- 
352 
(± 32) 
366 
(± 28) 
350 
(± 15) 
369 
(± 17) 
356 
(± 15) 
342 
(± 15) 
397 
(± 18) 
376 
(± 18) 
360 
(± 32) 
tOffest (95%) 
(± SD) 
- 
610 
(± 57) 
632 
(± 50) 
607 
(± 26) 
641 
(± 31) 
615 
(± 27) 
592 
(± 27) 
690 
(± 32) 
651 
(± 31) 
622 
(± 57) 
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In the case of experimental RTD, the lowest mean residence time (MRT) of 297 s was 
observed for COP. The MRT further increased from Tg-group 1 (approx. 320 s) to Tg-
group 2 (approx. 340 s) and Tg-group 3 (approx. 370 s). In the case of IMC, CBZ, and 
DPD-containing blends, the increase in RTD corresponded to an increase in API con-
tent (MRT: CBZ 4.7 % < IMC 5 % < IMC 20 % < DPD 32.5 % < IMC 45 %). CBZ 4.7 % 
with the lowest API content exhibited the lowest MRT of 310 s and IMC 45 %, with the 
highest API content, achieved the highest MRT of 361 s. The increased MRT at high 
API content might be a reason of the higher API particle fraction. When the API content 
is increased, API particles were longer present as in low API-content blends, since the 
process of API-dissolution within the polymer is prolonged. If a considerable fraction of 
API particles is present, the material tends to plug flow (likely due to insufficient tacki-
ness to extruder barrel wall) which decreased the forward transport in the extruder. 
Therefore, an increasing API or particle fraction was increasing the RTD, respectively. 
In the case of COP blends containing low melting point substances (IBU, PEG), the 
RTD further increased, compared to the other COP-blends. The MRT increased from 
PEG 1.38 % (MRT: 339 s) to IBU 10.5 % (MRT: 383 s), again as a function of API 
content (MRT: PEG 1.38 % < PEG 4 % < PEG 8.5 % < IBU 10.5 %). In general, an 
extruder is performing like a spindle pump but in an ineffective way. Therefore, adhe-
sion between the specimen and barrel is needed to transport material forward. In case 
of low melting point substances, this transport is decreased as a reason of a low vis-
cous melt prior the softening of the COP particles. This reduced forward transport ex-
plains the higher RTD compared to the other COP-blends. Additionally, the COP-
blends containing PEG and IBU were extruded twice at 150 °C to evaluate if the same 
behavior, as in SME measurements, was present. In all cases, no differences in RTD 
between the first and the second extrusion run was observed (data not shown). 
However, the highest influence on RTD in our experiments had the feed rate and the 
filling fluctuation of the volumetric feeder used, respectively. Furthermore, the RTD 
measurement at a small-scale extruder are always uncertain compared to measure-
ments at larger scale extruders. In general, RTD is mainly influenced by throughput 
and screw speed and less by temperature and melt viscosity [41,42].  
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Regarding the HME experiments and conventional simulation, the RTD was in good 
accordance to each other. However, tOnset and the mean residence time (MRT, tmean) 
were up to 60 s higher computed than measured. The highest deviation of MRT be-
tween experimental and computed MRT was found for pure COP with 18 %. Especially 
in simulation, the MRT seemed constant between the different Tg-groups. The highest 
MRT was found for IMC 45 %, which might be triggered by a low Tg and melt viscosity. 
Additionally, no tendency in the slight tPeak variation was found. Furthermore, tOffset dif-
fered between experimental data (472 s – 578 s) and conventional simulation (602 s – 
690 s). Since the RTD is measured in HME by using iron oxide and a camera, the 
camera might not be able to detect very low concentration of tracer, which led to a 
decrease in tOffset. In summary, although there was some deviation between simulated 
and measured RTD, the validation of the accuracy in simulation, when model-based 
melt viscosity etc. were used instead of measured properties, might be sufficient.  
In the case of simulation using model-based melt viscosity and physicochemical prop-
erties of COP, the RTD superimposed with the conventional simulation. The deviation 
in data did not exceed 3 % thus using model-based values in simulation did not influ-
ence the RTD calculation. Consequently, the use of model-based values in terms of 
HME simulation for the production of ASD was not influencing the computation of RTD. 
However, differences (up to 60 s) between computed and real-time measurements 
were present which might be related to the volumetric feeder (variance in feed rate) 
used or due to limitations in computation. 
6.8 Discussion 
In most cases Ludovic®, as an easy one-dimensional model to simulate hot-melt ex-
trusion with low computation time, the simulation was consistent with HME experi-
ments. The higher SME derived from HME trials compared to the simulation was likely 
triggered by energy loss between the gearbox and the rotating screws (Fig 6.2). There-
fore, this behavior might be related to the specific 12 mm extruder used and less to the 
simulation software itself. It is expected to be more accurate when using another ex-
truder, especially larger size extruders with better torque transmission and instrumen-
tation spread over the entire process length of the extruder (multiple temperature and 
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pressure readings). In general, deviations between experimental and simulated SMEs 
are multifactorial. It might be related to the torque transmission, but also due to a vague 
extruder temperature measurement, changes in viscosity during extrusion (due to API 
melting and/or degradation) or issues during simulation (simplifications). For evaluat-
ing the various factor susceptibility on overall simulation accuracy, additional experi-
ments and subsequent simulations at various scale and extrusion setup are needed. 
Especially, the simulation failed and calculated a much lower energy consumption than 
present when low melting point substances were regarded (Fig 6.2a). By extruding 
PEG and IBU containing COP-blends twice, the reason for this gap between computed 
and measured SME was identified as phase segregation effects during HME experi-
ments. Furthermore, the softening of the polymer was prolonged and shifted from the 
kneading block to the conveying zone, further increasing the SME. However, to vali-
date the use of model-based melt viscosity instead of measured melt viscosity for sim-
ulation purposes, Ludovic® was feasible. 
Conventional simulation and simulation by using only the glass transition temperature 
to estimate the melt viscosity of a blend, led to similar outcomes. Therefore, a similar 
accuracy in hot-melt extrusion simulation was achieved, compared to the conventional 
simulation. Furthermore, using the physical properties of COP (e.g. true density and 
heat capacity) instead of a desired blend was feasible without any exceptions (Table 
6.2, Fig 6.2). Using model-based melt viscosity data by taking the constants of Car-
reau-Yasuda equation (e.g. n, a) and WLF-fit (e.g. C1, C2) of pure COP and adjusting 
λ and η0 to the Tg of a desired blend, led to an accurate estimation in most cases (Fig 
6.3, 6.4). In contrast, an imprecise estimation of melt viscosity, for example due to a 
high drug content, would subsequently lead to a more and more vague HME simula-
tion, as it was seen for IMC 45 % and DPD 32.5 % (Fig 6.5). Furthermore, the accurate 
estimation of melt viscosity depended heavily on a valid Tg-measurement by means of 
DSC. It was seen for PEG 8.5 %, biased Tgs by inhomogeneity during DSC measure-
ment likely caused an inaccurate estimate of melt viscosity and furthermore an impre-
cise HME simulation.  
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In the case of residence time distribution, an increase as a function of API/plasticizer 
content was observed (Table 6.3). Due to the higher fraction of API/plasticizer parti-
cles, plug flow was increased. Thus, the forward transport in the extruder was de-
creased and the RTD prolonged. The presence of low melting point substances within 
the blend further prolonged the MRT, due to a decreased forward transport induced by 
a low viscous melt prior the softening of COP. Regarding the difference between con-
ventional simulated and experimental RTD, a variation of up to 18 % in MRT was ob-
served. This might be related to the volumetric feeder and/or small-scale extruder used 
or due to limitations in computation. However, the deviation of conventional simulation 
and simulation using model-based melt viscosity was negligible. Therefore, using 
model-based melt viscosity and the properties of the pure polymeric matrix to calculate 
RTD is sufficient. 
To conclude, simulation with model-based melt viscosity data provided similar results 
than conventional computation for both: energy consumption or residence time distri-
bution. Therefore, our method enables the “shortcut” of experimental data to a simple 
Tg measurement of a desired formulation and the characterization of the polymer ma-
trix only. This simplifies the use of hot-melt extrusion simulation at an early stage of 
development where several formulations need to be tested. It supports a rational de-
velopment and it leads to reduction of needed extrusion trials to define the best formu-
lation and process conditions to form ASD.  
6.9 Conclusion 
A method to “shortcut” experimental data for the use in hot-melt extrusion simulation 
(1D simulation software Ludovic®) was established and validated. Several process 
characteristics of HME (e.g. residence time distribution, energy consumptions) and 
physical properties (e.g. heat capacity, density, melt rheology) of the investigated mix-
tures has been considered. The use of model-based melt viscosity by using only the 
glass transition temperature of the blend, led to similar simulation outcomes as with 
measured melt viscosity, if a critical API content was not exceeded (approx. 30 %). By 
using model-based melt viscosity data and further physical properties (e.g. true den-
sity, heat capacity, melt viscosity) of the pure polymeric matrix, the experimental effort 
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prior to HME simulation was minimized. However, the accuracy of conventional simu-
lation needs to be improved and influencing factors, which increase deviations be-
tween experiment and simulation, has to be determined in more detail. In conclusion, 
our procedure enables the estimation of a good starting point for HME trials. This sup-
ports a rational development for forming amorphous solid dispersions and it leads to a 
reduction of extrusion trials needed to define the best formulation and process condi-
tions in HME.  
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7.1 Graphical abstract 
 
7.2 Abstract 
A validation for the use of model-based melt viscosity in hot-melt extrusion numerical 
simulations was presented. Here, the melt viscosity of an amorphous solid dispersion 
(ASD) was calculated by using its glass transition temperature (Tg) and the rheological 
flow profile of the pure polymeric matrix. All further required physical properties were 
taken from the pure polymer. For forming the ASDs, four active pharmaceutical ingre-
dients (APIs), that had not been considered in first place to establish the correlation 
between Tg and melt viscosity were examined. The ASDs were characterized in terms 
of density, specific heat capacity, melt rheology, API solubility in the polymeric matrix, 
and deviation from the Couchman–Karasz fit to, identify the influencing factors of the 
accuracy of the simulation using model-based melt viscosity. Furthermore, the energy 
consumption of the hot-melt extrusion (HME) experiments, conventional simulation, 
and simulation using model-based melt viscosity were compared. It was shown, with 
few exceptions, that the use of model-based melt viscosity in terms of the HME simu-
lation did not reduce the accuracy of the computation outcome. The commercial one-
dimensional (1D) simulation software Ludovic® was used to conduct all of the numeri-
cal computation. As model excipients, vinylpyrrolidone-vinyl acetate copolymer (COP) 
in combination with four APIs (celecoxib, loratadine, naproxen, and praziquantel) were 
investigated to form the ASDs. 
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7.3 Keywords 
hot-melt extrusion, melt rheology, glass transition temperature, amorphous solid dis-
persion, simulation, prediction model 
7.4 Chemical compounds studied in this article 
Celecoxib (PubChem CID: 2662); Loratadine (PubChem CID: 3957); Naproxen 
(PubChem CID: 156391); Praziquantel (PubChem CID: 4891); Copovidone (PubChem 
CID: 25086-89-9) 
7.5 Introduction 
Nowadays, one of the major challenges in pharmaceutical small molecule formulation 
development is the increasing number of poorly soluble active pharmaceutical ingredi-
ents (APIs) and the respective poor bioavailability. To enhance the solubility of these 
APIs, the formation and stabilization of amorphous solid dispersions (ASDs) is com-
monly used. For manufacturing ASDs, hot-melt extrusion (HME), as a continuous and 
solvent-free process, was often reported [1–6]. Unfortunately, HME is a time and API-
consuming procedure, especially in early ASD formulation development, as the various 
process parameters, such as screw speed, throughput, screw configuration, and tem-
perature profile lead to a complex multivariable process, which is challenging to opti-
mize or scale-up [7–9]. 
Simulation has been found to be a valid and useful tool to ease HME optimization, 
scale-up, and to improve the comprehension of the processes itself in order to reduce 
the remaining API crystallinity and degradation [7,9–12]. By using simulation, the tem-
perature, pressure, and shear profiles along the screws are computed and the process 
window for HME can be defined [13]. However, the main drawback of HME simulation 
is the need for experimental product input data to conduct computation. In some cases, 
these data are not easy to access, especially in terms of melt rheology and thermo-
sensitive APIs. Furthermore, the use of simulation for early formulation screening is 
limited, as the physicochemical characteristics would need to be laboriously measured 
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for every formulation under consideration. As simulation is an inevitable tool to evalu-
ate a potential adiabatic scale-up from small- to large-scale extruders, the above-men-
tioned drawbacks of HME simulation need to be solved [9]. 
Several challenges in performing the HME simulation were already addressed by sev-
eral researchers. In the case of screw configuration optimization, different algorithms 
and process modellings have been used to define the best operating conditions for an 
extrusion process [12,14]. Investigations into improve the understanding of the ex-
truder performance in mixing capability, mixing elements, and kneading blocks as a 
function of the staggering angle were evaluated [15]. It was shown that distributive 
mixing is more related to the staggering angle than to the disc width, and that mixing 
elements did not performed significantly better than normal conveying elements. Fur-
thermore, the pressure-dependent wall slippage at the barrel and screw surface as 
well as the modelling fillers in the HME process have been investigated, which is es-
pecially important for the extrusion simulation with melt suspensions [16,17]. Investi-
gations on the simulation of residence time distributions (RTD) revealed that the spe-
cific throughput, a ratio of throughput over screw speed, is one of the key process 
parameters in order to control RTD and to determine the flow conditions during extru-
sion [18,19]. 
In our recent work, we proposed a procedure to model the melt viscosity of an ASD by 
using only its glass transition temperature (Tg) and the rheological flow profile of the 
pure polymeric matrix [20]. It simplifies the application of the HME simulation by reduc-
ing the required physicochemical characterization of the ASD. Therefore, the experi-
mental effort was decreased without compromising the accuracy of the computation, 
which has been proven by comparing the simulation using model-based melt viscosity, 
conventional simulation, and the data of experimental trials [21]. However, all of the 
investigated APIs so far were already used to establish the Tg-melt viscosity correlation 
in the first place, and thus a validation with new APIs is needed.  
Therefore, the purpose of this work was to ease the HME simulation by providing evi-
dence for the Tg-melt viscosity correlation. Four APIs (celecoxib, loratadine, naproxen, 
and praziquantel), which were not used to establish the Tg-melt viscosity correlation in 
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the first place, were used to form model ASDs of various Tg. As the applied process 
simulation is not able to predict the physical stability of the ASDs, this paper focuses 
on the process simulation only. The physical stability of the ASDs would need to be 
evaluated by other models, as proposed by various authors [22–25]. The ASDs were 
further characterized in terms of density, specific heat capacity, melt rheology, API 
solubility in the polymeric matrix, and deviation from the Couchman–Karasz fit. The 
influence of these factors to the accuracy of the simulation using model-based melt 
viscosity was evaluated, whereas the density, specific heat capacity, and melt rheology 
are the input parameter for the simulation itself. The commercial one-dimensional (1D) 
simulation software, Ludovic® (Sciences Computers Consultants, Saint Etienne, 
France), was used to conduct the conventional HME simulation and simulation by us-
ing model-based melt viscosity and further physicochemical characteristics of the pure 
polymeric matrix only. Both simulation procedures were compared to the extrusion tri-
als by means of energy consumptions. 
7.6 Material and methods 
7.6.1 Material 
Praziquantel (PZQ) was obtained from Divis Laboratories Ltd. (Telangana, India), 
loratadine (LOR) was purchased from Sris Pharmaceutials (Telangana, India), 
naproxen (NAP) was received from Sigma Aldrich (St. Louis, MO, USA), and celecoxib 
(CXB) was obtained from Cadila Pharmaceuticals Ltd. (Ahmedabad, India). Vinylpyr-
rolidone-vinyl acetate copolymer (copovidone, Kollidon® VA 64, COP) was kindly do-
nated by BASF SE (Ludwigshafen, Germany) (Table 7.1). All of the investigated APIs 
belong to BCS (Biopharmaceutics classification system) Class II and were thermally 
stable over the applied temperature range. None of the selected APIs were used to 
establish the Tg-melt viscosity correlation in the first place, and thus served for model 
validation [20,21]. 
  
 7. Validation of model-based melt viscosity in hot-melt extrusion numerical simulation  
 
 
144 
Table 7.1 Physicochemical properties of substances used. The molecular weight was 
taken from PubChem Substance and Compound databases [26], all other parameters 
were experimentally determined. 
Substance Molecular 
weight [g/mol] 
Melting point 
[°C] 
Glass transition 
temperature [°C] 
Heat capacity 
step at Tg [J/g·K] 
Celecoxib (CXB) 381.4 160.9 56.8 0.39 
Loratadine (LOR) 382.9 134.6 34.9 0.30 
Naproxen (NAP) 230.3 156.1 6.71 0.23 
Praziquantel (PZQ) 312.4 138.3 35.9 0.37 
Copovidone (COP) 45,000 - 70,000 - 107 0.40 
1measured with 10% COP weight fraction because of the active pharmaceutical ingredients (APIs) 
recrystallization tendency. 
7.6.2 Methods 
7.6.2.1 Helium pycnometry 
The true density of the powder blends and extrudates were measured using the helium 
pycnometer AccuPyc 1330 (Micromeritics GmbH, Norcross, GA, USA) with 20 purge 
cycles at a fill pressure of 136.86 kPag. The samples were analyzed in 25 runs or until 
a standard deviation of 0.01% was reached, using a fill pressure of 136.86 kPag and 
an equilibration rate of 0.0345 kPag/min. The procedure was repeated two times for 
every material. The true density of the powder blends and extrudates were used as the 
input parameters for the HME simulation software, Ludovic®. 
7.6.2.2 Differential scanning calorimetry (DSC) 
In order to identify the heat capacities and glass transition temperatures of the investi-
gated blends, a DSC 2 (Mettler Toledo, Gießen, Germany) was used. It was equipped 
with an auto sampler, nitrogen cooling, and nitrogen as purge gas (30 ml/min), and the 
system was calibrated with n-octane, indium and zinc standards. In the case of the Tg-
determination as a function of the API weight fraction, at least three samples for each 
mixture, of approximately 10 mg, were analyzed in 40 μl aluminum pans with a pierced 
lid. The Tg-determination was conducted after the annealing of the sample in order to 
define the solubility of the API in the polymeric melt. Please see section 7.6.2.3 for a 
more detailed description of the DSC method. 
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The heat capacities were measured using a sapphire standard in TOPEM® mode 
(modulated DSC) with 1 K pulse height, 15–30 s pulse width, and an underlying heat-
ing rate of 2 K/min. For every blend, three samples of approximately 10 mg were 
weighed in 40 μl aluminum pans with pierced lids. All of the pans used, including the 
reference and the pan with the sapphire standard, did not differ more than 0.1 mg in 
weight from each other. All of the samples were annealed at elevated temperatures for 
a homogenous API-distribution during the subsequent heat capacity measurement. 
Every blend for DSC was prepared by using a MM400 ball mill (Retsch GmbH, Haan, 
Germany) with 30 Hz and 3x 5 min milling cycles. 
7.6.2.3 Solubility determination via DSC 
To determine the API solubility in vinylpyrrolidone-vinyl acetate copolymer (COP), a 
protocol of our previous work was used [23]. It determines the solubility of the APIs 
indirectly, using the glass transition temperature (Tg). The method itself consists of an 
annealing step and a subsequent Tg analysis of the annealed sample, as well as a 
further Tg analysis of a completely molten and amorphous sample at elevated temper-
atures (T > Tm). 
In more detail, every sample was annealed at a temperature approximately 60 °C 
above the predicted Tg, blend by the Couchman–Karasz fit, so as to enable a viscous 
system that promotes an equilibrated state of the solubilized API at the annealing tem-
perature (TAnnealing). Subsequently, the sample is cooled and heated again by 10 K/min 
to determine the Tg of this annealed sample. The mentioned heating step ended 10 K 
above the melting point of the API to obtain a completely amorphous system, which is 
further analyzed by a cooling–heating cycle with 10 K/min to evaluate the Tg of this 
amorphous system. 
This procedure is conducted by using different API/polymer weight fractions. At the 
end, the first determined Tg serves as an indicator of the soluble API fraction at 
TAnnealing, while the second Tg was used for the characterization of the weight fraction-
dependent curve progression of Tg by employing the Brostow Chiu Kalogeras 
Vassilikou-Dova fit (BCKV-fit, Equation 7.1), 
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𝑇𝑔 = 𝑤1𝑇𝑔,1 + (1 − 𝑤1)𝑇𝑔,2 + 𝑤1(1 − 𝑤1)[𝑎0 + 𝑎1(2𝑤1 − 1) + 𝑎2(2𝑤1 − 1)
2]            (7.1) 
where a0, a1 and a2 are variables [27]. The polynomial form of the BCKV-fit enables 
the consideration of positive and negative deviation from the Couchman-Karasz fit 
(CK-fit, Equations 7.2-3). It is therefore appropriate for the identification of the solubil-
ized API fraction in the annealed samples, by employing the API weight fraction-de-
pendent curve progression of glass transition temperature. 
𝑇𝑔 =
𝑤1𝑇𝑔,1+𝑘𝐶𝐾(1−𝑤1)𝑇𝑔,2
𝑤1+𝑘𝐶𝐾(1−𝑤1)
        with ∆𝑇𝑔 = 𝑇𝑔,2 − 𝑇𝑔,1    (7.2) 
𝑘𝐶𝐾 =
𝛥𝐶𝑝,2
𝛥𝐶𝑝,1
        (7.3) 
 
In the Couchman-Karasz equation, w is the weight fraction, kCK is the Couchman-
Karasz constant Cp the heat capacity step at Tg and the sub-scripts 1 and 2 refer to the 
API and polymer, respectively [28].  
To predict an API solubility phase diagram, the soluble API fraction at a respective 
temperature was fitted using Equation 7.4, 
𝑇𝐴𝑛𝑛𝑒𝑎𝑙𝑖𝑛𝑔 = 𝑦0 + 𝐴 ∙ 𝑒𝑥𝑝
𝑅0∙𝑥     (7.4) 
where x is the soluble API fraction at the respective temperature, A and R0 are fitting 
constants, and y0 corresponds to the API melting point, but was set as a variable. In 
general, solubility is referred to as an extrapolation of the dissolved API at 25 °C. Thus, 
the solubility curve represents the condition at which a crystalline API is solubilized by 
the polymeric matrix, forming a one phase amorphous solid dispersion. 
The obtained solubility curve was confirmed by x-ray powder diffraction (XRPD) meas-
urements, which were in good accordance to the DSC findings (data not shown). In 
most cases, the XRPD results showed a slightly lower solubility of approximately 5% 
the API in the polymeric melt than in DSC, as XRPD is more sensitive to crystalline 
residuals than DSC. 
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7.6.2.4 Small-amplitude oscillatory shear (SAOS) measurements 
The rheometer Haake® MARS® III of Thermo Scientific (Karlsruhe, Germany), 
equipped with a 20 mm plate-plate geometry was used. For all of the experiments, the 
gap height was set to 0.75 mm and the amplitude to 5.0%, which was determined as 
suitable by an amplitude sweep. The measurements were further conducted using the 
controlled deformation AutoStrain mode, in which the deflection is adjusted to a given 
amplitude range after every sine wave of deformation. Frequency sweeps were applied 
in the range of 10 Hz to 0.1 Hz in 10 K steps. The obtained frequency sweeps, in which 
the specimen was thermorheologically simple, were further employed to create a mas-
ter curve by means of time temperature superposition (TTS). Consequently, every sin-
gle frequency sweep is horizontally shifted into one master curve at a set reference 
temperature. The obtained melt viscosity flow profile was fit to a reduced Carreau-
Yasuda equation (CY-equation, Equation 7.5), 
𝜂 =  𝜂0 ∙ [1 + (𝜆?̇?)
𝑎](𝑛−1)/𝑎       (7.5) 
where n and a are constants, λ is a temperature-dependent relaxation time, and η0 is 
the zero-shear viscosity [29,30]. The shift factors, aT, derived from TTS, were em-
ployed in the William-Landel-Ferry fit (WLF fit, Equation 7.6) to characterize the tem-
perature-dependent behavior of the blend’s melt viscosity. 
log(𝑎𝑇) =
−𝐶1 (𝑇−𝑇0)
𝐶2+(𝑇−𝑇0)
       (7.6) 
C1 and C2 are empirical constants, T0 is the reference temperature, and T is the desired 
temperature [31,32]. 
7.6.2.5 Procedure to generate the model-based melt viscosity 
In our recent work, we proposed a correlation between Tg and zero-shear viscosity η0 
of an amorphous solid dispersion and its use in HME simulation [20,21]. At a set refer-
ence temperature, the rheological flow profile of pure COP with its variables in the CY-
fit and WLF-fit served as a starting point for the model-based viscosity calculation. The 
parameters n and a of the COP CY-fit and the variables in WLF-fit were considered as 
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constants. The zero-shear viscosity, η0, was adjusted via the Tg of the investigated 
blends, using our proposed Tg-melt viscosity correlation (Equation 7.7), 
𝜂0 = 𝑎 ∙ 𝑒
𝑏∙𝑇𝑔       (7.7) 
where a and b are the empirically determined variables [20]. In the case of a, a tem-
perature-dependency was obtained, but b remained constant over the investigated 
temperature range. To adjust λ of CY-fit as well, the ratio between η0,COP and η0,blend 
was calculated by Equation 7.8, 
  𝑎𝑇,𝑇𝑔 =  
𝜂0,𝑏𝑙𝑒𝑛𝑑
𝜂0,𝐶𝑂𝑃
     and  𝑎𝑇,𝑇𝑔 =  
𝜆𝑏𝑙𝑒𝑛𝑑
𝜆𝐶𝑂𝑃
     (7.8) 
and was applied to λCOP to identify λblend. 
7.6.2.6 Computation of extrusion experiments by using the software Ludovic® 
The simulation software Ludovic® V6.0.1 PharmaEdition (Sciences Computers Con-
sultants, Saint Etienne, France) for hot-melt extrusion was employed. As a one-dimen-
sional approach, it computes the non-isothermal flow conditions in the extrusion pro-
cesses and calculates various parameters along the screw profile (e.g., global energy 
distributions, temperature, pressure, shear rate, residence time, etc.). At the first re-
strictive screw element, an instantaneous melting of the material is assumed. The com-
putation begins at the die and proceeds backwards in an iterative way, until a final 
product temperature is reached. This procedure is needed, as the extruder is starve-
fed with an unknown filling ratio [33–35]. In the case of conventional simulation, the 
physical properties and melt viscosity of the desired API/COP-blend were used. In the 
adopted simulation, the physical properties of the pure COP and model-based melt 
viscosity were employed instead [21]. Both of the simulation assumptions use the iden-
tical simulation algorithm, but the product related input parameter for simulation varies, 
leading to a reduced experimental effort in the case of the adopted simulation. 
In more detail, the following product related input parameters need to be measured 
prior conventional simulation: heat capacity (solid and liquid state), density (solid and 
liquid state), thermal conductivity, glass transition temperature, and the melt viscosity 
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of the formulation. For the thermal conductivity, an approximation of 0.18 W·(m·K)-1 is 
made for all of the simulations. To decrease the experimental effort in our adopted 
simulation approach, the following approximation of the product related input parame-
ters were made: heat capacity and density were used from pure COP, and the glass 
transition temperature of the required API-polymer blend needs to be measured. The 
melt viscosity is estimated using the Tg, blend and the rheological profile of COP (please 
see section 7.6.2.5). 
7.6.2.7 Hot-melt extrusion experiments 
For performing the hot-melt extrusion experiments, a co-rotating twin-screw extruder 
ZE 12 (Three-Tec GmbH, Seon, Switzerland) was employed. It had a functional length 
of 25:1 L/D, 12 mm screws, 2 mm die, a maximum torque of 15 N·m and a fixed screw 
configuration, which is depicted in Figure 7.1. The screw speed was set to 100 rpm 
and the throughput was kept constant at 2.0 g/min using a volumetric feeding system. 
The specific mechanical energy (SME) during extrusion was determined by employing 
Equation 7.9, 
𝑆𝑀𝐸 =
2𝜋∙𝑛∙𝜏
?̇?∙60
       (7.9) 
where n is the screw speed [rpm], ṁ characterizes the feed rate [kg/h] and τ is the 
maximum torque per shaft [Nm] with a subtracted idling speed (1.2 Nm). Every physical 
mixture of 60 g for HME experiments was prepared using a Turbula mixer (Willy A. 
Bachofen AG – Maschinenfabrik, Muttenz, Swiss) for 10 min at 50 rpm. 
 
Figure 7.1 Extruder and screw configuration used with conveying elements (9, 12 and 
18 mm pitch) (blue) and kneading elements (30°,60° and 90° staggering angle) 
(green). Reproduced with permission from the authors of [21], Elsevier B.V., 2017. 
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The amorphous state of the obtained extrudates directly after extrusion were confirmed 
by polarized light microscopy with and without λ-filter (data not shown).  
7.7 Results 
7.7.1 API solubility in the polymeric matrix and the deviation from Couchman-
Karasz fit 
In general, the solubility of an API in a polymeric matrix depends on the extent of spe-
cific interactions between both materials (e.g., hydrogen bonding). To evaluate 
whether these specific interactions were influencing the respective melt viscosity of a 
mixture, phase diagrams for every API in COP were generated (Fig 7.2a-d).  
 
Figure 7.2a-d Phase diagrams of celecoxib (a), loratadine (b), naproxen (c) and 
praziquantel (d) in copovidone. 
Celecoxib achieved the highest solubility of 33% in copovidone at 25 °C (Fig. 7.2a). 
and a slightly lower solubility of 25% in COP was found for naproxen (Fig 7.2c). 
Regarding loratadine and praziquantel, these APIs were insoluble in copovidone at an 
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ambient temperature and therefore specific interactions between API and COP were 
assumed as negligible (Fig 7.2b and 2d). All of the conducted BCKV-fits in this 
publication featured a high goodness of fit (0.99> adjusted r2). In the case of 
exponential fit, a slightly lower but more than appropriate accuracy was found (0.98≥ 
adjusted r2). 
To evaluate, whether a deviation from the Couchman-Karasz fit (CK-fit, Equations 7.2-
3) is influencing the accuracy of the model-based melt viscosity calculation, all of the 
CK-fits in comparison to the BCKV-fits (Equation 7.1) and the measured Tgs of the 
API/COP blends in different weight fractions, are shown in Figure 7.3a-d.  
 
Figure 7.3a-d Determined glass transition temperatures (), Couchman-Karasz (CK) 
and Brostow Chiu Kalogeras Vassilikou-Dova (BCKV) fits of celecoxib (a), loratadine 
(b), naproxen (c) and praziquantel (d) in different weight fractions in copovidone. 
Celecoxib was the only API that had a positive deviation of up to 8 °C from the CK-fit. 
For naproxen, a negative deviation of approximately 16 °C was obtained. A similar 
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negative discrepancy between the CK-fit and BCKV fit of 13 and 14 °C was found for 
loratadine and praziquantel in COP, respectively. In general, it is reported that a 
deviation from the CK-fit is connected to the solubility of the API in the polymeric matrix 
[36]. If no deviation from the CK-fit is found, the API is assumed to be insoluble. As all 
of the investigated APIs deviated from the CK-fit, this connection between the 
deviations of the measured Tgs to the CK fit and the solubility of the API in the polymer 
was not observed. 
7.7.2 Evaluation of potential physical property changes 
To investigate the influence of API and its weight fraction on the physical properties of 
the respective API/COP blend, the true density (ρ) and specific heat capacity (cp) of 
the physical mixtures and extrudates were measured, listed in Table 7.2. In the case 
of pure COP, the true density increased slightly from powder (1,178 kg/m3) to the ex-
truded material (1,191 kg/m3) [21]. In comparison to the physical mixtures of the COP-
blends, the true density was similar to pure COP with a negligible increase of up to 4% 
(ρ ≤ 1,230 kg/m3). Furthermore, the extrudates of all COP blends showed an identical 
increase of up to 4% in true density (ρ ≤ 1,237 kg/m3). 
Table 7.2 Glass transition temperature identified by Brostow Chiu Kalogeras 
Vassilikou-Dova (BCKV) fit, true density and heat capacity of the COP-blends 
investigated. 
Mixture Tg [°C] ρ [kg/m3] 
powder 
ρ [kg/m3] 
extrudate 
Cp [J/(g·K)] 
at 25 °C 
Cp [J/(g·K)] 
at 150 °C 
COP 107 1178 1191 1.013 1.720 
CXB 10 % 104 1230 1208 1.142 1.819 
CXB 30 % 101 1279 1237 1.011 1.878 
LOR 10 % 96 1215 1202 1.143 2.003 
LOR 30 % 75 1200 1204 1.097 1.864 
NAP 10 % 92 1190 1202 1.182 1.963 
NAP 30% 71 1217 1209 1.117 1.883 
PZQ 10 % 96 1220 1200 1.165 1.899 
PZQ 30% 72 1200 1209 1.104 1.862 
 
In the case of the specific heat capacity, a temperature-dependent increase for the 
pure COP from 1.013 J/(g·K) at 25 °C to 1.720 J/(g·K) at 150 °C was observed [21]. 
Regarding the API/COP physical mixtures, an increase in specific heat capacity of up 
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to 14% (cp ≤ 1.182 J/(g·K)) at 25 °C and at 150 °C (cp ≤ 2.003 J/(g·K)) was found, 
respectively.  
The only slight deviation of the true density and specific heat capacity of COP-blends 
from the pure COP data were in good accordance to the findings in our recent work 
[21]. We already showed that a small deviation in both of the parameters did not affect 
the later use of pure COP data instead of the COP-blends data, as required by the 
input parameters for the Ludovic® simulation software. Furthermore, the accuracy of 
the computation outcomes for the 12 mm twin-screw extruder used was not reduced. 
Therefore, the small differences in the density and specific heat capacity of the ASDs 
compared with the pure polymeric matrix were assumed as negligible. In the case of 
the model-based simulation, the data of the pure COP instead of the COP-blend values 
were further investigated. 
7.7.3 Comparison of SAOS measurements and model-based melt viscosity 
calculation 
The measured melt viscosity and the model-based melt viscosity as a function of an-
gular frequency at 150 °C is shown in Figure 7.4a-d. In general, the model-based melt 
viscosity of the 10% API/COP-blends were in better accordance with the measured 
data than the respective 30% API/COP-blends. The best agreement was found for 
NAP10%, for which both of the viscosity curves were superimposed (η0,measured= 
7198 Pa·s to η0,estimated= 7141 Pa·s) (Figure 7.4c). Among all of the 10% API-blends, 
the highest deviation between the viscosities was found for CXB10% (η0,measured= 
40,791 Pa·s to η0,estimated= 56,292 Pa·s) (Figure 7.4a). In the case of the 30% API/COP-
blends, the discrepancy between the measured and model-based melt viscosity in-
creased for both CXB30% (η0,measured= 9381 Pa·s to η0,estimated= 29,114 Pa·s) and 
LOR30% (η0,measured= 1488 Pa·s to η0,estimated= 343 Pa·s) (Figure 7.4a-b). However, 
NAP30% showed a deviation between the model-based melt viscosity to the measured 
data (η0,measured= 259 Pa·s to η0,estimated= 165 Pa·s). In conclusion, the accuracy of the 
melt viscosity estimation via the blend’s Tg was a function of the API weight fraction. 
The border for estimating the melt viscosity with a sufficient accuracy seemed to be 
between a 10-30% API weight fraction, dependent on the API solubility. APIs soluble 
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at 25 °C within COP (e.g. celecoxib) might be underestimated, whereas the insoluble 
APIs (e.g. loratadine) might be overestimated. 
 
Figure 7.4a-d Comparison of estimated melt viscosity and small amplitude oscillatory 
shear (SAOS) experiments at 150 °C for celecoxib (a), loratadine (b), naproxen (c) and 
praziquantel (d) in copovidone. 
7.7.4 Energy consumption in HME experiments, conventional simulation and 
simulation using model-based melt viscosity 
The specific mechanical energy (SME) determined from HME experiments was com-
pared to the energy consumptions obtained from the conventional simulation and the 
simplified simulation aided by using model-based melt viscosity at extrusion tempera-
ture of 150 °C (Figure 7.5a-d). In the HME simulation, SME is the sum of the specific 
energy, dissipated energy and melting energy [37]. In our case, the melting energy 
remained unconsidered in the simulation, because the Ludovic® model does not in-
clude a melting/softening temperature input for the API heat of fusion. Instead, in the 
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relevant input parameter in Ludovic®, the melting temperature was filled with the glass 
transition temperature of the API/COP-blend. 
 
Figure 7.5a-d Energy consumption in hot-melt extrusion (HME) experiments, conven-
tional simulation, and simulation using model-based melt viscosity at 150 °C extrusion 
temperature for celecoxib (a), loratadine (b), naproxen (c) and praziquantel (d) in co-
povidone.6 
When all of the results are considered, because of the dependence of the dissipated 
energy on the melt viscosity, the dissipated energy decreased with both the lower vis-
cosity and higher API content. The conduction energy, which determined the energy 
generated by barrel regulation-induced heat flux, also decreased in a similar manner. 
 7. Validation of model-based melt viscosity in hot-melt extrusion numerical simulation  
 
 
156 
Because of the plasticizing effect of the APIs and the respective decreased melt vis-
cosity and glass transition temperature, all of the 10% API/COP blends achieved a 
higher SME than the corresponding 30% API/COP blend. 
In the conventional simulation and HME experiments, similar SME results were ob-
tained. Because of the 12 mm twin-screw extruder and the volumetric feeding system 
that were used, a variation in the feed rate might cause the slightly higher SME to be 
detected in the extrusion trials compared with the computed SMEs. For highly viscous 
melts, a loss of energy between the gearbox of the extruder and the screws or further 
friction was likely, which further led to discrepancies between the measured and sim-
ulated values. Furthermore, the determined torque for calculating the SME was meas-
ured by energy power and might have uncertainties for our small-scale extruder. In the 
case of the 10% API/COP-blends, the highest deviation between the measured and 
conventional simulated SMEs were seen for CXB10% (58 kWh/t) and NAP10% 
(27 kWh/t) (Fig 7.5a, c). The SMEs of LOR10% and PZQ10% nearly superimposed 
instead (Figure 7.5b and 7.5d). A similar variance in the data between the measured 
and conventional simulated SMEs was found for the 30% API/COP-blends. The SMEs 
of NAP30% were superimposed, whereas the highest deviation in data was found for 
PZQ30% (29 kWh/t) (Figure 7.5c and 7.5d). 
In the case of the model-based simulation, the computation outcomes were in good 
accordance with the conventional simulation (<20% deviation), except CXB30% and 
LOR30%. In the case of the loratadine containing samples, a higher discrepancy be-
tween the model-based and conventional SME was found. As a result of the high API-
content, the model-based computation for LOR30% differed from the conventional one 
and failed to calculate the correct SME. The same findings were observed for the 
celecoxib-containing blends. The SME of CXB10% was simulated similarly by both 
approaches, but in terms of CXB30%, the model-based simulation failed. However, the 
SMEs of the naproxen- and praziquantel-containing blends deviated not more than 
approximately 10 kWh/t from the results of the conventional simulation. For PZQ30%, 
the model-based simulation fits better than the conventional one to the HME experi-
ments, which might be coincidental. Therefore, the use of the model-based melt vis-
cosity in the simulation led to a similar outcome as a conventional HME simulation, as 
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long as a critical API weight fraction is not reached (approximately ≥30%) in the desired 
amorphous solid dispersion. Otherwise, the probability of an inadequate SME compu-
tation might increase. 
7.8 Discussion 
In the case of the solubility in copovidone of the four investigated APIs, celecoxib and 
naproxen were soluble, whereas loratadine and praziquantel were insoluble at room 
temperature. Regarding the deviations from the Couchman–Karasz model, celecoxib 
in copovidone was the only API that achieved a positive deviation from the CK-fit. For 
loratadine, naproxen, and praziquantel, a negative deviation from the CK-fit was ob-
served. The assumption that a deviation from the Couchman–Karasz fit is connected 
to the solubility of the API in the polymeric matrix was not confirmed by our solubility 
findings. All of the APIs had a variation from the CK-fit, but only naproxen and celecoxib 
were actually soluble in copovidone. Especially regarding the 10% API/COP blends, 
the influence of the deviation from the CK model to our adopted HME simulation using 
model-based melt viscosity, cannot be confirmed. In the case of the 30% API/COP 
blends, only celecoxib might show a decreased simulation accuracy, related to the 
positive deviation from the CK model. However, the failed CXB 30% adopted simula-
tion seems more connected to the high solubility of celecoxib in COP than to the devi-
ation from the CK-fit. 
Regarding the estimation of the rheological flow profiles of the investigated API/COP 
blends and the computed energy consumptions in the simulation thereof, the SMEs of 
the 10% API/COP blends corresponded to the experimental findings and to the con-
ventional HME simulation. Accordingly, a 10% API weight fraction did not influence the 
accuracy of the resulted HME simulation, using the mainly estimated product input 
parameter. It leads to the conclusion that a formulation with a 10% API weight fraction 
can be generally be predicted by our adopted HME simulation, independent of the 
API’s nature.  
 7. Validation of model-based melt viscosity in hot-melt extrusion numerical simulation  
 
 
158 
In the case of the 30% API content, the melt viscosity calculation and HME simulation 
for naproxen and praziquantel were consistent with the experimental data. The simu-
lation of SME for celecoxib and loratadine failed, which was a result of the inadequate 
calculated model-based melt viscosities. The rank order from the overestimated to un-
derestimated melt viscosity data compared to experimental results is CXB ‣ NAP ‣ 
PZQ ‣ LOR. This order corresponds perfectly to the solubility order in COP of CXB 
(33%, 25 °C) ‣ NAP (25%, 25 °C) ‣ PZQ (insoluble at 25 °C) ‣ LOR (insoluble at 27 °C). 
Therefore, at high API weight fractions, the solubility and the respective specific inter-
actions between the API and the polymeric matrix might become prominent and influ-
ence the viscosity by decreasing it. In our recent work, the influence of specific inter-
actions on the melt viscosity was already found for indomethacin, which is highly solu-
ble in copovidone (approximately 36% at ambient temperature) [21,23]. Regarding the 
model-based melt viscosity, it seems that not only the glass transition temperature is 
important for such calculation, but also the amount of specific interactions (e.g., solu-
bility) should be considered. If an API is less soluble or insoluble in the polymeric matrix 
of the formulation, our adopted HME simulation is applicable. For highly soluble APIs 
at high API weight fractions, the uncertainty of the HME simulation using the model-
based melt viscosity is increasing and should be carefully regarded. The adopted sim-
ulation approach might fail because of the influence of specific interaction between the 
API and polymer, reducing the melt viscosity to an unpredictable extent. 
Furthermore, the original data set for our Tg-melt viscosity correlation was mainly com-
prising soluble APIs in the range of naproxen and less insoluble APIs. Therefore, our 
original data set might have triggered this uncertainty in the model-based melt viscosity 
calculation independent of the API solubility in COP. An improvement of the melt vis-
cosity calculation would be the consideration of the influence of API solubility on the 
melt viscosity. This is still ongoing work, as the presented data set is not appropriate 
to allow for this consideration. Additionally, the overestimation of the CXB 30% melt 
viscosity might be further triggered by the rarely occurred positive deviation from CK-
fit. 
In general, the use of model-based melt viscosity for amorphous solid dispersions in 
the hot-melt extrusion simulation is feasible to compute energy consumptions thereof, 
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using the Ludovic® software. The experimental short-cut in the HME simulation is func-
tional; however, the assumptions have to be improved to enable the calculation at 
higher API weight fractions. In accordance with our purpose to simplify the use of HME 
computation in early stage development and to reduce the effort needed, we were able 
to prove the good suitability of our model. Therefore, this procedure would enable an 
enhanced and fast estimate of a good starting point for extrusion trials in early drug 
development for amorphous solid dispersions. 
7.9 Conclusion 
A hot-melt extrusion numerical simulation using a model-based melt viscosity and fur-
ther physical properties of the pure polymeric matrix led to accurate computation out-
comes, as did the conventional simulation, with only few exceptions. All of the HME 
simulations, conducted using the commercial 1D simulation software Ludovic®, were 
confirmed by the energy consumptions of the HME experiments. It was shown that 
even APIs, which were not considered to establish the Tg-melt viscosity correlation for 
amorphous solid dispersions in the first place, were impeccably simulated. However, 
the formulations with a high API weight fraction (≥30% w/w) should be regarded cau-
tiously, as a decrease in computation accuracy is likely. This decrease in accuracy was 
likely triggered by the influence of specific interactions as a result of the solubility of 
the APIs, which were not considered in establishing the Tg-melt viscosity correlation. 
In conclusion, reducing the experimental effort prior to the HME simulation using a 
model-based melt viscosity for simulation purposes, was proven as a valuable API-
independent method to simplify the HME process optimization in the early formulation 
development for forming amorphous solid dispersions. 
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8 Summary and outlook 
8.1 Solubility prediction of APIs in polymer melts 
A micro-scale prediction model to define the solubility of an API in a polymeric matrix 
in temperature-dependency by differential scanning calorimetry (DSC) was estab-
lished. It consists of an annealing step and a subsequent analysis of the glass transi-
tion temperature (Tg). By using a complex mathematical model (BCKV-equation), the 
soluble API fraction can be determined by employing the API/polymer ratio-dependent 
Tg curve progression. By using melt-rheological data and XRPD, the validity of the 
annealing step to allow the API-polymer blend to equilibrate at this temperature, was 
confirmed. However, further trials showed that the prediction model was not able to 
correlate to a processing temperature within the HME process. Furthermore, a con-
nection between the deviation from Couchman-Karasz equation as a hint for API sol-
ubility (e.g. specific interactions) in the polymeric matrix was not confirmed. Overall, 
our DSC methodology to identify the API solubility within a polymeric matrix and to 
estimate a temperature-dependent phase diagram for extrapolating the solubility to 
ambient condition was successfully established. It simplifies the formulation screening 
for ASD by hot-melt extrusion. 
A data review on the variety of available API solubility in literature was performed. Data 
out of the data review were compared to our own solubility prediction model and 
showed good agreement. The entire data set comprised seven polymers, commonly 
used for forming ASD, 37 APIs and two sugar derivates. The prediction models used 
in literature were mainly the melting point depression method, dissolution endpoint 
measurements, indirect solubility determination by Tg and the use of low molecular 
weight analogues. It was observed that the resulted API solubility depended less on 
the method used, but rather on the working group and authors who conducted the 
measurements. Due to difficulties in enabling an equilibrated state prior the API solu-
bility determination, the characterization might be generally prone to errors.  
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Regarding molecular weight, no connection or tendency of API solubility on the molec-
ular weight of PVP was observed. Furthermore, the highest API solubility were ob-
served for PVP, the poorest for PVAc. Therefore, the API solubility in the copolymer 
copovidone (PVP and PVAc) depended on the PVP/PVAc ratio used. In the case of 
SOL, the API solubility was always comparable to COP. PMMA, PEG and HPMC 
grades achieved a lower solubility as well, especially compared to PVP.  
In conclusion, a data set for training new developed solubility prediction models was 
established. It can serve for validation and training of even such systems, which are 
based on using only the physicochemical properties of a desired API. The establish-
ment and validation of such prediction models is still ongoing work.  
8.2 Hot-melt extrusion simulation with model-based melt viscosity 
A correlation between glass transition temperature and melt viscosity in temperature / 
angular frequency-dependency of an amorphous solid dispersion (ASD) was success-
fully established. This correlation was largely independent of the added active phar-
maceutical ingredient (API) or plasticizer to copovidone. Negligible dependencies on 
molecular weight, recrystallization tendency, weight fraction (up to 30%) and plasticiz-
ing effect were found. However, a positive deviation from the theoretical Couchman-
Karasz weight fraction-dependent progression of Tg might influence the accuracy of 
the predicted melt viscosity. Furthermore, hints of a connection between variable b of 
the Tg-viscosity correlation (Eq. 5.7) and the API solubility in the polymeric matrix were 
found. A high API solubility may increase the plasticization in the polymeric matrix, 
whereas a non-soluble API may lead to a higher melt viscosity than estimated. Unfor-
tunately, the present data set does not allow a solubility-dependent (e.g. specific inter-
action-dependent) consideration of the Tg-viscosity correlation, but it is an important 
factor to improve our established estimation of melt viscosity. Furthermore, the Tg-vis-
cosity correlation is polymer-dependent. Thus, building up a data base of the most 
commonly used pharma polymers would improve the application of the model-based 
melt viscosity on numerical hot-melt extrusion (HME) simulation, too. 
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The application of the Tg-viscosity correlation in hot-melt extrusion 1D numerical pro-
cess simulation was verified in dependence of energy consumption and residence time 
distribution. The use of model-based melt viscosity and further physicochemical pa-
rameters of the pure polymeric matrix in HME simulation led to similar results as the 
use of experimental melt viscosity in a conventional simulation procedure up to 30% 
API weight fraction. A proof of concept with APIs, which were not considered in estab-
lishing the Tg-viscosity correlation, confirmed the findings. In the case of mean resi-
dence time (MRT), an increase in dependence of an increase in API weight fraction 
was observed. The influence of melt viscosity was negligible. Instead, the simulation 
procedure with model-based melt viscosity was only verified by using a small-scale 
extruder (12 mm screw diameter) with limited variations in process conditions. There-
fore, trials on large-scale extruders in a wider set of process conditions should be con-
ducted. The use of model-based melt viscosity has been verified by using amorphous 
solid dispersions only. The applicability for formulation with solid particle fractions 
needs to be further evaluated. 
In conclusion, a method to “short-cut” rheological measurements for the use in HME 
numerical simulation to produce ASDs was established. It reduces the effort in meas-
urement down to a Tg-determination by DSC and rheological trials with the pure poly-
meric matrix, thus it simplifies the application of 1D HME simulation. Overall, our pro-
cedure enables the estimation of a good starting point for HME trials in early formula-
tion development at reduced material and costs. It supports the rational development 
for forming amorphous solid dispersions by means of HME and reduces experimental 
trials to define the best formulation and HME process conditions. 
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